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1.1 Neurodegenerative diseases – The costs of an aging society 
 Characteristic for neurodegenerative diseases is the progressive degeneration of 
neurons in the central or peripheral nervous system (CNS, PNS), resulting in a reduced 
innervation of target structures and leading to the loss of sensory, motor and/or higher 
cognitive functions, which causes progressive disability in affected persons. The most 
o o  eu odege e ati e diso de s a e Alzhei e s disease AD  a d Pa ki so s 
disease (PD), which mostly occur sporadically, but can also be inherited. In both diseases 
the neurodegeneration is caused by multifactorial mechanisms, e.g. protein misfolding 
and aggregation as well as mitochondrial dysfunction and activation of programmed cell 
death pathways (Bredesen et al. 2006; Skovronsky et al. 2006). Increasing life expectancy 
in the industrialized countries resulted in a higher incidence and prevalence of 
neurodegenerative disorders. The exact pathomechanisms remain unclear and thus, no 
curative therapies exist. The socioeconomic costs of neurodegenerative diseases are high 
and increase with disease progression (Skovronsky et al. 2006), thus the investigation of 
underlying pathomechanisms and the development of early diagnostic tools as well as 
therapeutic strategies that prevent further neurodegeneration and stop disease 
progression are of major importance.  
 
   
.  Parki so ’s disease  
1.2.1 History, epidemiology and phenotype 
 The fi st s ie tifi  des iptio  of PD as pu lished i   as A  essa  o  the 
shaki g pals   the B itish ph si ia  Ja es Pa ki so . I  this essa  he des i ed 
patients that showed the core motor clinical features of the disease, which was later 
named after him, including rigidity, postural instability, resting tremor and bradykinesia. 
The degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) 
was confirmed in 1919 by Tretiakoff (Lees et al. 2008) and in 1959 the hypothesis arose 




Lewy bodies were described in 1912 by Frederic Lewy, but it took another 85 years till the 
discovery of their major component, aggregated alpha-synuclein (Spillantini et al. 1997). 
 PD is the second most f e ue t eu odege e ati e disease afte  Alzhei e s 
disease. In industrialized countries its prevalence is about 0.3 % of the total population. 
As PD is an age-related disorder that has an average disease onset at around 60 years, its 
prevalence increases to 1 – 2 % in people older than 60 years of age (de Lau & Breteler 
2006; Dexter & Jenner 2013) and to 4 % in people older than 85 (Nuytemans et al. 2010). 
Men are more often affected than women. 
Approximately 5 % of all PD cases are inherited (familial PD) and caused by 
mutations in different genes, but duplications and triplications of alpha-synuclein have 
also been described; so far 17 autosomal dominant and autosomal recessive mutations 
have been identified (Dexter & Jenner 2013). However, the majority of PD cases occur 
sporadically without identifiable cause (idiopathic or sporadic PD). Nevertheless, many of 
the mechanisms underlying familial PD are also found in sporadic PD, e.g. oxidative stress, 
mitochondrial dysfunction and protein misfolding (Dexter & Jenner 2013).  
 The clinical diagnosis of PD is still strongly dependent on impaired motor 
functions. Diagnosis is established when the motor symptoms start to occur, which is 
comparably late in pathophysiological disease progression. The motor symptoms of PD 
include rigidity, postural instability, bradykinesia, resting tremor, flexed posture, freezing, 
mask-like facial expression and problems to speak and swallow (Jankovic 2008). In 
addition to these, also non-motor symptoms like autonomic dysfunction, olfactory 
dysfunction (hyposmia), sleep disorders and psychiatric problems, like dementia and 
depression, are found in PD (Jankovic 2008; Smith et al. 2012). Non-motor symptoms 
were a long time not recognized as symptoms of PD but are getting more into focus 
nowadays. For instance, rapid eye movement sleep behavior disorder and hyposmia are 




1.2.2 Disease progression and pathophysiology 
 One of the major shortcomings in PD treatment is its late diagnosis, as the clinical 




hallmark of PD is the degeneration of dopaminergic neurons in the SNpc that is 
responsible for the classical motor symptoms, the intraneuronal pathology starts in the 
medulla oblongata and spreads over the brain stem and the basal ganglia to the 
neocortex, explaining the occurrence of non-motor symptoms and underlining that PD is 
a systemic disorder (Braak et al. 2003; Pereira et al. 2012). Nevertheless, dopaminergic 
neurons in the SNpc are particularly prone to neurodegeneration and their loss leads to 
the progressive motor symptoms characteristically for PD. At time of clinical 
manifestation, the striatal loss of dopaminerigc axon terminals is stronger than the 
degeneration of nigral cell bodies, which leads to the assumption that degeneration starts 
in the terminals leading to axonal degeneration and in its progression to neuronal cell 
death Bu ke & O Malle  ; Tö ges et al. 2012). 
The neuromelanin-containing dopaminergic neurons in the SNpc are part of the 
basal ganglia and thus involved in the regulation of voluntary movements. Their long 
unmyelinated axons project into the striatum where the dopaminergic terminals provide 
input to the spiny striatal neurons and modulate their activity by targeting the dopamine 
receptors D1 and D2. Excitatory input is mediated by activation of D1 receptors on the 
GABAergic spiny cells that target the internal globus pallidus (GPi) directly, therefore 
called direct pathway, leading to its inhibition and an excitation of the thalamus and the 
motor cortex. D2 receptors on spiny neurons mediate inhibitory input to the external 
globus pallidus (GPe) which in turn lead to less excitatory outputs of the subthalamic 
nucleus that projects to the GPi and activates it via the indirect pathway. The GPi projects 
to the ventral nucleus of the thalamus which in turn has efferent projections to the motor 
cortex that controls motor behavior and among others provides input to the spinal cord, 
the striatum and the substantia nigra pars reticulata (SNpr) (Kandel et al. 2000). These 
complex circuits are crucial for voluntary movement generation and a disturbance in 
transmitter levels may lead to motor dysfunctions. Degeneration of dopaminergic 
terminals leads to a depletion of striatal dopamine and therefore to an increased 
activation of the GPi that in turn leads to a decreased activity of the thalamus and motor 





Figure 1.2/1: Diagra  of the asal ga glia ir uits i  a  healthy su je ts a d  Parki so ’s disease. The thickness of 
arrows indicates signal strength. Blue arrows represent activating input; read arrows indicate inhibiting input. Loss of 
SNpc signals in PD results in less cortical activation and thus to the cardinal motor symptoms in PD (GPe=external globus 
pallidus; GPi=internal globus pallidus; STN=subthalamic nucleus; SNr=substantia nigra reticulate; 
PPN=pedunculopontine nucleus; CM=centromedian nucleus; VA/VL=thalamus). (Smith et al. 2012, modified) 
 
 
1.2.3 Etiology and pathogenesis: Possible causes for PD 
There are several genes known to be involved in the formation of the rare familial 
forms of PD. Among them are mutations of the alpha-synuclein gene, the E3 ligase Parkin, 
LRRK2, DJ-1, Pink1 and ATP13A2 (Dexter & Jenner 2013). The causes leading to the 
formation of idiopathic PD are not fully understood. In recent years it has become clear 
that a variety of factors play a role, among them genetic predisposition and 
environmental risk factors (Schapira & Jenner 2011). The cellular mechanisms underlying 
degeneration of SNpc dopaminergic neurons are extensively studied and the most 
attention was paid to protein mishandling and aggregation and mitochondrial dysfunction 






Protein mishandling and aggregation 
 One major hallmark of PD are cytoplasmatic inclusions, so called Lewy bodies 
(LBs), that are found in dopaminergic neurons as well as other affected brain areas in PD 
patients (Braak et al. 2003; Forman et al. 2004). LBs consist mainly of aggregated alpha-
synuclein, neurofilaments, and ubiquitin (Spillantini et al. 1997). The role of LBs in the 
development of PD is still under debate and it is not clear whether they are detrimental 
and lead to neuronal cell death (Braak et al. 2003; Braak et al. 2003; Lu et al. 2005), or if 
they have protective properties by sequestering toxic material from the cytoplasm 
(Parkkinen et al. 2011; Tompkins & Hill 1997). Nevertheless, the presence of these large 
inclusion bodies in neurons of patients gives evidence that protein handling in affected 
neurons is malfunctioning. Another interesting point is the presence of alpha-synuclein in 
idiopathic PD cases. In familial PD, there are 5 alpha-synuclein mutations known till today 
(Proukakis et al. 2013), and together with polymorphisms of SNCA they lead to 
oligomerization, fibril formation and aggregation of alpha-synuclein (Lázaro et al. 2014). 
Interestingly, patients with idiopathic PD that do not have any alpha-synuclein mutation, 
show also aggregation and Lewy body formation, which again leads to the assumption 
that this is caused not only by excess protein but that malfunctioning protein degradation 
pathways are affected (Moore et al. 2003). A major player in protein degradation is the 
ubiqitin-proteasome system (UPS) which uses ubiqitin as a marker that targets cytosolic 
and nuclear proteins for proteolysis (Cooper 2000). Growing evidence suggests 
involvement of UPS malfunction in the formation of idiopathic and also familial PD 
(Giasson & Lee 2003; Moore et al. 2003). Evidence ranges from mutations in parkin, a 
gene encoding for the E3 ligase Parkin that is responsible for substrate recruitment, in 
familial PD (Kitada et al. 1998), to deficits in the 20/26s proteasome in idiopathic PD 
patients (McNaught et al. 2002; McNaught et al. 2003) and occurrence of LB-like 
inclusions after UPS inhibition in rats (McNaught et al. 2004). Nevertheless, further 
investigations are necessary to explain the role of the UPS in PD. 
 
Mitochondrial dysfunction and oxidative stress 
 Neurons are specifically dependent on mitochondrial function. They have a very 
high energy demand because of their high metabolic activity and their size and polarity 




synapses (Exner et al. 2012). Dopaminergic neurons in particular are highly susceptible for 
oxidative stress due to dopamine catabolism and require mitochondrial control systems. 
Thus, it is not surprising that mitochondrial dysfunction can lead to neurodegeneration. 
The idea that mitochondrial dysfunction could be involved in the formation of idiopathic 
PD as aised i  the s ith the dis o e  of -methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP). MPTP was a contaminant of illegal MPPP synthesis, a drug 
that was used intravenously and caused, if contaminated with MPTP, a parkinsonian 
syndrome. MPTP can cross the blood-brain-barrier and is then metabolized within glial 




 is transported into dopaminergic neurons via 
the dopamine transporter (DAT), where it inhibits complex I of the mitochondrial 
respiratory chain (Gerlach et al. 1991; Przedborski & Jackson-Lewis 1998). Even though 
the MPTP induced Parkinsonism is acute and toxin induced and therefore different from 
the slow progression of idiopathic PD, there are still shared features and till today 
complex I inhibitors (MPTP, 6-OHDA, rotenone) are used to model PD (Bezard & 
Przedborski 2011). Also in favor of the involvement of mitochondrial dysfunction due to 
complex I inhibition are reports that complex I activity is strongly reduced in the SNpc of 
PD patients (Janetzky et al. 1994; Mann et al. 1994; Schapira et al. 1990). Inhibition of 
complex I leads to a decreased ATP production and decreases the production of reactive 
oxygen species (ROS), leading to energy failure and oxidative stress. Oxidative stress in 
turn leads to damage of the mitochondrial DNA and enzymes of the respiratory chain, 
triggering further ROS production (Henchcliffe & Beal 2008; Lin & Beal 2006). Another 
factor emphasizing the potential role of mitochondria in the formation of PD is that many 
of the genes involved in the formation of familial PD directly or indirectly involve 
mitochondria (e.g. alpha-synuclein, LRRK2, DJ-1, Pink1 and parkin) (Lin & Beal 2006).  
Dopaminergic neurons have per se a higher oxidative burden than other neurons, 
because they produce H2O2 during the recycling of dopamine, which can interact with 
transition metals and form hydroxyl radicals. Furthermore the spontaneous autoxidation 
of dopamine leads to the formation of toxic ROS and H2O2 (Sidhu et al. 2004).  
Another factor suggested for excessive production of ROS in PD is the increased 
occurrence of transition metals. Especially elevated levels of free iron lead to an abnormal 
oxidation of dopamine to the toxic species 6-OHDA and dopamine-quinone. These species 




pool resulting in a vicious circle of mitochondrial impairment, oxidative stress and further 
imbalance in iron homeostasis (Jomova et al. 2010). 
 Oxidative stress could also be induced by non-neuronal cells. Infiltration of 
microglial cells into affected brain regions is characteristic for neurodegenerative 
diseases. In the healthy brain, microglia are evenly distributed and constantly active, 
scanning the parenchyma for pathogen- and damage-associated molecular patterns 
(PAMPs and DAMPs). If PAMPs or DAMPs are detected microglial cells infiltrate the 
espe ti e tissue a d ha ge thei  a ti atio  status f o  su eilla e  to phago toti  
to remove cellular debris. Furthermore they release different cytokines and chemokines 
that could enhance the inflammatory response or induce neuroprotection (Hanisch & 
Kettenmann 2007; Kettenmann et al. 2011; Schwartz et al. 2006). Among the factors 
released by microglial cells are also ROS (Hanisch & Kettenmann 2007). Reactive microglia 
are abundant in the SNpc of PD patients as well as in patients with MPTP induced 
parkinsonism and contribute to dopaminergic neuron degeneration (Hirsch & Hunot 
2009; McGeer & McGeer 2008). Interestingly, the post mortem tissues of MPTP users 
show a prolonged activation of reactive microglia, even years after the acute intoxication 
(Langston et al. 1999). Further evidence for the involvement of microglial released ROS in 
dopaminergic neuron degeneration is given by different in vivo and in vitro studies (Le et 
al. 2001; Liberatore et al. 1999; Wu et al. 2002).  
 As indicated, there is a complex interplay between mitochondrial function, glial 
activation, production of ROS and protein mishandling involved in dopaminergic 
neurodegeneration in PD, and until today neither the precise mechanisms nor the causes 
are fully understood. 
 
 
1.2.4 Symptomatic treatment of PD 
 Due to the lack of knowledge regarding the cause of PD, there is currently no 
curative therapy available. Patients are provided with symptomatic treatment that should 
attenuate the symptoms of PD. Till today the gold-standard in PD treatment is the 
pharmacological supplementation of dopamine by oral application of its precursor 




dopamine (decarboxylase inhibitor). In milder cases without advanced motor symptoms 
monoamine oxidase B (MOAB) inhibitors are given to diminish dopamine degradation 
after release (Connolly & Lang 2014). Major shortcomings of the dopamine replacement 
therapy are at one hand adverse effects like motor complications (e.g. levodopa induced 
dyskinesia), compulsive behavior, nausea and hallucinations, and at the other hand the 
inefficient targeting of dopamine-independent non-motor symptoms (e.g. depression and 
cognitive impairment) (Connolly & Lang 2014; Hurtig 1997). Additionally, after years of 
dopamine replacement therapy, usually symptoms arise that are not responsive to the 
drugs. 
 Alternatives to pharmacological treatment are rare; one possibility is deep brain 
stimulation (DBS). DBS requires the surgical implantation of electrodes into the 
subthalamic nucleus, the GPi or the thalamus. Via high frequency stimulation of the 
respective area PD symptoms are diminished (Benabid et al. 2009; Bronstein et al. 2011). 
Because of the surgical risks, DBS is only applied in rather advanced cases of PD. 
 
 
1.2.5 The need for regenerative or neuroprotective therapies – Approaches and 
problems 
 As mentioned above, PD can be diagnosed with the onset of clinical motor 
symptoms. A problem is that the first motor symptoms occur late in disease progression 
when approximately 60 % of the nigrostriatal projections are already degenerated 
(Jellinger 2012). By now, there is no reliable biomarker known that might predict disease 
onset. Thus, it is of major importance to develop treatment strategies that prevent 
further degeneration of remaining dopaminergic SNpc neurons or induce regeneration of 
the nigrostriatal system. 
 One major problem in the injured or diseased CNS is the prevention of neuronal 
regeneration by extracellular cues (e.g. glial responses) and a limited intrinsic 
regeneration capacity in adult neurons (Fitch & Silver 2008). Nevertheless, there is 
evidence that also adult neurons have the ability to sprout and thus, regeneration of the 
adult CNS is in principle possible. In toxin-induced animal models for PD spontaneous re-




In rats that received 6-OHDA injections in the SNpc vigorous axonal sprouting could be 
observed 4 months post-lesion (Finkelstein et al. 2000). In MPTP-intoxicated monkeys and 
mice, the extent of spontaneous regeneration was linked to the dimension of 
degeneration (Elsworth et al. 1999; Mitsumoto et al. 1998). These examples demonstrate 
that the adult dopaminergic nigrostriatal system in principle has the ability to regenerate 
after a lesion, but by now it is not known whether compensatory sprouting occurs in PD 
patients or how it could be facilitated or induced.  
 Recently, several approaches to induce regeneration of the nigrostriatal system or 
avoid further degeneration of SNpc neurons were proposed. Among them was extensive 
research on grafting of fetal dopaminergic neurons or embryonic/induced pluripotent 
stem cells (ES; IPS). Implantation of fetal dopaminergic neurons into toxin-induced animal 
models for PD led to improved motor symptoms and increased striatal innervation 
(Bankiewicz et al. 1990; Redmond et al. 1986). After these promising preclinical studies 
grafts of fetal dopaminergic neurons were also implanted into the brains of patients with 
PD. The grafts can survive in the brains of PD patients but the degree of symptomatic 
improvement is highly variable and strongly dependent on different factors. Additionally, 
severe side effects like dyskinesia can occur (Freed et al. 2001; Piccini et al. 2005). With 
the emergence of advanced stem cell technology transplantation of undifferentiated ES 
or IPS became a novel possibility in PD research. Stem cells are the optimal source for cell 
replacement therapy because they are self-renewing and multipotent. It has been shown 
that mouse ES transplanted to 6-OHDA lesioned rats can spontaneously differentiate into 
dopaminergic neurons (Bjorklund et al. 2002). Transplantation of neuronal precursor cells 
derived from monkey ES attenuated MPTP-induced neurological symptoms in monkeys 
(Takagi et al. 2005). As undifferentiated ES always bear the risk of tumor formation after 
transplantation there is the aim to differentiate dopaminergic neurons out of IPS. These 
cells can be sorted and might improve the safety of cell replacement therapies (Sundberg 
et al. 2013). 
 Another important approach to facilitate regeneration and provide 
neuroprotection of the nigrostriatal system is the application or expression of 
neurotrophic factors. Neurotrophic factors are important for the development and 
maintenance of neurons. Several neurotrophic factors have been investigated for their 




selective effect on dopaminergic neurons are glial cell-line derived neurotrophic factor 
(GDNF), neurturin, growth / differentiation factor 5 (GDF5), mesencephalic astrocyte-
derived neurotrophic factor (MANF) and cerebral dopaminergic neurotrophic factor 
(CDNF) (Sullivan & Toulouse 2011). The most promising factor is GDNF, belonging to the 
GDNF family of ligands, which has been extensively studied in vivo and in vitro and was 
already tested in clinical trials. GDNF has been shown to promote the differentiation and 
survival of dopaminergic neurons in culture. Additionally, treatment with GDNF could 
prevent those neurons from degeneration upon 1-methyl-4-phenylpyridinium ion (MPP+) 
treatment in vitro (Hou et al. 1996; Krieglstein et al. 1995; Lin et al. 1993). Similar 
neuroprotection and functional effects could also been observed in different animal 
models of PD, consequently it acts also on the adult dopaminergic neurons (Cheng et al. 
1998; Kearns & Gash 1995; Kordower et al. 2000). The administration site and mode 
(transfusion of the recombinant protein or expression by viral vectors) are crucial for the 
effectiveness of GDNF delivery (Sullivan & Toulouse 2011). After first successful trials of 
intrastriatal GDNF delivery in human PD patients (Patel et al. 2005; Slevin et al. 2005), 
another randomized placebo-controlled trial reported no relief of motor symptoms (Lang 
et al. 2006). In addition, safety issues were raised when antibodies against GDNF were 
found in approximately 10 % of patients that received striatal GDNF infusion, which could 
lead to adverse effects (Tatarewicz et al. 2007). General consensus is that GDNF is a 
valuable treatment option, but needs further preclinical studies to overcome safety issues 
and develop sustainable effects. 
 Another possibility to achieve protection or regeneration of dopaminergic neurons 
is the pharmacological modulation of intrinsic signaling and disease relevant pathways. 
Potential candidates to prevent neurodegeneration are inhibition of apoptotic and 
necrotic cell death pathways as well as application of ROS scavengers and energy 
mimetics and inhibitors of alpha-synuclein toxicity (Dawson & Dawson 2002). 
Furthermore modulation of kinase activity (e.g. Akt, JNK, LRRK2, MAPK, ROCK) is a 
promising treatment option for PD because there is evidence that inhibition or activation 
of certain kinases is preventing neurodegeneration in preclinical studies (Burke 2007; 
Deng et al. 2011; Saal et al. 2015; Tönges et al. 2012). 
 Despite all efforts, the development of an applicable tool to prevent dopaminergic 




successful and new ideas for treatment strategies are urgently needed. It is known that 
endogenous microRNAs (miRNAs) exert different functions in the CNS. As they usually 
target not only one but multiple proteins and pathways, they might be powerful tools for 
understanding PD pathology and development of new treatment strategies.  
 
   
1.3 miRNAs – Biogenesis, function and role in neurodegenerative diseases 
1.3.1 Discovery, biogenesis and function of miRNAs 
 Approximately 1.5 % of the human genome accounts for protein-coding 
sequences, the remaining genome is associated with introns, regulatory DNA sequences, 
retrotransposons and non-coding RNAs or by now without known function. Non-coding 
RNA genes produce regulatory RNA species that play an important role in translation, 
post-transcriptional regulation of gene expression and modification of RNA. By now 
different classes of non-coding RNAs have been revealed, among them ribosomal RNA 
(rRNA), transfer RNA (tRNA), long non-coding RNA (long ncRNA) and small ncRNAs (Eddy 
2001). The group of small ncRNAs is comprised of different species, including small 
interfering RNA (siRNA), small nucleolar RNA (snoRNA), piwi-interacting RNA (piRNA) and 
miRNA (Stefani & Slack 2008). 
 The first miRNA was discovered and described in Caenorhabditis elegans by Lee et 
al. in 1993. They found that lin-4, a gene known to be important in larval development, 
was not protein-coding but produced a pair of small RNAs. They also noticed that one of 
these ‘NAs has a tise se o ple e ta it  to the UT‘ of the li -14 gene. The idea and 
discovery that this let-4 RNA might post-transcriptionally regulate the expression of the 
lin-14 protein was brought up and published by Arasu and colleagues (1991) and 
Wightman and colleagues (1993) from the Ruvkun lab. Since then a rising number of 
miRNAs has been discovered in animals, plants and some viruses and it became clear that 
they play a role in a variety of biological functions and might regulate the majority of 
protein-coding genes. 
 miRNAs are between 21 and 26 nucleotides (nt) long and transcribed from miRNA 
genes either individually or in clusters of 2 – 7 miRNAs, or are excised from the introns or 




miRNA genes are also found in repetitive regions, suggesting that transposable elements 
play a role in creation of new miRNA genes (Mendes et al. 2009). 
 miRNA biogenesis takes place in the nucleus (transcription and primary 
processing) and the cytoplasm (further processing and incorporation into RNA-induced 
silencing complex (RISC)). There are different ways how mature miRNAs can be 
generated, but the majority is derived from the so-called canonical pathway which is 
dependent on the RNase III enzymes Drosha and Dicer (Ghildiyal & Zamore 2009). The 
miRNA gene is typically transcribed by the RNA Polymerase II (in some cases RNA 
polymerase III), resulting in a long primary transcript with hairpin structure, the so-called 
pri-miRNA. This pri-miRNA is cleaved at its base by the nuclear protein complex formed 
out of Drosha and the double stranded RNA (dsRNA) binding protein DGCR8, releasing a 
hairpin that is usually between 55 and 70 nt long, the pre-miRNA (Yang & Lai 2011; Yeom 
et al. 2006). The pre-miRNA is exported to the cytoplasm by Exportin-5, which recognizes 
its  o e ha gs. I  the toplas  the heli al tu s of the hai pi  a e cleaved by Dicer, 
leading to the formation of an unstable ~ 22 nt long miRNA duplex structure. The 
unwinding of the duplex structure usually happens in association with Ago proteins, 
which together with the mature miRNA form the RNA silencing effector RNA induced 
silencing complex (RISC) (Kim & Kim 2012). RISC can post-transcriptionally regulate 
protein expression in different ways: When the miRNA:mRNA pair shows perfect 
complementarity it leads to degradation of the mRNA. When there is a not sufficient 
complementarity for cleavage this leads to translational repression or deadenylation 





Figure 1.3/1: The canonical miRNA biogenesis pathway. miRNA genes are transcribed by RNA polymerase II (or III; RNA 
Pol II/III) and processed by Drosha/DGCR8. The pre-miRNA is exported to the cytoplasm where it is further processed 
and incorporated into Ago for RISC formation (Modified from Winter et al. 2009).   
  
In addition, miRNAs can derive from different non-canonical pathways that are 
either Drosha/DGCR8-independent but Dicer-dependent or vice versa. Drosha/DGCR8 
independent are pre-miRNAs deri i g f o  i t o s  ‘NA duple es apped to sho t 
introns), tRNAs, box H/ACA- and box C/D snoRNAs and endogenous shRNAs (summarized 
in figure 1.3/2 a). An example for Dicer-independent miRNA biogenesis is miR-451; the 
pri-miR-451 is processed by Drosha/DGCR8 resulting in a pre-miRNA that is with ~ 18 nt 
to short for Dicer processing. This pre-miR-451 is directly incorporated into Ago2 where it 
is sliced, resulting in a mature miR-451-RISC (see figure 1.3/2 b) (Yang & Lai 2011). 
Keeping in mind the fast progression of research in this field it would not be surprising if 
even more miRNA biogenesis pathways emerge in future studies.  
 Since their discovery substantial knowledge has been accumulated, giving 







Figure 1.3/2: Non-canonical miRNA biogenesis pathways. (a) Drosha/DGCR8-independent miRNA biogenesis pathways. 
(b) Dicer-independent miRNA biogenesis (modified from Yang & Lai 2011).  
 
 
1.3.2 The role of miRNAs in neurodegenerative diseases 
 The importance of miRNA-mediated regulation of protein expression in nervous 
system development and maintenance is well-established (Kapsimali et al. 2007; Miska et 
al. 2004). Initial studies in animals lacking proteins of the miRNA biogenesis machinery 
(e.g. Dicer, DGCR8) showed that miRNAs are crucial for brain development and long-term 
neuronal integrity (Davis et al. 2008; Kim et al. 2007; Schaefer et al. 2007). In addition 
several brain specific miRNAs have been discovered; miR-124 for example counteracts 
REST and induces neuronal fate and is important for CNS development, miR-134 is 
important for dendritic spine formation and miR-132 is involved in neurite outgrowth 
(Magill et al. 2010; Makeyev et al. 2007; Schratt et al. 2006; Visvanathan et al. 2007). 
 Evidence that miRNA dysregulation occurs in neurodegenerative diseases was 
given by miRNA profiling studies of human brain tissue of patients and analysis of animal 




cerebral cortex is decreasing with disease progression. miR-9 is regulating REST, which is 
usually suppressing the expression of neuronal genes in non-neuronal cells. With 
decreasing miR-9 levels REST accumulates in the cytoplasm and translocates to the 
nucleus where it suppresses the expression of neuronal genes and thus might induce 
neurodegeneration (Packer et al. 2008). Another study showed that neuronal miR-132 is 
downregulated in the brains of HD patients and in a mouse model for HD (Johnson et al. 
2008). Also pre-symptomatic HD patients show elevated levels of miR-34b in their blood 
plasma, indicating the potential of miRNAs as biomarkers (Gaughwin et al. 2011). 
 I  the hippo a pus of Alzhei e s disease AD  patie ts as ell as i  the APPP“ -
21 mouse model miR-34c was significantly increased. This miRNA targets Sirt1, a protein 
that is involved in memory function and learning (Zovoilis et al. 2011). Another miRNA 
deregulated in AD is miR-29a which showed decreased expression in brains of patients 
compared to controls (Hébert et al. 2008; Shioya et al. 2010). miR-29a is regulating the 
protein expression of BACE-1, a protein that is involved in the cleavage of amyloid 
p e u so  p otei  APP  a d ge e atio  of to i  a loid β Aβ -species. Thus, down 
regulation of miR-29a might lead to aberrant BACE-  a d the efo e to i eased Aβ le els 
(Hébert et al. 2008).  Decrease in miR-107 in AD at an early stage of pathology could be 
shown in different studies; interestingly this miRNA is also involved in the regulation of 
BACE-1 expression (Nelson & Wang 2010; Wang et al. 2008). Additionally, several studies 
report that miRNA levels in CSF and plasma are changed in AD patients, suggesting a 
potential role as a diagnostic marker (Alexandrov et al. 2012; Cogswell et al. 2008; Müller 
et al. 2014).  
 Deregulation in miRNA expression is also shown in the brain of PD patients. miRNA 
profiling showed decreased expression of miR-34b and miR-34c in the amygdala, frontal 
cortex, SN and cerebellum of PD patients in motor stages (Braak stages 4 & 5) as well as in 
pre-motor stages (Braak stages 1-3) of the disease. This reduction in miR-34b and miR-34c 
was coupled to an altered mitochondrial function, oxidative stress and reduction in 
cellular ATP content (Miñones-Moyano et al. 2011). miR-133b is important for 
dopaminergic neurons and usually enriched in the midbrain but markedly decreased in 
the midbrain of PD patients (Kim et al. 2007). It plays a crucial role in dopaminergic 
neuron development (see 1.3.3) and thus it is reasonable to suggest its involvement in 




 In addition to these profiling studies, different miRNAs have been discovered that 
regulate PD-associated genes. Expression of alpha-synuclein, a protein that plays a critical 
role in the formation of familial PD and is found in Lewy bodies, is post-transcriptionally 
regulated by miR-7. In the MPTP mouse model for PD as well as in a cell culture model 
using MPP
+
-toxicity miR-7 is down regulated, which could explain the increased alpha-
synuclein expression in these models. Furthermore, the authors could show that cells are 
protected by miR-7 from alpha-synuclein mediated oxidative stress (Junn et al. 2009). This 
interaction was confirmed in cortical neurons and HEK cells (Doxakis 2010). Another 
miRNA that regulates alpha-synuclein expression in cortical cell culture and HEK cells is 
miR-153 (Doxakis 2010). Increased alpha-synuclein expression could also be caused by 
increased fibroblast growth factor 20 (FGF20) expression resulting from a single 
nucleotide polymorphism (SNP) in the FGF20 gene that disrupts the binding side for miR-
433. These kind of SNP in the FGF20 gene is associated with a higher risk for PD (Wang et 
al. 2008). In Drosophila dopaminergic neurons it was shown that pathogenic LRRK2 
inhibits let-7 and miR-184* which leads to increased expression of the transcription 
factors E3F1 and DP resulting in cell death. When let-7 and miR-184* were inhibited 
artificially in wildtype flies this resulted in a phenotype similar to animals carrying 
pathogenic LRRK2 (Gehrke et al. 2010). Beside the miRNAs that have a direct regulatory 
effect on PD-associated genes, there are also miRNAs associated with pathways affected 
in PD. Among others miR-98, miR-124, miR-130, miR-142 and miR-204 might be 
regulators of genes involved in the autophagy-lysosomal pathway (Jegga et al. 2011), 
regarding the importance of this pathway in PD it is possible that these miRNAs play a 
critical role in PD pathogenesis. 
 
 
1.3.3 The role of miRNAs in dopaminergic neuron biology 
 In order to develop new therapeutic strategies for PD it is critical to understand 
the factors involved in midbrain dopaminergic neuron development, maintenance and 
also degeneration. It was demonstrated by several studies that miRNAs are important for 
the development and survival of neurons (De Pietri Tonelli et al. 2008; Makeyev et al. 




neuron development and survival was demonstrated in vitro and in vivo with Dicer 
deficient models. siRNA-mediated Dicer knockdown in Drosophila led to loss of 
dopaminergic neurons and deficits in motor behavior (Gehrke et al. 2010). In murine ES 
cells elimination of miRNAs by Dicer depletion resulted in inhibited differentiation and 
loss of TH-positive (differentiated) cells under appropriate differentiation signals 
compared to a wildtype control ES cell line. When Dicer deficient ES cells were 
transfected with small RNAs isolated from mouse embryonic midbrain the phenotype was 
rescued (Kim et al. 2007). A conditional knockout of dicer in post-mitotic dopaminergic 
neurons led to a progressive loss of midbrain TH-positive neurons and their striatal 
projections that became first apparent in animals 2 weeks of age and was almost 
complete in 6 week old animals. This was accompanied by induction of apoptosis in the 
SN and dramatically reduced locomotion in the open field test (Kim et al. 2007). Wnt1-
cre-mediated conditional Dicer knockout in mice led to malformation of the midbrain and 
the cerebellum and an almost complete elimination of midbrain dopaminergic neurons 
due to impaired differentiation confirming the importance of miRNAs for dopaminergic 
neurons (Huang et al. 2010). 
 Midbrain enriched miR-133b is deficient in the midbrain of PD patients and other 
dopaminergic neuron deficient models (6-OHDA mice and Aphakia mice deficient for Ptx3 
(Hwang et al. 2003)). Even though Aphakia mice maintain a population of dopaminergic 
neurons within the VTA they showed a prominent miR-133b deficiency, suggesting that 
miR-133b expression is directly regulated by the Pitx3 transcription factor. This was 
confirmed by an increase in miR-133b after Pitx3 overexpression in ES cells. 
Overexpression of miR-133b in ES cells and primary midbrain neuronal cultures (PMN) 
resulted in a significant decrease of the dopamine marker DAT, whereas early 
differentiation markers like Nurr1 appeared unaltered. Also dopamine release in miR-
133b overexpressing cultures was decreased. Inhibition of miR-133b by OMe-modified 
RNA oligonucleotides in this cell culture models led to an increased expression of DAT and 
TH. The authors could show that Pitx3 is a target for miR-133b, thus miR-133b and Pitx3 
create a negative feedback loop in which Pitx3 increases miR-133b expression, whereas 
miR-133b inhibits Pitx3 translation. This results in the regulation of the final 
differentiation of midbrain dopaminergic neurons and their activity (Kim et al. 2007). 




model, which showed normal development and function of dopaminergic neurons in the 
midbrain, suggesting that maybe other members of the miR-133 family compensate for 




1.3.4 The potential of miRNAs providing neuronal protection and regeneration 
 Despite that the role of miRNAs in central nervous system function is not yet fully 
understood there are already numerous studies indicating that they play a role in 
neuroprotection and regeneration. The neuroprotective effect of miRNAs is best studied 
in stroke and epilepsy models; nevertheless it was also shown in models of 
neurodegenerative diseases, e.g. HD. Increased levels of miR-22 decreased 
neurodegeneration in primary cortical and primary striatal neuron cultures treated with a 
mutated human huntingtin fragment. Additionally, in neuronal cultures exposed to a 
complex II/III inhibitor increased miR-22 levels led to a higher number of surviving 
neurons. The beneficial effects of increased miR-22 levels are mediated by a reduced 
caspase activation and targeting of the pro-apoptotic factors MAPK14/p38 and Tp53inp1. 
Interestingly, it was shown that miR-22 is downregulated in the brains of AD and HD 
patients (Jovicic et al. 2013). Viral overexpression of miR-22 resulted in reduced 
inflammation and neuroprotection in a rat model of focal cerebral ischemia and 
reperfusion as well as in primary cortical neurons (Yu et al. 2015). Neuronal injury in 
stroke and neurodegenerative disorders is e.g. mediated by overstimulation of ionotropic 
glutamate receptors due to extracellular accumulation of glutamate. This response is 
regulated by miR-223, which targets glutamate receptor subunits. Increased miR-223 was 
neuroprotective in a mouse model for transient global ischemia, whereas inhibition of 
miR-223 led to increased neuronal apoptosis (Harraz et al. 2012). In a mouse model for 
epilepsy, seizure preconditioning by kainic acid led to upregulation of 25 miRNAs, among 
them miR-184. Inhibition of miR-184 expression in preconditioned animals resulted in a 
significant increase of seizure-induced neuronal cell death after status epilepticus. The 
authors conclude that the increase in miR-184 levels upon preconditioning contributes to 




tolerance development (McKiernan et al. 2012). Another example for miRNAs involved in 
epilepsy is miR-134. miR-134 is up regulated in animal models and patients with temporal 
lobe epilepsy, inhibiting miR-134 in the hippocampus of mice by antagomirs, rendered 
mice refractory to seizures and decreased neuronal injury after status epilepticus 
(Jimenez-Mateos et al. 2012). A study on the interplay between miR-125b and tau-
phopshorylation revealed miR-125b potential role in AD pathology. miR-125b expression 
is increased in the brains of AD patients, leading to the assumption that inhibition of this 
miRNA in AD might have neuroprotective effects (Banzhaf-Strathmann et al. 2014). 
 Regarding the regeneration of nervous system structures there are indications 
that miRNAs are involved in regeneration of axons and synapses. In a mouse model of 
spinal cord injury miR-486 was shown to be up regulated. miR-486 directly targets 
NeuroD6 which is involved in the regulation of ROS homeostasis. Inhibition of miR-486 
expression induced the expression of NeuroD6 and led to functional recovery in injured 
animals (Jee et al. 2012). Another example for miRNAs involved in neurite regeneration is 
miR-222. Increased miR-222 resulted in increased axonal outgrowth after sciatic nerve 
transection in rats by targeting PTEN (Zhou et al. 2012). Regarding regeneration in 
neurodegenerative disorders it was shown in a mouse model of ALS that miR-206 
significantly delays disease progression. Furthermore, it is required for the regeneration 
of neuromuscular synapses after nerve injury (Williams et al. 2009). 
Even though the role of miRNAs in neuroprotection and neuroregeneration is still 
emerging, there is already evidence that these small non-coding RNAs are powerful 











1.4 Aims of this thesis 
 Even though in recent years miRNAs in the context of neurodegenerative 
diso de s e e e te si el  studied, thei  ole i  Pa ki so s disease is still ot full  
elucidated. Understanding miRNA-dependent regulations in dopaminergic neuron biology 
and PD can provide valuable insights into PD pathogenesis and also might lead to new 
therapeutic strategies for neuroprotection and regeneration of the nigrostriatal system. 
Thus, the aim of my work was to elucidate miRNA expression changes in primary midbrain 
neurons (PMN) upon development and neurite outgrowth and in the degenerating and 
regenerating substantia nigra. Furthermore, I wanted to exploit the neuroprotective and 
neuroregenerative potential of miRNAs in dopaminergic neurons in vitro and in vivo. 
Therefore, I formulated the following questions: 
 
1. How does miRNA expression change in PMNs during development and neurite 
outgrowth? Does the pro-dopaminergic growth factor GDNF have influence on miRNA 
expression in PMNs? 
In order to address these questions small RNA sequencing and differential expression 
analyses of (GDNF-treated) PMN cultures at different developmental stages was 
performed. As we assume that the cellular mechanisms that drive neurite outgrowth and 
differentiation during development are the same as those that play a role in regenerative 
responses, this study was performed with the goal to find miRNAs with a therapeutic 
potential.  
 
2. How does miRNA expression in the midbrain change during degeneration and 
regeneration of the nigrostriatal system in the 6-OHDA mouse model for PD? 
For analyses of miRNA expression changes during degeneration and regeneration of the 
nigrostriatal system we employed the 6-OHDA mouse model for PD and performed small 
‘NA se ue i g of the id ai s s all o -coding RNAs and differential expression 
analyses to get a better understanding of the mechanisms involved in degeneration and 




3. Could changes in the levels of specific miRNA lead to protection and regeneration of 
dopaminergic neurons in vitro and in vivo? 
In order to investigate the influence of increased levels of specific miRNAs, I used 
synthetic miRNA mimics and investigated their effects on dopaminergic neurons in PMNs 
in vitro and the MPTP mouse model for PD in vivo. 
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6-OHDA     Sigma Aldrich (Taufkirchen, Germany) 
0.9 % Saline      Braun (Melsungen, Germany) 
APS      Sigma Aldrich (Taufkirchen, Germany) 
Acrylamide     Applichem (Darmstadt, Germany) 
B-27 Supplement    Gibco (Karlsruhe, Germany) 
Bepanthene     Braun (Melsungen, Germany) 
Bromphenol blue    Sigma Aldrich (Taufkirchen, Germany) 
BSA       Applichem (Darmstadt, Germany) 
Citric acid (C6H8O7 * H2O)   Roth (Karlsruhe, Germany) 
DAKO Diluent     DAKO (Hamburg, Germany) 
DAPI      Sigma Aldrich (Taufkirchen, Germany) 
DEPC      Sigma Aldrich (Taufkirchen, Germany) 
DEPC water     Sigma Aldrich (Taufkirchen, Germany) 
Dermabond     Ethicon (Norderstedt, Germany) 
DPX      Fluka (Steinheim, Germany) 
EDTA      Applichem (Darmstadt, Germany) 
Ethanol absolute    Applichem (Darmstadt, Germany) 
FCS      Biochrom; PAA (Berlin; Pasching, Germany) 
Glucose     Merck (Darmstadt, Germany) 
Glutamine     Lonza (Cologne, Germany) 
Glycerol     Roth (Karlsruhe, Germany) 
Glycine     Applichem (Darmstadt, Germany) 
GlycoBlue Coprecipitant   ThermoFisher Scientific (Waltham, MA, USA) 
H3BO3      Sigma Aldrich (Taufkirchen, Germany)  
HBSS      Gibco (Karlsruhe, Germany)  
HEPES      Applichem (Darmstadt, Germany) 
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HPLC water     Merck (Darmstadt, Germany) 
Ketamine     Medistar (Ascheberg, Germany) 
Laminin     Sigma Aldrich (Taufkirchen, Germany) 
L-AA      Sigma Aldrich (Taufkirchen, Germany) 
Luminol     Calbiochem (Darmstadt, Germany) 
Methanol     Applichem (Darmstadt, Germany) 
Mineral oil     Sigma Aldrich (Taufkirchen, Germany) 
Mowiol - 488     Sigma Aldrich (Taufkirchen, Germany) 
MPTP hydrochloride    Sigma Aldrich (Taufkirchen, Germany) 
MPP
+
      Sigma Aldrich (Taufkirchen, Germany) 
Na2B4O7 * 10 H2O    Sigma Aldrich (Taufkirchen, Germany) 
NaO2C2H3     Roth (Karlsruhe, Germany) 
NaHCO3     Merck (Darmstadt, Germany) 
NaN3      Sigma Aldrich (Taufkirchen, Germany) 
NaO2C2H     Roth (Karlsruhe, Germany) 
NaOH      Applichem (Darmstadt, Germany) 
Neurobasal – A medium   Gibco (Karlsruhe, Germany) 
NGS      Biochrom; PAA (Berlin; Pasching, Germany) 
NH4Cl      Merck (Darmstadt, Germany) 
Non – fat dried milk    Applichem (Darmstadt, Germany) 
p - cumaric acid    Applichem (Darmstadt, Germany) 
PFA      Applichem (Darmstadt, Germany) 
PBS      Applichem (Darmstadt, Germany) 
PLO      Sigma Aldrich (Taufkirchen, Germany) 
Precision Plus Dual Color Standard  BIO-RAD (Munich, Germany) 
SDS      Applichem (Darmstadt, Germany) 
Sodium octosulfonic acid   Fluka (Steinheim, Germany) 
Sterofundin     Braun (Melsungen, Germany) 
Sucrose     Applichem (Darmstadt, Germany) 
TEMED     Roth (Karlsruhe, Germany) 
Thionine acetate    Sigma Aldrich (Taufkirchen, Germany) 
TRI Reagent     Sigma Aldrich (Taufkirchen, Germany) 
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Tris base     Applichem (Darmstadt, Germany) 
Tris HCl     Applichem (Darmstadt, Germany) 
TritonX 100     Applichem (Darmstadt, Germany) 
Trypsin     Biochrom; PAA (Berlin; Pasching, Germany) 
Tween20     Applichem (Darmstadt, Germany) 
Xylazine     Ecuphar (Greifswald, Germany) 
Xylene      Sigma Aldrich (Taufkirchen, Germany) 




DAB Peroxidase Substrate Kit SK-4100  Vector Laboratories (Burlingame, USA) 
miScript II RT Kit     Qiagen (Hilden, Germany) 
miScript SYBR Green PCR Kit    Qiagen (Hilden, Germany) 
TruSeq Small RNA Sample Prep Kit   Illumina (San Diego, CA, USA) 
VECTASTAIN ABC Peroxidase Standard Kit PK-4000 Biozol (Eching, Germany) 
 
  
2.1.3 Buffers, solutions and cell culture medium 
 
Antibody solution for immunohistochemistry (IHC): 1 % NGS, 0.1 % TritonX 100 in PBS 
Primary antibody solution for Western blot: 5 % BSA in TBS-T 
APS (10 %) solution: Ammonium persulfate in distilled H2O 
Blocking solution for IHC: 10 % NGS, 0.1 % TritonX 100 in PBS 
Blocking solution for Western blot: 5 % non-fat dried milk in TBS-T 
Borate buffer 100mM: solution 1: 19.7 g Na2B4O7 * 10 H2O in 500 ml distilled water; 
solution 2: 3.09 g H3BO3 in 500 ml distilled water. Adjust the pH of solution 2 with solution 
1 to 8.5 
Culture medium: 2 % B27-supplement, 1 % glutamine, 0.1 % 200 mM L-AA in Neurobasal-
A medium 
DAPI solution: 1 µg/ ml DAPI in PBS 
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ECL-1: 10 µl/ ml 250 mM luminol, 4.4 µl/ ml 90 mM p-cumaric acid, 100 µl/ ml 1M Tris pH 
8.5 in distilled water 
ECL-2: 0.9 µl/ ml 30 % H2O2, 100 µl 1M Tris pH 8.5 in distilled water 
Gelelectrophoresis buffer: 192 mM glycine, 0.1 % SDS, 25 mM Tris HCl, pH 8.3 
HPLC buffer: 6.973 g/ l NaO2C2H3, 7.365 g/ l C6H8O7 * H2O, 0.105 g/ l sodium octosulfonic 
acid, 0.048 g EDTA. Adjust pH to 4.3 using 1M C6H8O7, 105 ml/ l CH4O in 800 ml HPLC 
water 
Laemmli buffer: 312.5 mM Tris pH 6.8, 10 % SDS, 50 % Glycerin, 0.005 % Bromphenolblau, 
100 mM DTT 
Mowiol: 6 g glycerol, 2.4 g mowiol, 6 ml H2O, 12 ml Tris pH 7.2 
PBS: 9.5 mg/ ml PBS in distilled water 
PBS-T: 0.1 % TritonX 100 in PBS 
PFA (4 %) solution: 40 mg/ ml PFA, 9.5 mg/ ml PBS, 1-3 pellets NaOH in distilled water 
RIPA buffer: 10 mM Hepes, 142 nM KCl, 5 mM MgCl, 2.1 mM EGTA and IGEPAL including 
complete proteasome inhibitor and phosphatase inhibitor 
Running phase gel (10 %): 2.83 ml 30 % acrylamide bisacryl, 2.125 4 x Tris pH 8.8, 3.54 ml 
distilled water, 4.25 µl TEMED, 42.5 µl 10 % APS   
Secondary antibody solution: 5 % non-fat dried milk in TBS-T  
Stacking phase gel: 0.65 ml 30 % acrylamid bisacryl, 1.25 ml 4 x Tris pH 6.8, 3.05 ml 
distilled water, 5 µl TEMED, 25 µl 10 % APS 
TBS: 10 mM Tris HCl, 150 mM NaCl in distilled water 
TBS-T: 0.1 % Tween20 in TBS, pH 7.6 
Transfer buffer: 192 mM glycine, 20 % methanol, 25 mM Tris HCl, pH 8.3 






Anti-Akt, from rabbit, polyclonal (Cell Signaling Technology, Cambridge, UK) 
Anti-phospho-Akt, from rabbit, polyclonal (Cell Signaling Technology, Cambridge, UK) 
2. Materials and Methods 
34 
 
Anti-B-cell lymphoma 2 (anti-Bcl2), from mouse, monoclonal (Santa Cruz Biotech, Dallas, 
TX, USA) 
Anti-dopamine transporter, from rat, polyclonal (Merck Millipore, Darmstadt, Germany) 
Anti-Glycerinaldehyd-3-phosphate dehydrogenase (anti-Gapdh), from mouse, monoclonal 
(HyTest Ltd., Turku, Finland)  
Anti-FoxO1, from rabbit, monoclonal (Cell Signaling Technology, Cambridge, UK) 
Anti-FoxO3a, from rabbit, monoclonal (Cell Signaling Technology, Cambridge, UK) 
Anti-Ionized calcium binding adapter molecule 1 (anti-Iba1), from rabbit, polyclonal 
(Wako Pure Chemical Industries, Neuss, Germany) 
Anti-p44/42 Mitogen-activated protein kinase (anti-Erk1/2), from rabbit, polyclonal (Cell 
Signaling Technology, Cambridge, UK) 
Anti-phospho-p44/42 Mitogen-activated protein kinase (anti-pErk1/2), from mouse, 
monoclonal (Cell Signaling Technology, Cambridge, UK) 
Anti-phospho-S6 ribosomal protein (anti-phospho S6), from rabbit, polyclonal (Cell 
Signaling Technology, Cambridge, UK) 
Anti-Signal transducer and activator of transcription 3 (anti-Stat3), from rabbit, polyclonal 
(Santa Cruz Biotech, Dallas, TX, USA) 
Anti-TAO protein kinase 1 (anti-Taok1), from rabbit, polyclonal (Abcam, Cambridge, UK) 
Anti-βTubulin (anti-Tubulin), from mouse, monoclonal (Sigma Aldrich, Taufkirchen, 
Germany) 




Anti-rabbit Alexa Fluor 488, from goat (Dianova, Hamburg, Germany) 
Anti-rabbit biotinylated, from goat (Dianova, Hamburg, Germany) 
Anti-rat biotinylated, from goat (Dianova, Hamburg, Germany) 
Anti-rabbit Cy3, from goat (Dianova, Hamburg, Germany) 
Anti-rabbit Dy Light 488, from goat (Dianova, Hamburg, Germany) 
Anti-mouse horse radish peroxidase (HRP) conjugated, from goat (Cell Signaling 
Technology, Cambridge, UK) 
Anti-rabbit HRP conjugated, from goat (Cell Signaling Technology, Cambridge, UK) 





96 well micro test plate   Sarstedt (Nümbrecht, Germany) 
6-, 12- and 24-well cell culture plates  Sarstedt (Nümbrecht, Germany) 
Bead mill homogenizer Precellys 24  Peqlab (Erlangen, Germany) 
Bioanalyzer 2100    Agilent (Santa Clara, CA, USA) 
Brain matrix mouse    World Precision Instruments (Berlin, Germany) 
Cage incubator    Okolab (Pozzuoli, Italy) 
Camera Legria HFM36   Canon (Krefeld, Germany) 
Ceramin beads 1.4 mm   Peqlab (Erlangen, Germany) 
CFX96 Touch Real-Time PCR Detection System BIO-RAD (Munich, Germany) 
Coulochem II electrochemical detector ESA (Bedfort, CA, USA) 
Cover slides 24 x 60 mm   Menzel (Braunschweig, Germany) 
Cover slides diameter 12 mm  Menzel (Braunschweig, Germany) 
Cryostat CM 3050S    Leica Microsystems (Mannheim, Germany) 
Cryomatrix     Thermo Scientific (Waltham, CA, USA) 
Curix 60 Developer    Agfa (Cologne, Germany) 
Cyclone 25 PCR thermocycler  Peqlab (Erlangen, Germany) 
Electrophoresis power supply  GE Healthcare (Chalfton St. Gilles, UK) 
Gilson pipettes    Gilson (Villiers de belle, France) 
Glass capillaries    World Precision Instruments (Berlin, Germany) 
Guard cell     ESA (Bedfort, CA, USA) 
IVC animal cages    Tecniplast (Hohenpeißenberg, Germany) 
Micro-centrifuge 5415R   Eppendorf (Hamburg, Germany) 
Micro Injector Nanoliter 2000 Pump Head World Precision Instruments (Berlin, Germany) 
Mini drill with 0.8 mm drill head  Dremel (Leinfelden-Echterdingen, Germany) 
Mini-PROTEAN Tetra-Cell system  BIO-RAD (Munich, Germany) 
Mouse jaw holder with ear bars  World Precision Instruments (Berlin, Germany) 
Multipipette puller    World Precision Instruments (Berlin, Germany) 
NanoDrop 1000    Thermo Scientific (Waltham, CA, USA) 
Peristaltic perfusion pump   Idex (Wertheim, Germany) 
PVDC transfer membrane   Applichem (Darmstadt, Germany) 
2. Materials and Methods 
36 
 
Spacer plates / short plates   BIO-RAD (Munich, Germany) 
Spectra / Por7 MWCO 1000 membranes Carl Roth (Karlsruhe, Germany) 
Stereotactic frame    David Kopf Instruments (Tujunga, CA, USA) 
SuperFrost Plus Microscope Slides  Menzel (Braunschweig, Germany) 
SYS Micro4 controller    World Precision Instruments (Berlin, Germany) 
Whatman blotting paper   GE Healthcare (Chalfton St. Gilles, UK) 
 
 
 2.1.6 Software 
 
AxioVision 4.6 (Carl Zeiss Microimaging) 
CFX Manager Software (BIO-RAD) 
CorelDRAW X6 (Corel Corporation) 
Cromeleon Chromatography Data System (Dionex by Thermo Fisher Scientific GmbH) 
ImageJ 1.47v (N.I.H.) 
KyPlot 2.0 (KyensLab Incorporated) 
Observer XT (Ethovision) 
R 3.1.3 (R-project) 
Sigma Plot 10.0 (Systat Software GmbH) 




2.2.1 Animal surgery, injections and tissue processing 
2.2.1.1 Animals 
 For preparation of primary midbrain neuron cultures female C57Bl6/J mice 
(Charles River or central animal facility, University Medicine Göttingen) were used as 
donor animals for embryonic day (E) 12.5 embryos. 
 All animals used for in vivo experiments were 8-10 weeks old male C57Bl6/J mice 
(Charles River) that were housed in groups of 5 animals in individually ventilated cages 
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(IVC; 365 x 207 x 140 mm). Animals were housed under a 12 hours light dark/ cycle with 
food and water ad libitum. Three days prior to surgeries mice received metamizol (1.5 
mg/ ml) in drinking water to ensure optimal analgesic conditions. All experiments were 
performed in accordance to the national German animal protection law under the grant 
no. 13/1118 approved by the local authorities.  
 
 
2.2.1.2 Stereotactic injection of 6-OHDA 
 To prepare the micro injector a self-pulled glass capillary was filled with mineral oil 
and connected to the micro injector. Withdrawal of substances was performed under 
control of a SYS-Micro4 Controller. An air bubble of 500 nl was withdrawn in order to 
separate the mineral oil from the substance that should be injected. 6-Hydroxydopamine 
solution (6-OHDA) was freshly prepared by dissolving the substance in 0.2 % L-ascorbic 
acid (LAA) in phosphate-buffered saline (PBS) at a concentration of 2 µg/ µl and 
withdrawn into the capillary. 
 Animals were anesthetized with a mixture of ketamine (150 mg/kg body weight) 
and xylazine (10 mg/kg body weight) in Sterofundin infusion solution. To control 
anesthesia toe pinch and eyelid-closure reflexes were checked. The mouse was placed in 
a stereotactic frame and fixed by ear bars and jaw holder, the eyes were protected with 
Bepanthen eye salve (figure 2.2/1 a). The scalp was desinfected and a longitudinal cut 
along the midline was executed with a scalpel. The skin and connective tissue were 
carefully held at the sites by small hooks, so that bregma and lambda were exposed 
(figure 2.2/1 a). The coordinates for injection in the right striatum relative to bregma 
were: Anterior – posterior (AP) +0.04 cm; medio – lateral (ML) -0.18 cm; dorso – ventral 
(DV) -0.35 cm (Alvarez-Fischer et al. 2008; Paxinos & Franklin 2004). The bregma and 
lambda coordinates were measured and drilling coordinates were set. A minimal 
trepanation of the skull was performed using an electrical mini drill equipped with a 0.8 
mm drill head. The capillary was brought to the right position and depth and 2 µl 6-OHDA 
solution were injected at a flow rate of 0.5 µl per minute. After the injection the capillary 
was left in place for 4 minutes in order to prevent reflux via the injection tract. After the 
needle was removed the scalp was closed using surgical tissue adhesive (Dermabond). 
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The animal received a subcutaneous injection of 1 ml 37°C warm Sterofundin and was 
placed on a warming pad until awakening. In the subsequent days the animal was treated 
with metamizol, monitored closely and received mashed food.   
 
 
Figure 2.2/1: Illustration of the injection sites for stereotactic injection. a shows the animal fixed with ear 
bars (1) and jaw holder (2), the skin is opened and Bregma (B) and Lambda (L) are exposed. b and c illustrate 
the injection coordinates in the putaminal striatum (yellow area in b) for the 6-OHDA injection and the 
midbrain with the SNpc (yellow area in c) for the oligo injection (adapted from Paxinos & Franklin, 2001).   
 
 
2.2.1.3 Stereotactic injection of synthetic miRNA mimics or scrambled negative 
control siRNA 
 For stereotactic injections of synthetic miRNA mimics for mmu-miR-182-5p and 
mmu-miR-183-5p or negative control scrambled siRNA (NC siRNA; facultative with 
fluorescent label) (Qiagen) in the right substantia nigra (SN) of mice, HPLC-purified miRNA 
mimics or siRNA ready for in vivo applications were employed. To prepare oligos for 
injection all handling was done under aseptic conditions. Sterile cold PBS was added to 
the oligo tube to a final concentration of 125 µM (250 µM or 50 µM respectively for 
fluorescently labelled NC siRNA), mixed and incubated at RT for 3 min. The solution was 
portioned in suitable aliquots; snap frozen and stored at -80°C for not longer than a 
month. After thawing, oligo solutions were not re-frozen. Immediately before injections 
the oligos were thawed on ice. In order to form transfection complexes 1.35 µl HiPerfect 
transfection reagent per 10 µl oligo were added, mixed intensively, left at RT for 5 min 
and placed on ice. Directly before filling of the capillary, the oligo – HiPerfect mixture was 
warmed in the hand for 1 min and mixed.  
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 The animal was anesthetized and prepared for surgery as described above. After 
fixation of the head and opening of the scalp the coordinates for an injection in the right 
SN relative to bregma were set (AP: - 0.29 cm; ML: - 0.12 cm; DV: - 0.45 cm (Alvarez-
Fischer et al. 2008; Paxinos & Franklin 2004)). 2 µl oligo – HiPerfect mixture were injected 
at an injection rate of 150 nl per minute. The needle was left in place for 4 min after the 
injection to prevent reflux via the trajectory tract. After removing the capillary, the 
animals were treated as mentioned above. 
 
  
2.2.1.4 A subchronic mouse model of PD - Intraperitoneal injections of 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridin (MPTP)  
In order to investigate the neuroprotective and –regenerative effect of increased 
mmu-miR-182-5p and mmu-miR-183-5p levels, the subchronic mouse model of PD was 
applied. Therefore the animals received intraperitoneal injections of 30 mg/ kg body 
weight MPTP on 5 consecutive days beginning 48 h after injection of the respective oligo 
into the SN. For injections MPTP was dissolved in 0.9 % saline, control animals received 
just saline. Handling of MPTP and MPTP injected mice was performed according to 
appropriate guidelines (Przedborski et al. 2001).  
 
 
2.2.1.5 Behavioral tests 
 In order to assess motor behavior of animals after miRNA injections and MPTP 
treatment, mice had to perform the open field test and the cylinder rearing test 13 days 




2.2.1.5.1 Open field test 
 General motor behavior was analyzed using the open field test. Animals were 
placed in the center of an 80 cm x 80 cm open arena with side walls of 20 cm height for 5 
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min. A camera was placed above the arena and recorded all behavior of the animal. 
Videos were analyzed using The Observer XT software and total distance moved, the time 
spent moving, and the relative time spent in the center of the arena were quantified. By 
this, the a i als  o e e t as auto ati all  t a ked a d the a e a as fielded i  to a 
68 cm x 68 cm sized center area surrounded by a 12 cm broad margin area. 
 
  
2.2.1.5.2 Cylinder rearing test 
In order to analyze a potential effect of miRNA mimic injection, forelimb use 
during natural exploratory behavior was assessed using the cylinder rearing test (Schallert 
et al. 2000; Tönges et al. 2012). To this, each animal was placed in a transparent 25 cm 
high Plexiglas cylinder that measured 11.5 cm in diameter. Behind the cylinder a 90° 
angulated mirror was placed to allow observation of forelimb movements when the 
animal turns away from the observer. All behavior was recorded by a camera. The test 
duration was 5 minutes, beginning with the placement of the animal. During a full rear 
the first contact of a forelimb was recorded as an independent wall placement event for 
the respective limb. If the animal used a single paw to assist a rear the rating criteria were 
ight  a d left  a o di g to the fo eli  used. If the a i al assisted a ea  ith oth 
pa s, the e e t as ated as oth  a d if the ea  as pe fo ed ithout fo eli  use 
it as ated as f ee . ‘ati g of the e o ded eha io  as do e a uall . 
 
 
2.2.1.6 Animal euthanasia and tissue processing  
2.2.1.6.1 Transcardial perfusion of mice 
 For histological analysis of tissues, a rapid and thorough fixation of specimens is 
essential. For preservation of morphological structures and inhibition of biochemical 
processes that lead to degradation of cells transcardial perfusion with 4 % 
paraformaldehyde (PFA) in PBS is the common method. To this, animals were deeply 
anesthetized by CO2 administration. After anesthesia the abdominal skin was opened by a 
longitudinal cut and removed. Then the thoracic diaphragm and the ribs were bilaterally 
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cut to open the thorax. The heart was exposed, the pericardium removed and a perfusion 
cannula connected to a perfusion pump filled with ice-cold sterile PBS was inserted into 
the left ventricle of the still beating heart. Shortly after inserting the cannula the right 
auricle was opened by a small cut in order to allow the blood to void and enable the PBS 
to clean the whole cardiovascular system from blood, including the brain. Perfusion was 
performed with PBS for 5 min, followed by a 5 min perfusion with ice-cold 4 % PFA in PBS 
to fixate the tissue. Optimal perfusion was indicated by a twitching of the tail and a color 
change of the liver from red to yellow-white. After perfusion, the brain was removed and 
transferred into 4 % PFA in PBS for two days at 4°C for post-fixation. Afterwards, brains 
were transferred into 30 % sucrose-PBS solution for another two days to dehydrate the 
tissue. Dehydrated brains were stored at -80°C until cryosectioning. 
 
 
2.2.1.6.2 Cryosectioning of mouse brains 
 PFA-fixed dehydrated still frozen brains were embedded in Cryomatrix coronally 
cryosectioned into 30 µm thick sections using a Leica Cryostat CM3050S. Precisely the 
area of the striatum (Bregma AP + 1.18 to – 0.70 mm) and the midbrain (Bregma AP – 
2.18 to – 4.04 mm) were cut and sections were stored free floating in 0.1 % sodium azide 
in PBS at 4°C until immunohistochemistry. 
 
 
2.2.1.6.3 Preparation of the striatum and the substantia nigra from fresh brain 
tissue 
 For neurochemical analysis of dopamine and its metabolites in the striatum or 
isolation of RNA or proteins from the SN the brain tissue should be native and not fixed. 
Here, animals were sacrificed by cervical dislocation. After decapitation, the brain was 
removed and the areas of interest were isolated, snap frozen in liquid nitrogen and stored 
at –80°C till further processing. 
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2.2.2 Cell culture 
 To investigate miRNA expression during development of primary neurons, the 
effect of glial cell-line derived neurotrophic factor (GDNF) on miRNA expression levels, as 
well as the effect of manipulation of miRNA expression on neurite growth, 
neuroprotection, neurite regeneration and protein expression, murine primary midbrain 
neuron cultures were employed. Donor animals were provided by the central animal 
facility of the UMG or Charles River. 
 
 
2.2.2.1 Preparation of cover slips and coating of culture plates 
 For immunocytochemistry, primary midbrain neurons were seeded onto glass 
coverslips (diameter: 12 mm). Those were cleaned and degreased by shaking in acetone 
for 5 min, followed by 3 washing steps in pure ethanol for 30 min each. Subsequently the 
coverslips are rinsed 3 times in double distilled water. After drying the degreased 
coverslips were baked at 180°C for 4 h. 
Cell culture plates and coverslips were coated with poly-l-ornithine (PLO) and 
laminin under sterile conditions. To this, poly-l-ornithine in 0.15 M sodium borate buffer 
(1 mg/ml) was diluted to a final concentration of 0.1 mg/ml in sterile double-distilled 
water and an adequate amount, depending on the size of the culture plate, pipetted into 
the wells of the culture plate, and incubated for at least 4 h at RT. Afterwards, the cell 
culture plates were rinsed 3 times with sterile water. Laminin (1 µg/ml) in Neurobasal 
culture medium without supplements was transferred to the wells and incubated for at 
least 1 h in an incubator at 37°C with 5 % CO2 and 95 % humidity. Subsequently, laminin 
solution was removed and wells were washed 3 times with Neurobasal culture medium 
without supplements.  
 
  
2.2.2.2 Primary midbrain neuron culture 
Primary midbrain neuron cultures were prepared under serum free conditions 
from embryonic day 12.5 (E12.5) C57Bl6/J mice. Pregnant female mice were sacrificed 
with carbon dioxide (CO2) and the uteri were transferred into cold Ha k s ala ed salt 
2. Materials and Methods 
43 
 
solution (HBSS). The following steps were all performed under aseptic conditions. The 
embryos were removed and placed into ice cold HBSS. The ventral mesencephalon was 
isolated and the meninges removed. Midbrains were collected in ice cold HBSS and 
centrifuged at 800 rpm for 1 min. The pellet was then incubated in 1ml 0.25 % trypsin for 
12 min at 37°C. After addition of 50 µl DNAse (5 mg/ml) the tissue was centrifuged for 2 
min at 800 rpm. Afterwards the supernatant was removed and 1 ml fetal calf serum (FCS) 
was added and the tissue was dissociated by gentle trituration with a fire polished 
Pasteur pipette. The cell suspension was centrifuged for 4 min at 800 rpm and the 
resulting pellet was resuspended in culture medium. Neurons were counted with a 
Neubauer counting chamber and were seeded into poly-l-ornithine and laminine coated 
cell culture plates or glass coverslips. 
 
 
2.2.2.3 Transfection of primary midbrain neurons 
 In order to achieve elevated miRNA levels, primary midbrain neurons were 
transfected with a synthetic miRNA mimic or a scrambled negative control siRNA on day 
in vitro (DIV) 1. We employed synthetic miRNA mimics, which mimic the mature 
endogenous miRNA after transfection for mmu-miR-182-5p and mmu-miR-183-5p (see 
sequences below). As a control we used a validated scrambled negative control siRNA (NC 
siRNA; AllStars Negative Control siRNA). This scrambled siRNA has no homology to any 
known mammalian gene, for its validation several cell based assays as well as Affymetrix 
Gene Chip arrays were employed and resulted in minimal nonspecific effects on gene 
expression and phenotype. To ensure that observed effects are not the result of 
increased miRNA levels per se we used a mimic for mmu-miR-1a-3p as an additional 
control. This miRNA has been shown to have no effect on neurite growth before (Vo et al. 
2005). To compare the effect of elevated miRNA levels with the effect of GDNF 
treatment, an experimental group was included were cells were transfected with NC 
siRNA and treated with GDNF at a final concentration of 10 ng/ml. In order to form 
transfection complexes, miRNA mimics or NC siRNA were diluted in culture medium and 
HiPerfect transfection reagent was added (2 µl per 100 µl transfection complexes). The 
amount of the different components was dependent on cell density and the size of the 
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cell culture plate (table 2.2/1). The solution was mixed extensively for 1 min and 
incubated for 10 min at RT to allow the formation of transfection complexes. For 
optimization of transfection, cells were transfected with miRNA mimics or NC siRNA at a 
final concentration of 100 pM, 5 nM and 50 nM. All experiments concerning the effect of 
miRNA mimics were conducted at a final oligo concentration of 5 nM. 
After incubation, the mixture was gently added droplet-wise to the medium of the 
cultured midbrain neurons. Three hours after addition of the transfection complexes, half 
of the culture medium was removed and the same amount fresh culture medium was 
added. 
 
Table 2.2/1: Cell numbers in different plate formats 
Plate format Cell number Cell density per cm
2
 Final amount of medium 
6 well 3 x 10
6
 3 x 10
5
 2400 µl 
12 well 1.5 x 10
6
 3 x 10
5
 1200 µl 
24 well 650.000 3 x 10
5






To investigate the potential neuroprotective effect of increased mmu-miR-182 and 





 is the active metabolite of the dopaminergic neurotoxin MPTP. In vivo, the lipophilic 
MPTP can cross the blood-brain-barrier and enter the brain tissues, where it is converted 




 has a strong 
selective toxicity for dopaminergic neurons, because its uptake into the cell is mediated 
by the dopamine transporter (DAT), which is present on this neuronal subtype. After 
entering the cell, MPP
+
 accumulates in the mitochondria, where it inhibits NADH 
dehydrogenase (complex I) leading to a blockage of mitochondrial respiration, resulting in 
the formation of reactive oxygen species (ROS) and consequently to oxidative stress 
(Kopin 1992). 24 hours post-transfection (DIV2), MPP
+
 was carefully added to the culture 
medium at a final concentration of 2µM. For control groups the same amount of PBS was 
added to the culture medium. After 24 h (DIV3) the complete culture medium was 
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removed and fresh culture medium without MPP
+ 
was added. Cells were cultured for 
another 24 h (DIV4), then rinsed with PBS and fixed with 4 % PFA in PBS for 10 min at RT. 
Afterwards coverslips were rinsed with PBS and stored in PBS until staining. 
 
 
2.2.2.5 Scratch lesion 
 For assessment of potential effects of elevated miRNA levels on neurite 
regeneration in dopaminergic neurons, a mechanical scratch lesion was applied to 
primary midbrain neuron cultures. One day post-transfection (DIV2) a 200 µl pipette tip 
was quickly scratched 2 times across each coverslip, resulting in a transection of neurites 
along the scratch border. Two days later (DIV4) coverslips were rinsed with PBS, fixed and 
stored until staining as mentioned above. 
 
 
2.2.3 Molecular biology and biochemical techniques 
2.2.3.1 Isolation of total RNA from cell cultures and brain tissue 
 For Isolation of total RNA from cell cultures and brain tissues TRI-reagent was 
used. TRI-reagent is a combination of phenol and guanidine isothiocyanate that allows 
simultaneous isolation of RNA, DNA and proteins from one sample (Simms et al. 1993). 
Unless otherwise noted all procedures were performed at RT. For isolation of total RNA 
from cell cultures 1 ml TRI-reagent per 10 cm
2
 cell culture surface was employed. After 
removal of culture medium, cells were rinsed with cold PBS and 500 µl TRI-reagent was 
given to each well and allowed to incubate for 3 min. Afterwards the TRI-reagent-cell-
lysate was transferred to an Eppendorf cup, another 500 µl TRI-reagent were added and 
the suspension was homogenized by pipetting repeatedly up and down. The suspension 
was allowed to stand for another 3 min to ensure a complete lysis of cell material. 
Subsequently, 100 µl 1-Bromo-3-chlorpropane were added and the mixture was 
extensively mixed by shaking for 15 sec and incubated for 3 min at RT. To allow 
separation of the organic-, aqueous- and interphase the mixture was centrifuged for 15 
min at 12.000 x g at 4°C. The aqueous phase containing the RNA was transferred to a new 
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tube whereas the organic- and interphase were stored at -80°C for eventual protein 
isolation. 500 µl isopropanol and 15-20 µg GlycoBlue were added to the aqueous phase, 
mixed vigorously and stored at -20°C for at least 90 min or overnight (ON) to allow RNA 
precipitation. This was followed by centrifugation for 25-30 min at 12.000 x g at 4°C. 
Afterwards the supernatant was carefully discarded and the RNA pellet was washed twice 
with 75 % ethanol followed by 5 min centrifugation at 12.000 x g at 4°C and dissolved in 
20-30 µl DEPC-H2O.  
For isolation of total RNA from brain tissue, frozen tissue was homogenized in 500 
µl TRI-reagent with the help of a sterile micropistil. After homogenization another 500 µl 
TRI-reagent were added and the mixture was allowed to incubate for 5 min. All following 
steps were similar to those for total RNA isolation from cell cultures. 
 
 
2.2.3.2 Preparation of protein lysates from cell cultures 
 To prepare protein lysates for Western blotting culture medium was removed and 
cells were placed on ice and rinsed with cold 5 % glucose solution. After removal of 
glucose solution ice-cold RIPA buffer was added to the cells and incubated for 10 min on 
ice to allow cell lysis. After incubation cells were scraped off the well using a silicon cell 
scraper and transferred into a tube. Lysates were sonicated on ice and protein 
concentration was measured using a BCA assay. After determination of protein 
concentrations Laemmli buffer containing 10 % dithiothreitol (DTT) was added, followed 
by heating for 10 min at 95°C.  
 
 
2.2.3.3 Isolation of proteins from brain tissue 
 When brain tissue was used for simultaneous RNA and protein extraction, TRI-
reagent was used (see 2.2.3.1 for RNA protocol). For isolation of proteins from the 
organic phase after phase separation the remaining aqueous phase overlaying the 
interphase was carefully removed. The DNA from the interphase and organic phase was 
precipitated by addition of 300 µl 100% ethanol. The sample was mixed by inversion and 
incubated for 5 min at RT. Subsequently it was centrifuged for 5 min at 2000 x g at 4°C. 
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The supernatant was transferred into a Spectrapor MW 1000 membrane, the DNA pellet 
was discarded. Samples were dialyzed against 0.1% SDS at 4°C overnight. After dialysis 
the white globular mass containing the protein was transferred into a new tube, resolved 
in 4 M Urea in 0.5 % SDS and stored at -20°C until addition of Laemmli buffer and Western 
blotting. 
Protein lysates from brain tissue without prior RNA isolation were prepared when 
no RNA was needed. To this, the frozen tissue was homogenized manually in cold RIPA 
buffer using a micropistil, incubated for 10 min on ice, followed by sonication.  
Protein concentrations were measured as described below, Laemmli buffer 
containing 10 % DTT was added and samples were boiled at 95°C for 10 min. Samples 
were stored at -20°C until blotting.  
 
 
2.2.3.4 Determination of nucleic acid concentrations 
 RNA concentration and purity were analyzed using a NanoDrop 1000 
spectrophotometer by measuring the absorption at 260 nm (A260) according to 
a ufa tu e s i st u tio s to dete i e ‘NA o e t atio  a d analyzing the 260/280 
ratio and the 230/280 ratio to check the RNA purity. Before RNA was used for preparation 
of small RNA libraries for sequencing, the RNA integrity was verified with Agilent RNA 
6000 Nano Chip in the Agilent 2100 Bioanalyzer electrophoresis system. This system 
calculates the RNA integrity number (RIN) for a given sample. The RIN is an algorithm that 
assigns integrity values to RNA measurements. The RIN ranges from 1 to 10, whereas 1 
means the RNA is maximal degraded and 10 means that the RNA is intact. For preparation 
of small RNA libraries only samples with a RIN > 9 were used. 
 
 
2.2.3.5 Determination of Protein concentrations 
 Protein concentrations were measured employing the Pierce BCA protein assay kit 
a o di g to a ufa tu e s i structions. After 30 min incubation at 37°C absorption was 
measured at 562 nm (A562) using the Rainbow Spectra Tecan. 
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2.2.3.6 Reverse transcription  
 Synthesis of complementary DNA (cDNA) from total RNA isolates was performed 
using the miScript II RT kit from Qiagen. This kit allows the reverse transcription of total 
RNA including miRNAs. Mature miRNAs are polyadenylated by poly(A) polymerase and 
converted into cDNA by a reverse transcriptase with oligo-dt priming. For reverse 
transcription reactions 500 ng total RNA were used. A reverse transcription master mix 
including 10 x HiSpec Buffer, 5 x Nucleics Mix and miScript Reverse Transcriptase Mix was 
prepared and added to 500 ng total RNA in 6 µl PCR-grade water. All steps were 
performed on ice. The total reaction volume was 10 µl per reaction. The mixture was 
incubated in a Cyclone 25 PCR thermocycler for 60 min at 37°C followed by a 5 min 
incubation step at 95°C to inactivate the miScript Reverse Transcriptase Mix. Resulting 




2.2.3.7 Quantitative real time PCR (qRT-PCR) 
 In order to determine miRNA expression levels quantitative real time PCR was 
conducted in the CFX96 Touch Real-Time PCR Detection System. For miRNA expression 
analyses, optimized mature miRNA-specific primers (Qiagen, Hilden, Germany) and cDNA 
at a dilution of 1:10 were used (table 2.2/2). miRNA expression was normalized to the 
endogenous control RNU6. Quantitative real time PCR was carried out using the miScript 
“YB‘ G ee  PC‘ kit a o di g to a ufa tu e s i st u tio s ith li g o ditio s as 
described in table 2.2/3. A dissociation (melting) curve analysis was included in every run. 
Relative expression levels were calculated using the ΔΔCt ethod. 
Table 2.2/2: miRNA specific primers used for qPCR 
Small RNA amplified Primer 
mmu-miR-182-5p Mm_miR-182_2 miScript Primer Assay 
mmu-miR-183-5p Mm_miR-183_1 miScript Primer Assay 
RNU6 Hs_RNU6-2_11 miScript Primer Assay 




Table 2.2/3: qPCR cycling conditions  
Step Time Temperature 
Initial activation 15 min 95 °C 













2.2.3.8 Small RNA sequencing and analysis of sequencing data 
 Small RNA sequencing was performed in the lab of Prof. Dr. André Fischer (DZNE, 
Göttingen) on an Illumina HiSeq 2000 system. Small RNA libraries were prepared from 1 
µg total RNA using the Illumina TruSeq Small RNA Sample Preparation kit. Primary 
analysis of sequencing data was performed by the groups of Prof. Dr. Stefan Bonn and 
Prof. Dr. André Fischer (DZNE, Göttingen). 
For processing of sequencing data a customized software pipeline was used. For 
quality check and demultiplexing the CASAVA 1.8.2 software (Illumina) was used. For 
alignment the basic local alignment search tool (BLAST) was used. Reads were aligned to 
MiRBase version 19 with a cutoff score of p < 5 x 10
-7
 and a single mismatch allowed. 
In order to compare the miRNA expression levels between samples, a differential 
expression analysis was performed using R and the DESeq package. Heatmaps were 
created using the ggplot2 package. 
 Computational miRNA target prediction analysis was performed using 
TargetScanMouse 6.2 (Lewis et al. 2005). For functional annotation of predicted miRNA 
targets the data mining environment provided by the DAVID platform (Huang et al. 2009) 
was used. The functional annotation module was applied for gene ontology terms using 
an EASE score of 0.1 and a minimum number of 2 counts. For checking enrichment of 
miRNA targets in specific Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways 
DIANA mirPath was employed (Papadopoulos et al. 2009). In order to search for already 
experimentally validated target genes, the miRTarBase database (Hsu et al. 2014) was 
used. 
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2.2.3.9 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
 In order to separate proteins according to their molecular weight SDS-PAGE was 
performed. During SDS-PAGE proteins are separated by gel electrophoresis in presence of 
the denaturating detergent SDS, which allows a separation by size that excludes the 
effects of electric charge and conformation. In order to collect proteins with different 
sizes to allow movement through the gel at the same rate, a 5 % stacking phase 
polyacrylamide gel with a pH of 6.8 was polymerized over the resolving gel. Depending on 
the size of the protein of interest, resolving phase gels with a polyacrylamide content 
between 8 and 15 % and a pH of 8.8 were used. For electrophoresis the BIO-RAD Mini-
PROTEAN Tetra-Cell system was utilized. Gels were placed into the electrophoresis 
chamber and filled with electrophoresis buffer. Depending on the protein that should be 
analyzed, 15 – 20 µg protein were loaded into the gel pockets. Initially, electrophoresis 
was carried out at 50 V for 20 min to allow samples to enter the stacking gel. This was 
followed by electrophoresis at 100 V till the smallest proteins were reaching the end of 
the resolving gel. As a marker for molecular weight of the proteins BIO-RAD Precision Plus 
Dual Color Standard was used.                                        
 
                                                                                                                                                                                               
2.2.3.10 Immunoblotting 
 After electrophoresis the proteins were transferred to a PVDC membrane using 
the BIO-RAD Mini-PROTEAN Tetra Cell blotting system. To this, the membrane was 
activated in methanol for 30 sec and placed next to the gel between two sheets of 
Whatman filter paper and sponge pads that were soaked in transfer buffer. The blotting 
cassette was inserted in the blotting system that was filled with ice cold transfer buffer. 
Protein transfer was performed by application of a current at constant voltage of 25 V 
overnight at 4°C. After transfer, the membrane was incubated in blocking solution 
containing 5 % non-fat milk in TBS-T for 60 – 90 min at RT. Afterwards the membrane was 
rinsed 3 times for 10 min each and incubated with the primary antibody in TBS-T 
containing 2% BSA over night at 4°C. Subsequently, the membrane was rinsed 3 times in 
TBS-T for 10 min each and the secondary, horseradish peroxidase (HRP) coupled, goat 
anti-rabbit or goat anti-mouse antibody diluted in 1 % non-fat milk in TBS-T was applied 
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for 1 h at RT. The membrane was then washed 4 times for 10 min in TBS-T. For detection 
of protein bands, the membrane was incubated with a reagent for enhanced 
chemiluminescence (ECL) and the signal was produced by the HRP coupled to the 
secondary antibody. ECL-1 and ECL-2 were mixed in equal parts for at least 1 min directly 
before incubation on the membrane. The membrane was then exposed to 
autoradiography films for different times between 1 and 120 sec using an 
autoradiography cassette and developed in a Curix 60 Developer. 
 
 
2.2.3.11 Neurochemical analysis of dopamine and dopamine metabolites in the 
murine striatum 
 In order to investigate the functionality of dopaminergic terminals in the striatum, 
the content of dopamine (DA) and its metabolites homovanillic acid (HVA) and 3,4-
dihydroxyphenylacetic acid (DOPAC) were analyzed using high performance liquid 
chromatography (HPLC). To this, animals were sacrificed by cervical dislocation to exclude 
potential effects of anesthetic additives and allow immediate processing of the brain 
tissue. For isolation of the striatum, the brain was placed on an ice-cold surface, the two 
hemispheres were separated along the midline, and the right striatum was dissected. The 
tissue was transferred into 2 ml cryovials containing 0.6 – 0.8 g of 1.4 mm Precellys 
ceramic beads and snap frozen in liquid nitrogen. 50 µl 0.1 M HClO4 per mg striatal tissue 
were added to prevent enzymatic action and samples were homogenized using a bead 
mill homogenizer. Afterwards vials were centrifuged at 12.000 rounds per minute (rpm) 
at 4°C for 5 min, the supernatant was transferred into a new tube and centrifuged at 
13.000 rpm at 4°C for 10 min. For analysis of DA, HVA and DOPAC amounts, 50 µl 
supernatant were transferred to HPLC vials and analyzed by HPLC. 
 The HPLC was performed in a system composed of a Guard cell, that was kept at 
600 mV to oxidize impurities in the eluent, a C18 reverse-phase HR-80 catecholamine 
column and an ESA Coulochem II electrochemical detector equipped with a 5011A 
analytic model detector (E1 = 50 mV, E2 = 400 mV). For sample loading the HPLC 
autosampler was cooled down to 6°C and samples were loaded. The autosampler 
automatically injected 20 µl of each sample to the column. As mobile phase filtered and 
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degased HPLC buffer running with a constant flow rate of 0.4 ml per minute was used. 
During reverse-phase HPLC with ionizable substances it is important that the buffer is 
creating a stable pH to avoid changes in retention time and consequently in the 
chromatogram. Dopamine, HVA and DOPAC standards were run every 15 samples to 
allow an absolute measurement of the catecholamines in the samples. In order to 
prepare the standards, 10 µM stock solutions were diluted with 0.1 M HClO4 to final 
concentrations of 0.15, 0.3 and 1.5 µM. Data was collected and processed by a 
Chromeleon Chromatography Data System. Analysis was performed by integrating the 
area under the specific peak curve and given in ng per mg wet tissue. 
 
 
2.2.3.12 Immunocytochemistry (ICC) 
 In order to identify dopaminergic neurons in the primary midbrain neuron culture 
an immunolabeling against the dopaminergic marker tyrosine hydroxylase (TH) was 
performed. After fixation the coverslips were incubated for 10 minutes in 100 mM 
ammoniumchloride in PBS to quench autofluorescence. Afterwards the coverslips were 
washed 3 times with PBS, followed by a permeabilization and blocking step for 10 min in 
Dako Antibody Diluent. After blocking, the coverslips were incubated with the primary 
polyclonal rabbit anti-tyrosine hydroxylase antibody (dilution: 1:1000 in Dako Antibody 
Diluent) for 90 minutes at RT. Subsequently, the coverslips were rinsed 3 times with PBS 
for 5 minutes each. Then the secondary Cy3-labeled goat anti-rabbit antibody (dilution: 
1:500 in Dako Antibody Diluent) was applied and incubated for 30 min at 37°C. After 
removing the antibody solution cells were washed 3 times in PBS and nuclear staining was 
performed using DAPI-solution for 5 minutes. After removing the DAPI-solution, 
coverslips were rinsed 3 times in PBS and mounted with Mowiol on microscope slides. 
 
 
2.2.3.13 Immunohistochemistry (IHC) 
 In order to demonstrate transfection of dopaminergic neurons in the substantia 
nigra (SN) of mice with fluorescent NC siRNA 30 µm thick coronal free floating sections of 
the midbrain were stained against TH. After washing the sections 3 times in PBS-T, 
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unspecific antibody binding was blocked with 10 % normal goat serum (NGS) in PBS-T for 
30 min at RT. Afterwards sections were incubated with a primary rabbit anti-TH antibody 
diluted 1:1000 in 1 % NGS in PBS-T for 24 h at 4°C in order to label dopaminergic neurons. 
After removing the antibody solution sections were rinsed 3 times in PBS-T and incubated 
with a secondary goat anti-rabbit AlexaFluor 488 or DyLight 488 labeled antibody diluted 
1:250 in PBS-T for 2 h at RT. Subsequently, the sections were rinsed 3 times with PBS-T 
and incubated with DAPI solution for 1 min for nuclear staining. After nuclear staining the 
sections were washed 3 times in PBS and collected on SuperFrost Plus microscope slides. 
After drying the sections at RT they were mounted with Mowiol. 
 To analyze the effect of the transfection reagent on microglial invasion of the 
substantia nigra after stereotactical injection of small RNAs, immunolabeling against the 
microglial marker Iba1 was performed using the same protocol as described above, but 
with a primary rabbit anti-Iba1 antibody diluted 1:500 in 1 % NGS in PBS-T. 
 In order to stereologically evaluate dopaminergic cell numbers in the SN, free 
floating sections were stained against TH followed by a Nissl staining. Sections were 
rinsed 3 times in TBS and endogenous peroxidases were quenched by incubation in 40 % 
methanol and 1 % H2O2 in TBS for 15 min. Afterwards sections were washed again in TBS 
and unspecific antibody binding  was blocked with 10 % NGS in TBS for 30 min at RT. Then 
the sections were incubated with a primary rabbit anti-TH antibody diluted 1:1000 in 1 % 
NGS in TBS for 24 h at 4°C. After removing the antibody solution the sections were 
washed 3 times in TBS, followed by incubation with a secondary biotinylated goat anti-
rabbit antibody diluted 1:200 in TBS at RT for 2 h and treatment with the VECTASTAIN 
Elite ABC Peroxidase Standard kit for 2 h at RT to enhance the signal. Afterwards sections 
were washed again 3 times for 5 min in TBS and the staining was visualized using the 
chromogen DAB (DAB Peroxidase Substrate kit) for 5 min. The reaction was stopped by 
application of distilled water and sections were collected on SuperFrost Plus microscope 
slides. Slides were allowed to dry at RT and subsequently a Nissl staining was performed. 
To this, sections were rehydrated in distilled water for 5 min and incubated in thionine 
acetate for 7 min, followed by a 2 min washing step in distilled water. Afterwards the 
tissue was dehydrated by incubation in ascending alcoholic solutions (70 %, 90 % and 95 
% ethanol) for 2 min each, and subsequent incubation in 100 % isopropanol for 5 min and 
xylene 3 times for 5 min each. The moist sections were mounted with DPX. 
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 For analyses of striatal dopaminergic fiber density free floating sections were 
stained according to the DAB protocol described above for dopamine transporter (DAT), 





2.2.4.1 Imaging and analysis of primary midbrain neuron cultures 
 For investigation of dopaminergic neurite length, neuronal survival and neurite 
regeneration primary midbrain cultures on glass coverslips immunolabeled against TH 
were analyzed. To this, coverslips were imaged with a Zeiss Axioplan microscope 
equipped with a 16-bit greyscale CCD camera using the 20x objective and AxioVision SE64 
4.9.1 Software with the MosaiX module. Per coverslip two 2.1 mm
2
 large areas were 
randomly imaged and analyzed. All images in one experiment were acquired with the 
same exposure time and for analyses the same color intensities were used. Images were 
analyzed using ImageJ 1.48 software. For analyses of dopaminergic neurite length and 
neurite regeneration the NeuronJ macro was applied and for counting of dopaminergic 
cell bodies in the MPP
+
 experiments the CellCounter tool was used. 
 
 
2.2.4.2 Stereological quantification of microglial invasion in the SN of mice 
 In order to investigate the effect of HiPerfect transfection reagent on microglial 
invasion after stereotactical injection of small RNAs in the murine SN the number of Iba1-
immunoreactive (IR) cells within a diameter of 330 µm around the injection side was 
assessed. To this, every 4
th
 section was analyzed stereologically using Stereo Investigator 
software on an Axioplan microscope equipped with a MBF Q-imagin camera. At 5x object 
magnification a circle with a diameter of 330 µm with the injection side as center point 
was outlined and Iba1-positive cells were counted at 40x objective magnification using 
the optical fractionator function of the Stereo Investigator software. Cells were counted 
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in frames sized 50 x 50 µm and the total number of Iba1-positive cells was extrapolated 
by the optical fractionator for the whole area of interest over all analyzed slides.  
 
 
2.2.4.3 Stereological quantification of dopaminergic neurons in the murine SN 
In order to analyze the number of dopaminergic (TH-positive) neurons and the total 
number of neurons (Nissl-positive cells) in the SN every 4
th
 DAB stained section over the 
whole SN was counted using Stereo Investigator software on an Axioplan microscope 
equipped with a MBF Q-imagin camera. At 2.5x objective magnification the SN was 
manually outlined and the Nissl-positive and TH-positive cells were counted at 40x 
objective magnification in counting frames sized 50 x 50 µm as described above for the 
whole unilateral SN per animal. The number of Nissl-positive cells was evaluated to 
exclude a mere downregulation of TH-expression and confirm a real loss of neurons. 
 
 
2.2.4.4 Measurement of the dopaminergic fiber density in mouse striata 
 To analyze the density of striatal dopaminergic fibers frontal sections between 
bregma +0.62 and -0.10 mm were stained against TH and DAT. All sections of one animal 
were imaged using an Axioplan microscope equipped with a 16-bit greyscale CCD camera 
using the 2.5 x objective and AxioVision SE64 4.9.1 Software with the MosaiX module. The 
mean grey value of the striatum and cortex were measured using ImageJ 1.48 with the 
freehand selection tool and further processing with background subtraction. Five sections 
per animal were analyzed and the mean TH-positive / DAT-positive signal was calculated 
in relation to the TH-positive signal / DAT-positive of the respective controls. 
 
 
2.2.5 Statistical analyses 
 For statistical analysis Kyplot software (Version 2.0, KyensLab Incorporated, Tokyo, 
Japan) and SigmaPlot software (Version 11, Systat Software GmbH, Erkrath, Germany) 
were used. Parametric statistical methods were applied, as considered valid for most 
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biological samples (Zar, J.H., Biostatistical Analysis, 4
th
 Edition. Prentice Hall, Upper Saddle 
River, NJ, US. 1999). For group comparisons, one- a  ANOVA ith Du et s post-hoc test 
was applied. The statistical tests and the number of experiments or animals used for 
analysis are indicated in the respective figure legends. Data are given as mean ± SEM. 







3.1 miRNAs in maturation and neurite outgrowth of primary midbrain neurons 
(PMN) – Providing tools for neuronal protection and regeneration? 
 In order to analyze differences in miRNA expression levels upon maturation and 
neurite outgrowth of primary midbrain neurons (PMN) a massive parallel sequencing of 
small non-coding RNAs was performed. It was assumed that the cellular mechanisms that 
drive maturation and neurite outgrowth during development are similar to those that 
might enhance neuroprotection and regeneration after neuronal lesion. Detailed 
knowledge and understanding about the changes in miRNA levels during development of 
PMNs could provide new therapeutic strategies for the treatment of neurodegenerative 
diseases like PD, where these neurons degenerate. In addition to that, the effect of the 




3.1.1 miRNA expression levels in developing PMNs – Major changes occur during 
early development 
For comparison of miRNA expression levels in developing PMNs total RNA was 
isolated at three different time points in vitro: At day 1 in vitro (DIV 1), which is shortly 
before or after the neurons become post-mitotic, at DIV 5, which represents an 
intermediate time point, and at DIV 10, were the PMN culture is mature (Figure 3.1/1 a). 
Cultures were partially treated with GDNF to analyze the effect of this pro-dopaminergic 
growth factor on miRNA expression levels. Massive parallel sequencing of small RNA 
libraries and differential expression analysis were performed.  
Massive parallel sequencing of PMN small RNA libraries derived between 5 and 15 
million reads per condition. From the total 1410 known miRNAs encoded in the mouse 
genome, 848 were detected in PMN cultures. Figure 3.1/1 b shows the proportion of 
sequence counts per miRNA with respect to the total number of counts attributed to 
miRNAs in PMNs at the respective maturation state. PMNs at DIV 1 (left panel) show high 





Figure 3.1/1: Small RNA sequencing reveals changes in the miRNAome of PMNs during maturation. (a) Experimental 
layout. Total RNA was isolated at day 1, day 5 and day 10 in vitro (DIV) (DOP = day of preparation). Additionally, cultures 
were treated with GDNF. (b) Proportion of sequence counts per miRNA with respect to the total number of counts 
attributed to miRNAs in PMNs at the respective maturation state. Red miRNA names indicate miRNAs expressed 




growth. (c) Plot correlation displaying results of the differential expression analysis for all samples (n=5 per condition). 
(d) Top panel: Plot correlation for the differential expression analysis comparing the miRNAomes of PMNs at DIV1 and 
DIV5. Bottom panel: Results for the differential expression analysis investigating the effect of GDNF treatment at DIV5.  
 
These miRNAs are highly expressed in neuronal progenitor cells and predicted to maintain 
the progenitor state (Bian et al. 2013; Nielsen et al. 2009). 
In comparison to this, at DIV 5 (middle panel) miR-92a and miR-92b are less expressed. 
Instead, several miRNAs known to be enriched in neurons (indicated in blue) are 
expressed at higher levels, e.g. miR-434-3p and miR-541 (Jovicic et al. 2013). The 
comparison between the miRNAomes at DIV 5 and DIV 10 (right panel) shows that PMNs 
at both time points have similar expression levels of neuron specific miRNAs.   
The results for the differential expression analysis between all samples are shown 
in the correlation plot in Figure 3.1/1 c. It revealed that the major changes in miRNA 
expression occur during early development of PMNs, between DIV 1 and DIV 5, reflecting 
the already visible changes in the miRNAomes of PMNs at these time points as described 
above. The plot shows that samples are clearly clustered into two groups. One group 
contains all samples from DIV 1, independent if treated with GDNF or not. The second 
group contains all samples from DIV 5 and DIV 10. The upper panel of figure 3.1/1 d 
shows the plot correlation between samples of DIV 1 and DIV 5, the two conditions are 
notably clustered into two different groups, indicating strong differences in their miRNA 
expression profiles. The lower panel of figure 3.1/1 d displays the correlation plot for the 
comparison of DIV 5 samples treated with GDNF and DIV 5 samples that did not receive 
treatment with the pro-dopaminergic growth factor. Those samples are not clustered into 
different groups, but form a single cluster, indicating no major differences in miRNA 
expression patterns. These results show that the major changes in miRNA expression of 
PMNs occur between DIV 1 and DIV 5. Furthermore it becomes clear that GDNF leads only 
to minor changes in the expression of single miRNAs (see 3.1.2).  
The comparison between miRNA expression patterns in PMNs at DIV 1 and DIV 5 
revealed 163 miRNAs with significantly regulated expression levels. This equals a 
proportion of 19.62 % (see figure 3.1/2 a). Of the 15 most abundant miRNAs miR-434-3p 
was significantly upregulated at DIV 5, whereas miR-92a showed a significant decrease in 





Figure 3.1/2: Massive regulation of miRNA expression during maturation of PMNs and functional analysis of 
regulated miRNAs. (a) Proportion of regulated miRNAs among all miRNAs detected in PMNs. (b) Highly regulated 
i‘NAs ≥  fold ha ge i  e p essio  ith on average more than 500 reads per condition upon maturation and 




downregulated miRNA seeds. Enrichment of gene ontology (GO) terms for biological processes as well as biological 
process terms from the PANTHER database and KEGG pathways were analyzed. 
 
Out of the  sig ifi a tl  egulated i‘NAs  e e e  st o gl  egulated ≥  fold , 
thereof the 14 most abundant miRNAs are displayed in figure 3.1/2 b with the relative 
expression levels given in log2 fold change. 
In order to analyze the biological functions of these miRNAs, target prediction 
analyses were performed. Subsequently, the target gene lists of upregulated and 
downregulated miRNAs were combined, respectively, and a functional annotation to 
biological processes, biological process terms from the PANTHER database and KEGG 
pathways was performed. The results of these analyses are displayed in figure 3.1/2 c, 
showing the top five processes and pathways in which the miRNA target genes are 
involved. The left panel shows the results for the target genes of the downregulated 
miRNAs and the right panel for the upregulated miRNAs. According to the functional 
annotation data the target genes of upregulated as well as downregulated miRNAs are 
involved in key processes important for neuronal development. For the functional 
a otatio  of ta get ge es of do egulated i‘NAs the te s e ous s ste  
de elop e t , eu oge esis  a d eu ot ophi  sig ali g path a  e e a o g the top 
five processes, indicating that changes in the expression of miRNAs targeting these genes 
have a high impact on the mentioned processes. In addition to this, more general terms 
like de elop e tal p o ess , ell st u tu e a d otilit  as ell as PI K-Akt signaling 
path a  e e also listed, efle ti g the i pa t of i‘NA e p essio  ha ges o  ellula  
physiology and metabolism. 
The functional annotation of target genes of upregulated miRNAs showed the 
te s a o  guida e  a d eu oge esis  as di e tl  eu o -related terms, displaying the 
effect of expression changes of the listed miRNAs on neuronal development. 
Furthermore, the target genes of the upregulated miRNAs are involved in regulation of 
gene expressio  a d t a s iptio , as sho   the te s egulatio  of ge e e p essio , 
‘NA t a s iptio  a d ‘NA t a s iptio  egulatio .   
In addition to these combined analyses, individual functional annotation analyses 




miRNA candidates with a neuroprotective potential or influence on neurite development. 
As these results do not play a continuative role in this thesis they are not shown here.   
 
 
3.1.2 GDNF treatment lead to specific changes in the miRNAome of PMNs – Only 
miR-182 and miR-183 are significantly regulated 
 In order to analyze the effect of GDNF treatment on miRNA expression levels in 
PMN cultures, miRNA expression was compared between PMN cultures treated with 
GDNF and control-treated cultures at DIV 1, DIV 5 and DIV 10. In contrast to the massive 
changes in miRNA expression during development, GDNF treatment led to a very specific 
regulation of just two miRNAs, miR-182 and miR-183. 
In figure 3.1/3 a the downregulation of miR-182 and miR-183 between DIV 1 and 
DIV 5 analyzed by small RNA sequencing is displayed. The sequencing showed an almost 
3-fold (-2.84 log2 fc) downregulation for miR-182 and a nearly 2-fold (-1.95 log2 fc) 
downregulation for miR-183 in PMNs at DIV 5 compared to PMNs at DIV 1. In contrast to 
this decrease of miR-182 and miR-183 levels in untreated PMNs, the small RNA 
sequencing of libraries derived from PMNs treated with GDNF showed an increase in the 
expression of both miRNAs at DIV 5 (figure 3.1/3 b). The expression levels of miR-182 at 
DIV 5 increased 3-fold (3.02 fc) upon GDNF treatment, whereas miR-183 expression 
increased a little more than 2-fold (2.10 fc). 
 In order to confirm the data derived by massive parallel small RNA sequencing and 
to obtain more insight into the regulation of miR-182 and miR-183 expression upon GDNF 
treatment, total RNA from either GDNF- or control-treated cultures was isolated at DIV 1, 
DIV 3, DIV 5 and DIV 7 and qRT-PCR to analyze miR-182 and miR-183 expression was 
performed. Figure 3.1/3 c displays the results of these analyses. Already at DIV 1 GDNF 
treatment led to an increase in the expression of both miRNAs (miR-182: 1.8 ± 0.2 fc; miR-
183: 2.0 ± 0.2 fc), even though this increase was not statistically significant. At DIV 3 miR-
182 (2.0 ± 0.2 fc) as well as miR-183 (2.4 ± 0.1 fc) expression levels were significantly 
higher in PMN cultures treated with GDNF. In addition to this, the sequencing data 
showing that GDNF leads to an increased expression of those miRNAs at DIV 5 was 




increased 2-fold (2.0 ± 0.1 fc) and miR-183 expression showed a 1.8 ± 0.2 fold increase. 
Also at DIV 7 GDNF treated PMN cultures showed a significant increase in miR-182 (1.6 ± 
0.1 fc) and miR-183 (2.1 ± 0.2 fc) expression levels. 
 
 
Figure 3.1/3: GDNF treatment of PMNs leads to a specific upregulation of miR-182 and miR-183. (a) Massive parallel 
sequencing of small RNA libraries shows a downregulation of miR-182 and miR-183 in PMNs upon maturation (n = 5). 
(b) GDNF treatment of PMNs leads to a specific upregulation of miR-182 and miR-183 as revealed by small RNA 
sequencing. (c) qRT-PCR confirms upregulation of miR-182 and miR-183 in GDNF treated PMNs (n = 4).  
 
 
3.1.3 Functional annotation of miR-182 and miR-183 target genes – Potential role 
in dopaminergic neuron biology 
 To gain a first insight in the role of miR-182 and miR-183 in dopaminergic neuron 




This was followed by the functional annotation of these genes to certain biological 
processes and KEGG-pathways. 
 In figure 3.1/4 a the results for the functional annotation analyses of miR-182 (left 
panel) and miR-183 (right panel) target genes are displayed, showing the top five terms 
for the gene ontology biological process analysis (top), the Panther database biological 
process terms (middle) and the KEGG pathway analysis (bottom).  
   
 
Figure 3.1/4: Functional analysis of miR-182 (left panel) and miR-183 (right panel) target genes (TargetScan mouse 
6.2). (a) Analyses of enrichment of gene ontology (GO) terms for biological processes as well as biological process terms 




According to the gene ontology analysis, the target genes of miR-  a e i ol ed i  ell 
otio , ell p oje tio  o ga izatio , eu o  p oje tio  de elop e t , ell 
o phoge esis i ol ed i  eu o  de elop e t  a d eu o  de elop e t . In addition 
to this the Pa the  a d KEGG path a  a al sis e ealed te s like eu oge esis , 
i t a ellula  sig ali g as ade , lo g-te  dep essio  a d lo g-term potentiatio  as 
ell as eu ot ophi  sig ali g path a , the latter underlining the connection with 
GDNF. Taken together the functional annotation analyses of miR-182 target genes 
indicate a potential important role of this miR-182 in dopaminergic neuron development 
and differentiation. 
 For miR-183 target genes the gene ontology biological process analysis revealed 
te s like ell adhesio , ell- ell adhesio  a d iologi al adhesio . This is 
complemented by the result of the Panther database analysis, which showed terms like 
ell st u tu e a d otilit  a d ell-adhesio  ediated sig ali g  as ell as  the esults 
of the KEGG path a  a al sis, hi h e ealed te s like dopa i e gi  s apse  a d 
W t sig ali g path a  a o g othe s. The fu tio al a otation analyses of miR-183 
target genes show that this miRNA also might have important functions in the 
developmental biology of dopaminergic neurons. 
 For a better understanding of the role of miR-182 and miR-183 in dopaminergic 
neurons these two miRNAs were subject of an extensive characterization in vitro and in 
















3.2 miRNA expression changes upon dopaminergic neuron degeneration and 
regeneration – Insights from the 6-OHDA mouse model for PD 
In order to analyze the role of miRNAs upon degeneration and regeneration of 
dopaminergic neurons in vivo, a massive parallel sequencing of small non-coding RNA 
libraries derived from SNpc containing midbrain samples of striatal 6-OHDA lesioned 
animals was performed. In addition one group of animals received daily physical training. 
Spontaneous regeneration in the nigrostriatal system of rodents after toxic impairment is 
well described (Höglinger et al. 2004; Stanic et al. 2003). Furthermore it is known that 
physical activity is neuroprotective and enhances neuroregeneration (Tillerson et al. 
2003; Tillerson et al. 2002). Detailed knowledge about miRNAs involved in the 
degeneration and regeneration of the murine nigrostriatal system could help to gain 
further insight into the pathomechanism of dopaminergic neurodegeneration as well as 
to find potential new therapeutic targets that might enhance neuroregeneration or 
inhibit further degeneration of dopaminergic neurons. 
 
 
3.2.1 The miRNAome of the murine SNpc containing midbrain 
The animals received a stereotactic injection of 4 µg 6-OHDA into their right 
striatum, leading to the progressive die-back of dopaminergic fibres and subsequently 
neuronal cell bodies in the SNpc. In order to analyze the changes in the miRNAome during 
degeneration, animals were sacrificed 4 weeks (degeneration model) after striatal 
injection, which is the time point when maximal degeneration occurred. For analysis of 
the miRNAome upon regeneration, animals were sacrificed 12 weeks (regeneration 
model) after the striatal 6-OHDA injection. At this time point the regenerative response 
begins (figure 3.2/1 a). 
Small RNA sequencing of murine SNpc containing midbrain samples yielded 
between 3.3 and 21 million reads per condition. Among all small non-coding RNA reads 
71.14 percent were belonging to mature miRNAs, whereas the other 28.86 percent were 
other small non-coding RNAs (figure 3.2/1 b). Out of 1410 known mature murine miRNAs, 






Figure 3.2/1: Small RNA sequencing of the midbrain in the 6-OHDA mouse model for PD. (a) Experimental layout for 
the 4 weeks post unilateral striatal 6-OHDA injection degeneration model and the 12 weeks post unilateral striatal 6-
OHDA injection regeneration model. (b) Contribution of miRNAs to the total number of small (18 – 26 nt) non conding 
RNAs detected in the murine midbrain by small RNA sequencing. (c) Proportion of detected mature miRNAs regarding 
the total number of known mature murine miRNAs in miRBase. (d) Proportion of sequence counts per miRNA with 
respect to total number of counts attributed to miRNAs in the untreated murine midbrain. (e) Left panel: Results of the 
differential expression analysis comparing the miRNAomes of untreated midbrains with the miRNAomes of midbrains of 
the 4 weeks 6-OHDA degeneration model. Middle panel: Plot correlation displaying the results of the differential 
expression analysis comparing the miRNAomes of untreated midbrain samples with the miRNAomes of midbrains 12 




differential expression analysis comparing the midbrain miRNA expression 12 weeks after striatal 6-OHDA injection 
between animals receiving DPA or not (n = 5 animals per condition).    
 
In figure 3.2/1 d the proportion of sequence counts per miRNA with respect to 
total number of counts attributed to miRNAs in the untreated murine midbrain is 
displayed. The most abundant miRNA in the murine brain is miR-9 (Chiang et al. 2010), in 
contrast to this, in the midbrain of unlesioned mice, brain-specific miR-181a showed the 
highest expression. Also other brain miRNAs as miR-127, miR-9, miR-99b and miR-125b 
are expressed at high levels.  
 
 
3.2.2 Changes in miRNA expression of the murine midbrain upon degeneration of 
the nigrostriatal system 
 In order to analyze the changes in the miRNAome of the murine midbrain upon 
degeneration of the nigrostriatal tract, a differential expression analysis comparing the 
miRNAome of unlesioned animals with the miRNAome of degeneration model animals (4 
weeks after striatal 6-OHDA injection) was performed. The plot correlation in figure 3.2/1 
e (left panel) shows that miRNA expression was regulated 4 weeks after 6-OHDA lesion; 
with the exception of one sample the 4 weeks 6-OHDA samples are clustered into one 
group, whereas the samples from unlesioned samples are clustered in a second group.  
The differential expression analysis revealed that out of 780 detected miRNAs the 
expression of 5 miRNAs was significantly changed in the degeneration model compared to 
unlesioned control animals. miR-501-3p, miR-100 and miR-331-3p were significantly 
upregulated during degeneration, whereas miR-486 and miR-3107 showed a decreased 
expression (figure 3.2/2 a). To understand which pathways are mainly affected by the 
differential expression of these miRNAs, a target prediction analysis followed by an 
annotation of these genes to KEGG pathways was performed. Figure 3.2/2 c (left panel) 
shows the top five KEGG pathways involving genes that are affected by those miRNAs. 
Among them are very general pathways important for neuronal differentiation, cellular 
function and survival as MAPK sig ali g path a , W t sig ali g path a  a d TO‘ 




on the physiology of dopaminergic neurons and confirms the cellular mechanisms that 
are affected during neurodegeneration. 
 
 
Figure 3.2/2: Significantly regulated miRNAs in the murine midbrain 4 weeks (degeneration) and 12 weeks 
(regeneration) after striatal 6-OHDA lesion and functional analysis of their target genes. (a) Differentially expressed 
miRNAs in the murine midbrain 4 weeks after striatal 6-OHDA lesion (degeneration). (b) Significantly regulated miRNAs 
12 weeks after striatal 6-OHDA lesion (regeneration). (c) Enrichment for KEGG pathways among miRNA target genes. 
 
 
3.2.3 miRNAs involved in spontaneous regeneration of SNpc dopaminergic 
neurons after 6-OHDA lesion 
 In order to compare miRNA expression levels in the midbrain of unlesioned mice 
with animals starting spontaneous recovery (regeneration) 12 weeks after striatal 6-
OHDA lesion, a differential expression analysis was performed. In addition to this, the 




 The plot correlation in figure 3.2/1 e (middle panel) displays the results of the 
differential expression analysis comparing the miRNAome of unlesioned animals with the 
miRNAome of animals 12 weeks after 6-OHDA lesion (regeneration). There is no 
clustering of the samples in the two different conditions visible indicating that only minor 
changes in the miRNAome occur during regeneration. Out of 780 miRNAs detected in the 
murine SNpc containing midbrain by small RNA sequencing, 12 miRNAs were significantly 
changed in their expression. Compared to the expression changes upon degeneration of 
dopaminergic neurons, the changes are milder during regeneration. Three miRNAs were 
upregulated including miR-132*, miR-128-1* and miR-146b, whereas 9 miRNAs were 
downregulated during regeneration of the nigrostriatal tract. Among the downregulated 
miRNAs were miR-100, which is up regulated upon degeneration, miR-199a, miR-199b 
and miR-99a (figure 3.2/2 b). Analysis of enrichment of KEGG pathways among miRNA 
target genes revealed that especially proteins involved in growth associated pathways as 
E B sig ali g path a , glio a  a d eu ot ophi  sig ali g path a  a e affe ted  
the regulated miRNAs. This reflects the cellular mechanisms involved in a regenerative 
response. 
 In figure 3.2/1 e (right panel) the results of the differential expression analysis 
concerning the effect of physical activity on the miRNAome 12 weeks after 6-OHDA lesion 
are displayed. Compared to animals without additional daily training, there was no 
significant change in miRNA expression in the midbrain of trained animals. Thus, the 
















3.3 Transfection of GDNF-regulated miR-182 and miR-183 – Beneficial effects on 
dopaminergic PMNs in vitro?  
 The previous experiments showed that GDNF treatment of PMNs resulted in an 
increase in miR-182 and miR-183. In order to analyze the effects of these miRNAs on 
dopaminergic PMNs, cultures were transfected with synthetic miR-182 and miR-183 
mimics or a scrambled NC siRNA as control, which has no homology to any known 
mammalian gene and thus, even incorporated into RISC, has no effect on protein 
expression. The focus of this study was put on neurite length, neurite regeneration and 
neuroprotection in dopaminergic PMNs. Furthermore, the miRNA-mediated effects were 
compared to the effects of GDNF treatment. 
 
3.3.1 Increase in miR-182 and miR-183 leads to longer neurites in dopaminergic 
PMNs 
 In order to find the optimal concentration of miRNA mimic for transfection of 
PMNs, cells were transfected at DIV 1 with different concentrations (100 pM, 5 nM and 
50 nM) of synthetic miRNA mimic. 24 h and 72 h later total RNA was isolated from 
transfected cultures and miR-182 and miR-183 levels were quantified by qRT-PCR. In 
figure 3.3/1 b the results of the qRT-PCR 24 h post-transfection are displayed. The left 
panel shows the miR-182 levels after transfection with indicated concentrations of miR-
182 mimic relative to expression levels in NC siRNA transfected cells given in log2 fold 
ha ge a d a al zed  the ΔΔ-Ct method. Even transfection with the lowest dose of 100 
pM miR-182 mimic led to a strong increase in miR-182 levels (9.6 ± 0.1 log2 fc). Further 
increase in miR-182 mimic used for transfection led to additional dose dependent 
increase in miR-182 levels detected by qRT-PCR (5 nM = 12.9 ± 0.7 log2 fc; 50 nM = 13.9 ± 
0.1 log2 fc). The right panel in figure 3.3/1 b shows the qRT-PCR results for PMNs 
transfected with different concentrations of miR-183 mimic 24 h post-transfection. 
Similar to PMNs transfected with miR-182, miR-183 transfection showed a dose 
dependent increase in miR-183 levels detected by qRT-PCR (100 pM = 8.6 ± 0.3 log2 fc; 5 




also 72 h post-transfection. For further analyses the 5 nM dosage was chosen, as it had no 
toxic effects and guaranteed optimal transfection. 
 
 
Figure 3.3/1: Increased levels of miR-182 and miR-183 result in longer neurites in dopaminergic neurons in PMN 
cultures. (a) Experimental layout for transfection experiments. At DIV1 PMN cultures were transfected with a synthetic 
miRNA mimic or a scrambled NC siRNA (NC). At DIV4 (72 h post-transfection) cultures were fixated for analysis of 
neurite length. (b) Relative miR-182 (left panel) and miR-183 (right panel) expression in cultures transfected different 
concentrations of the respective mimic 24 h post-transfection compared to cultures transfected with NC (n = 3 
independent cultures). (c) Representative micrographs of dopaminergic PMN transfected with NC, the respective 
miRNA mimics or NC and treated with GDNF [10 ng / ml]. PMN were immunostained against TH (scale bar = 50 µm). (d) 
Quantification of the total neurite length per TH + cell normalized to NC transfected cultures (n = 3 independent 
cultures; 2 coverslips per condition; 2 areas of 2000 µm
2 
per coverslip; at least 50 TH + neurons per coverslip; mean ± 
SEM; one-way ANOVA with Du ett s post-hoc test). 
 
To analyze the effect of increased miR-182 and miR-183 on dopaminergic PMNs, 




mimic. For comparison of miRNA effects with GDNF effects, PMNs were transfected with 
5 nM NC siRNA and treated with 10 ng / ml GDNF. At DIV 4 (72 h post-transfection) PMN 
cultures were fixed and immunostained against TH to label the dopaminergic neurons. 
Figure 3.3/1 c shows representative micrographs of TH-immunolabelled dopaminergic 
neurons in the different experimental conditions. The total neurite length per TH-positive 
neuron relative to NC siRNA transfected neurons was quantified and is displayed in figure 
3.3/1 d. After miR-182 mimic transfection dopaminergic PMNs showed a significant 
increase in neurite length compared to cultures transfected with NC siRNA (174.3 ± 11.3 
%). Also miR-183 mimic transfection led to significantly longer neurites in dopaminergic 
PMNs (170.4 ± 10.3 %). A combined transfection of miR-182 and miR-183 mimics showed 
just a small additional increase in neurite length of dopaminergic PMNs compared to the 
singular transfection (183.9 ± 12.0 %). Thus, there was no additive effect of both miRNAs 
visible. Nevertheless, also the effect of the combined transfection on dopaminergic 
neurite length was significant compared to the effect of NC. PMN cultures transfected 
with NC siRNA and treated with GDNF also showed a significant increase in neurite length 
of dopaminergic neurons (180.4 ± 11.6 %). Interestingly, the effect mediated by increased 








 In order to analyze a potential neuroprotective effect of increased miR-182 and 
miR-183 levels in dopaminergic PMNs, the MPP
+
 neurotoxicity model was applied. PMN 
cultures were transfected with miRNA mimics or NC siRNA at DIV 1. At DIV 2 (24 h post-
transfection) MPP
+
 was supplied to the cell culture medium at a final concentration of 2 
µM for 24 h. At DIV 3, cell culture medium was removed completely and fresh medium 
was added. One day after the medium change (DIV 4) the cells were fixed and 
dopaminergic cell survival was analyzed after TH immunostaining (figure 3.3/2 a). 






Figure 3.3/2: Increase in miR-182 and miR-183 leads to a higher survival of dopaminergic PMNs after MPP
+
 
treatment. (a) Time course of experimental procedure. (b) Representative micrographs of PMN cultures transfected 
with miRNA mimic, NC or NC + GDNF treatment and treated with PBS (left panel) or 2 µM MPP
+ 
(right panel) for 24 h. 
Cultures were immunostained against TH (scale bar = 100 µm). (c) Quantification of TH + PMNs after transfection with 
miRNA mimics, NC or treatment with 10 ng / ml GDNF and with addition of PBS for 24 h as an experimental control. (d) 




addition of 2 µM MPP+ for 24 h normalized to PBS treated cells (n = 3 independent cultures; 2 coverslips per condition; 
2 areas of 2000 µm
2 
per coverslip). Data is given as mean ± SEM; one- a  ANOVA a d Du ett s test post-hoc test. 
 
The left panel shows micrographs of PMN cultures as controls, transfected with 
the different oligos and treated with PBS instead of MPP
+
. The corresponding 
quantification is displayed in figure 3.3/2 c. The relative number of TH positive neurons 
normalized to the dopaminergic neuron number in PMN cultures transfected with NC 
siRNA is shown.  
There was no significant difference between the number of TH positive PMNs in 
NC siRNA transfected PMNs and miR-182 (90.6 ± 7.0 %) and miR-183 mimic (85.4 ± 5.1 %) 
transfected cultures. The combined transfection with both miRNA mimics had also no 
significant effect on dopaminergic cell numbers in PBS treated PMNs (93.6 ± 7.9 %). The 
application of GDNF on NC siRNA transfected PMNs had also no significant effect on 
dopaminergic neuron cell numbers compared to NC siRNA transfected PMNs (104.3 ± 7.3 
%).  
 Representative micrographs of PMNs transfected with the different oligos and 
treated with the neurotoxin MPP
+
 are displayed in the right panel of figure 3.3/2 b. The 
quantification of TH positive neurons after MPP
+
 treatment (figure 3.3/2 d) shows that in 
PMNs transfected with NC siRNA only 30.5 ± 2.9 % of the dopaminergic cells survived the 
MPP
+
 treatment. Cultures transfected with miR-182 mimic showed a significantly higher 
survival of 47.6 ± 3.8 % compared to NC siRNA transfected PMNs. A significant 
neuroprotective effect is also visible in PMNs transfected with miR-183 mimic, where 48.2 
± 2.7 % of dopaminergic neurons survived. Again the combined transfection of miR-182 
and miR-183 mimic led to no additional effect, but still there was a significantly higher 
survival of TH positive neurons (53.3 ± 5.1 %) compared to NC siRNA treated cells. PMNs 
transfected with NC siRNA and treated with GDNF showed also a significantly higher 
number of surviving dopaminergic neurons. With 49.4 ± 2.9 % survival, the 
neuroprotective effect of GDNF treatment is again comparable to the effects of increased 






3.3.3 Increased miR-182 and miR-183 levels improve neurite regeneration in 
dopaminergic PMN 
 For assessment of the neurite regeneration stimulatory potential of miR-182 and 
miR-183 increase, a mechanical neurite transection of PMN cultures was performed. At 
DIV 1 cells were transfected with either miRNA mimics or NC siRNA. For comparison of 
miRNA and GDNF effects another condition was included in which PMNs were transfected 
with NC siRNA and treated with GDNF. 24 h post-transfection (DIV 2) the PMN neurites 
were mechanically transected by application of a scratch lesion that was performed using 
a 200 µl pipette tip. Each coverslip received two scratch lesions that were applied in the 
same orientation and covered the diameter of the coverslip. Two days after the neurite 
transection (DIV 4) PMNs were fixed and TH immunolabelling was performed 
(experimental layout see figure 3.3/3 a). Neurite regeneration was evaluated by 
measuring the length of dopaminergic neurites crossing the scratch border. 
In NC siRNA transfected cultures a limited number of dopaminergic neurites are 
regenerating across the scratch border as shown in representative pictures in figure 3.3/3 
b.  
In comparison, miR-182 mimic transfected PMNs showed a strong significant increase in 
neurite regeneration (315.8 ± 51.0 %) as indicated in figure 3.3/3 c which shows the total 
length of TH-positive neurites growing over the scratch border. Also in PMNs transfected 
with miR-183 mimics a significant increase in dopaminergic neurite regeneration was 
observed (221.3 ± 27.1 %). The combined transfection of both miRNAs led also to 
significant increase in TH-positive neurites growing over the scratch border (327.2 ± 34.7 
%), although again no additive effect of both miRNAs was visible. GDNF treatment also 
increased the regenerative growth of dopaminergic neurites (255.1 ± 34.6 %) in PMNs 
after scratch lesion, which in this case is not as high as in cultures transfected with miR-
182 mimics. The quantification shown in figure 3.3/3 c is not taking into account if the 
regenerating neurites are longer or if there are just more regenerating dopaminergic 
neurites. In order to exclude the bias of neurite number, a second quantification was 
performed. This time, only the length of the 10 longest neurites crossing the scratch 
border was evaluated and the mean length was calculated. The results are displayed in 





Figure 3.3/3: miR-182 and miR-183 transfection results in increased regeneration of TH + neurites after mechanical 
scratch lesion. (a) Experimental layout. (b) Representative micrographs of TH immunostained and DAPI counter stained 
miRNA mimic, NC or GDNF treated PMN cultures after mechanical scratch lesion. The scratch border is indicated by the 
white dotted line (scale bar = 50 µm). (c) Quantification of the total length of TH + neurites over the scratch border 
relative to NC transfected PMNs (n = 3 independent cultures; 2 coverslips per condition; 2 scratch lesions per coverslip). 
(d) Quantification showing the mean length of the 10 longest TH + neurites crossing the scratch border relative to NC 
transfected PMN cultures (n = 3 independent cultures; 2 coverslips per condition; 2 scratch lesions per coverslip). Data 
is given as mean ± SEM; one- a  ANOVA a d Du ett s test post-hoc test. 
 
 Compared to NC siRNA, miR-182 and miR-183 mimic transfection significantly 
increased the length of regenerating dopaminergic neurites (miR-182: 168.6 ± 8.5 %; miR-
183: 138.5 ± 6.7 %). The combined transfection of both miRNAs led to no further increase 
(174.6 ± 10.6 %) in regenerating neurite length compared to the singular transfection of 
miR-182. The effect of GDNF treatment was not as strong (142.3 ± 6.4 %) as miR-182 






3.4 Neurite outgrowth, neuroprotection and neurite regeneration – Mechanisms 
underlying the beneficial effects of miR-182 and miR-183 increase in 
dopaminergic PMNs 
 Taken together the present results suggest that GDNF-regulated miR-182 and miR-
183 play an important role in neurite outgrowth and regeneration of dopaminergic 
neurons in vitro. Furthermore, the results of the MPP
+
-intoxication experiment 
demonstrate that those miRNAs also exert dopaminergic neuroprotection. The upcoming 
chapter aims to elucidate the mechanisms behind the observed effects. In order to show 
that the observed effects are not caused by mere transfection of miRNA mimics per se, 
but are indeed specific for miR-182 and miR-183 increase, PMNs were transfected with 
miR-1a-3p. miR-1a-3p is a heart-specific miRNA that was already used as a control and 
showed no effect on neurite outgrowth in cortical neurons (Vo et al. 2006). For further 
investigation of the signaling pathways involved in miR-182 and miR-183 mediated 
effects, protein levels of their already experimentally validated target genes as well as of 
key mediators of survival and growth associated signaling pathways were analyzed. 
 
 
3.4.1 Increased neurite growth, regeneration and neuronal survival are not an 
effect of miRNA increase per se 
 To exclude the possibility that the observed effects of miR-182 and miR-183 
increase on neuronal survival and neurite growth are not an effect of miRNA 
overexpression per se, all experiments were repeated according to the previously 
described protocols transfecting miR-1a-3p. 
 In figure 3.4/1 a the increase in miR-1a-3p detection by qRT-PCR 24 h after 
transfection with 5 nM miRNA mimic is displayed. In order to analyze the effect of miR-
1a-3p on neurite outgrowth of dopaminergic neurons transfected PMN cultures were 
fixed at DIV 4 and immunolabeled for TH. There was no significant difference in neurite 
length of TH positive dopaminergic neurons between cells transfected with miR-1a-3p 
mimic (100.7 ± 4.7 %) and cells transfected with a NC siRNA as shown in figure 3.4/1 b. 
Furthermore the effect of miR-1a-3p on dopaminergic neuronal survival after MPP
+
 





Figure 3.4/1: Effects on neuronal survival and neurite growth and regeneration are not caused by miRNA 
overexpression per se. (a) Relative miR-1a-3p expression in cultures transfected with 5 nM miRNA mimic normalized to 
expression levels in cultures transfected with NC (n = 3 independent cultures). (b) Quantification of neurite length of 
dopaminergic neurons in PMN cultures transfected with miR-1a-3p and NC (n = 3 independent cultures; 2 coverslips per 
condition; 2 areas of 2000 µm
2 




after transfection with miR-1a-3p mimic or NC and with addition of PBS for 24 h as an experimental control. (d) Relative 
quantification of surviving TH + PMNs after transfection with miR-1a-3p or NC and addition of 2 µM MPP+ for 24 h 
normalized to PBS treated cells (n = 3 independent cultures; 2 coverslips per condition; 2 areas of 2000 µm
2 
per 
coverslip). (e) Quantification of the total length of TH + neurites over the scratch border relative to NC transfected 
PMNs (n = 3 independent cultures; 2 coverslips per condition; 2 scratch lesions per coverslip). (f) Quantification showing 
the mean length of the 10 longest TH + neurites crossing the scratch border relative to NC transfected PMN cultures (n 
= 3 independent cultures; 2 coverslips per condition; 2 scratch lesions per coverslip). Data is given as mean ± SEM; one-
a  ANOVA a d Du ett s test post-hoc test. 
 
One day after transfection, cultures were treated with 2 µM MPP
+
 for 24 h. At DIV 4 cells 
were fixed and immunolabeled for TH to analyze dopaminergic cell numbers. Figure 3.10 
c shows the effect of miR-1a-3p on dopaminergic cell numbers without additional 
treatment. There is no significant difference between NC siRNA-treated cultures and miR-
1a-3p mimic-transfected PMNs in TH-positive cell numbers. After MPP
+
 treatment 
dopaminergic cell numbers in NC siRNA-transfected cells decreased to 30.5 ± 2.9 % and in 
miR-1a-3p mimic-transfected cultures to 33.5 ± 3.0 % (figure 3.4/1 d), there is no 
significant difference in survival of dopaminergic neurons after MPP
+
 treatment in miR-
1a-3p transfected PMNs compared to NC siRNA transfected PMNs. 
 Regarding neurite regeneration of dopaminergic neurons two days after 
mechanical scratch lesion, there was no significant difference between NC siRNA- and 
miR-1a-3p mimic-transfected cultures (figure 3.4/1 e and f). The total length of 
regenerating dopaminergic neurons over the scratch border in miR-1a-3p mimic 
transfected cells was 121.5 ± 13.7 % compared to NC siRNA transfected PMNs. The mean 
length of the 10 longest dopaminergic neurites over the scratch border in miR-1a-3p 
transfected cells was 112.6 ± 7.0 % of the NC.  
 Taken together, the miR-1a-3p transfection experiments indicate that the 
observed effects of miR-182 and miR-183 mimic transfection on dopaminerigc neurons 
are specific effects and not simply caused by miRNA mimic transfection per se. In the 
following chapter the possible mechanisms underlying the pro-dopaminergic effects of 







3.4.2 Increased miR-182 and miR-183 levels lead to a reduction in Foxo3 and 
Foxo1 protein expression 
For further investigation of the mechanisms underlying miR-182 and miR-183 
increase-mediated beneficial effects on dopaminergic neurons, the protein expression 
levels of already experimentally validated target genes for miR-182 and miR-183 were 
analyzed. It was previously reported that miR-182 regulates the protein expression levels 
of the transcription factors Foxo1 and Foxo3 (Guttilla & White 2009; Segura et al. 2009). 
Taok1 was previously described as regulated by miR-183 (Patel et al. 2013), but also 
Foxo1 was predicted to be a target of miR-183 (TargetScan Mouse 6.2). All of these target 
proteins were previously reported to have an impact on neuronal survival and / or 
development (Chong et al. 2008; Tavares et al. 2013; Yuan et al. 2009). Protein levels 
were analyzed by Western blot in lysates prepared from PMN cultures transfected at 
DIV1 with miR-182, miR-183 or NC siRNA. Lysates were prepared 24 h post-transfection. 
Western blot analyses of Foxo3 protein levels revealed a significant down-
regulation of Foxo3 in miR-182 transfected cultures 24 h post-transfection (Figure 3.4/2 
a). Foxo3 levels were decreased to 75.9 ± 5.6 % in cells transfected with miR-182. 
Although not significant, a similar trend could be observed in cultures treated with GDNF 
(81.7 ± 5.8 %). Transfection of miR-183 mimic had no effect on the protein levels of Foxo3 
in PMN cultures (88.6 ± 7.8 %). Regarding the protein levels of Foxo1 after transfection 
with miRNA mimics or treatment with GDNF (figure 3.4/2 b), quantification of 5 
independent cultures showed a significant decrease in Foxo1 levels in all three treatment 
groups (miR-182: 63.4 ± 2.4 %; miR-183: 68.0 ± 6.4 %; NC + GDNF: 53.4 ± 5.7 %). Analyses 
of 5 independent cultures revealed no significant effect of miR-182 or miR-183 
transfection, as well as GDNF treatment on Taok1 protein expression in PMNs, although 
there was a trend to decreased Taok1 levels in cells transfected with miR-183 (66.8 ± 5.6 





Figure 3.4/2: Increased levels of miR-182 and miR-183 lead to a decrease in Foxo protein levels. Western blot analyses 
of Foxo3 (a), Foxo1 (b) and Taok1 (c) protein levels in miR-182, miR-183 or GDNF treated PMNs 24 h post-transfection. 
Band intensities for Foxo3 show a reduction in miR-182 transfected cells that is also confirmed by the quantification 
below (a) (n = 5 independent cultures). Foxo1 protein levels (b) are decreased in PMNs transfected with miR-182, miR-
183 or treated with GDNF (n = 4 independent cultures). There is a trend for decreased Taok1 levels in PMNs transfected 
with miR-183, although this is not significant (c) (n = 4 independent cultures). Data is given as mean ± SEM; one-way 
ANOVA a d Du ett s test post-hoc test. 
 
 
3.4.3 Effects of increased miR-182 and miR-183 on survival and growth 
associated signaling pathways 
 For further elucidation of the mechanisms underlying miR-182 and miR-183 
mediated beneficial effects on dopaminergic neurons, the levels of proteins involved in 
survival and growth associated signaling pathways were evaluated in miR-182 and miR-
183 transfected PMNs. Lysates were prepared 24 h post-transfection and Western blot 
analyses were performed for the known survival / growth associated proteins Akt, pAkt, 






3.4.3.1 miR-182 and miR-183 mimic transfection lead to increased phosphorylation of 
Akt 
 Akt is a protein involved in the PI3K-Akt signaling pathway, a signal transduction 
pathway that mediates cellular survival and growth in response to external stimuli and 
plays an important role also in neuronal cells (Brunet et al. 2001; Kennedy et al. 1997). 
Here, the levels of Akt and its phosphorylated active form pAkt were analyzed in miR-182 
and miR-183 transfected PMNs 24 h post-transfection.  
Transfection of miR-182 and miR-183, as well as GDNF treatment had no effect on 
Akt protein levels as displayed in figure 3.4/3 a (miR-182: 102.8 ± 2.5 %; miR-183: 91.6 ± 
3.2 %; NC + GDNF: 96.3 ± 2.3 %). Nevertheless, miR-182 and miR-183 mimic transfected 
PMNs showed a significant increase in pAkt levels and therefore a higher activation of the 
PI3K-Akt signaling pathway (figure 3.4/3 b). 
 
 
Figure 3.4/3: Increased miR-182 and miR-183 lead to increased phosphorylation of Akt. Western blot analyses of Akt 
(a) and phospho-Akt (b) (pAkt) protein levels in miR-182, miR-183 or GDNF treated PMNs 24 h post-transfection. Band 
intensities for Akt show no effect of miRNA increase or GDNF treatment that is also displayed in the quantification 
below (a) (n = 5 independent cultures). In miR-182 and miR-183 transfected PMNs there is a significant increase in pAkt 






In miR-182 mimic-transfected cells the pAkt levels reached on average 141.1 ± 10.1 % of 
controls. Transfection of miR-183 led to an increase to 141.8 ± 13.2 % in pAkt levels. 
Transfection with the NC siRNA followed by GDNF treatment resulted in a non-significant 
trend to increased Akt phosphorylation (136.0 ± 12.3 %). 
 
 
3.4.3.2 Transfection of miR-182 and miR-183 lead to a trend of increased MAPK (Erk) 
signaling 
 The MAPK signaling pathway plays a critical role in mediation of cell survival and 
growth and is also important for neuronal plasticity (Bonni et al. 1999; Impey et al. 1999). 
The effect of miR-182 and miR-183 increase on the MAPK signaling pathway in PMNs was 
investigated by evaluation of Erk1 and Erk2 (Mapk) levels, as well as the evaluation of the 
levels of their activated phosphorylated forms pErk1 and pErk2. 
 Increased miR-182 levels in PMNs resulted in a trend for increased Erk1 and Erk2 
expression as shown in figure 3.4/4 a, which was not significant (Erk1: 134.1 ± 10.0 %; 
Erk2: 121.6 ± 8.2 %). Furthermore, miR-182 transfection led to an even stronger, yet 
insignificant trend of increased pErk1 (292.0 ± 88.2 %) and pErk2 (180.2 ± 23.6 %) in PMNs 
(figure 3.4/4 b). miR-183 transfection led also to a small increase in Erk1 (126.3 ± 7.7 %) 
and Erk2 (118.2 ± 5.9 %) levels, as well as to a higher phosphorylation of Erk1/2 (pErk1: 
205.1 ± 38.7 %; pErk2: 141.7 ± 20.9 %). Transfection with NC siRNA and subsequent 
treatment with GDNF resulted in comparable increased Erk1/2 and even higher increase 
in pErk1/2 levels (Erk1: 115.2 ± 12.8 %; Erk2: 117.6 ± 10.3 %; pErk1: 404.5 ± 42.2 %; pErk2: 





Figure 3.4/4: Higher miR-182 and miR-183 levels lead to trend of increased Mapk (Erk) signaling. Western blot 
analyses of Erk (a) and phospho-Erk (b) (pErk) protein levels in miR-182, miR-183 or GDNF treated PMNs 24 h post-
transfection. Band intensities for Erk show a trend for higher Erk1 and Erk2 levels in PMNs treated with miRNA mimics 
or GDNF (a) (n = 5 independent cultures). Also in all three treatment groups there is a trend for an increased 
phosphorylation of Erk1 (pErk1) and Erk2 (pErk2) detectable (b) (n = 5 independent cultures). Data is given as mean ± 








3.4.3.3 Influence of increased miR-182 and miR-183 on Stat3, phospho-S6 and Bcl2 
expression in PMNs 
 In addition to the miR-182 and miR-183 mediated influence on the Akt and MAPK 
signaling pathways, the effect of those miRNAs on other growth associated proteins was 
investigated. Protein expression of Stat3, phospho-S6 and Bcl2 in miR-182 and miR-183 
mimic transfected PMNs was analyzed 24 h post-transfection. Stat3 is a transcription 
factor that is important for cell growth and apoptosis (Zhong et al. 1994). Phospho-S6 is 
the activated form of the ribosomal component S6 and a downstream target of the 
mammalian target of rapamycin (mTOR) and is therefore involved in protein translation 
and associated with cell growth and survival (Jeon et al. 2008). The anti-apoptotic protein 
Bcl2 is associated with the mitochondrial membrane and protects cells from oxidative 
stress induced cell death by prevention of cytochrome c release or binding of the 
apoptosis-activating factor (Czabotar et al. 2013). Lysates of transfected PMNs were 
prepared 24 h post-transfection and Western blotting was performed. 
   
 
 
Figure 3.4/5: Effect of miR-182 and miR-183 increase on Bcl2, Stat3 and phospho-S6 protein levels. Western blot 
analyses of Bcl2 (a), Stat3 (b) and phospho-S6 (c) protein levels in miR-182, miR-183 or GDNF treated PMNs 24 h post-
transfection. Band intensities for Bcl2 show a trend for higher Bcl2 levels in PMNs treated with miRNA mimics or GDNF 
(a) (n = 5 independent cultures). Also in all three treatment groups there is a trend for an increased Stat3 detectable (b) 
(n = 5 independent cultures). Increased miR-182 levels lead to a significant increase in phospho-S6 expression (c) (n = 5 




Bcl2 expression increased in miR-182 (131.9 ± 9.1 %) and miR-183 (134.9 ± 12.2 %) 
transfected PMNs, as well as after GDNF treatment of the cells (157.8 ± 26.7 %), although 
none of these changes were significant (displayed in figure 3.4/5 a). A similar alteration 
was detectable in Stat3 protein levels after transfection with miR-182 or miR-183 and 
treatment with GDNF. miR-182 increase resulted in increased Stat3 levels of 139.7 ± 14.2 
%, for miR-183 transfection the Stat3 levels were at 130.7 ± 16.6 % and GDNF treatment 
increased Stat3 expression to 121.8 ± 10.7 %. These changes did not reach significance 
(figure 3.4/5 b). Phospho-S6 levels were significantly altered in two of three experimental 
groups. Transfection of miR-182 mimic increased phospho-S6 levels to 128.6 ± 3.3 %, 
whereas miR-183 transfection led to no significant changes in phospho-S6 expression 
(104.8 ± 7.2 %). GDNF treatment of NC siRNA transfected PMNs resulted in significantly 





3.5 Effects of increased miR-182 and miR-183 levels in the acute MPTP mouse 
model for PD 
 After demonstrating the beneficial effects of GDNF-regulated miR-182 and miR-
183 on dopaminergic neurons in culture, the present analysis aimed to elucidate if similar 
pro-dopaminergic effects could be observed in the adult murine brain in vivo. Therefore, 
the acute MPTP mouse model for PD was applied. Animals received a stereotactical 
injection of miR-182 or miR-183 mimics or NC siRNA into the right SNpc and were treated 
with MPTP for 5 consecutive days beginning at day two post-injection.  
The first parts of this chapter are dealing with the optimization of the nigral miRNA 
mimic injection, whereas the following chapters cover the effects of miR-182 and miR-183 
increase in the MPTP mouse model for PD. 
 
 
3.5.1 Stereotactical injection of fluorescently labeled NC siRNA leads to 
transfection of dopaminergic neurons in the murine SNpc 
 In order to verify the transfection of dopaminergic neurons in the SNpc by 
stereotactic injection of miRNA mimics / NC siRNA, a NC siRNA fluorescently labeled with 
AF-546 in two different concentrations (100 pmol and 500 pmol) with or without lipid-
based HiPerfect transfection (HiP) reagent was injected into the right SNpc of mice. 48 
hours post-injection animals were perfused and brain tissue was processed for cryo-
sectioning and immunohistochemistry. Sections were immunolabeled for TH to show the 
transfection of dopaminergic neurons in the SN (figure 3.5/1 a). In figure 3.5/1 b 
representative micrographs of the ipsilateral and contralateral SNpc of injected animals 
are shown. Compared to animals injected only with PBS and HiP, the animals injected 





Figure 3.5/1: Transfection of SN dopaminergic neurons of mice with fluorescently labeled NC siRNA in vivo. (a) 
Experimental layout. Fluorescently labeled NC siRNA at different concentrations and either with or without addition of 
the lipid-based transfection reagent HiPerfect (HiP) was injected into the right SN of 8 weeks old male C57Bl/6J mice 
(DOI = day of injection). 48 post-injection animals were sacrificed and tissues were prepared for IHC. (b) Representative 
micrographs of SN in injected animals. Left panels: Contralateral uninjected side showing in the left panel the channel 
for NC siRNA and in the right panel the merge of NC siRNA, TH and DAPI signals. Right panels: Ipsilateral injected side 




Independent of the transfected amount of siRNA, there was a clear co-localization 
of the AF-546 signal of the NC siRNA and the TH signal that was used as a marker for 
dopaminergic neurons, leading to the conclusion that the nigral injection of small RNA 
species resulted in a transfection of ipsilateral dopaminergic SNpc neurons 48 h post-
injection. At this time point no spreading of the AF-546 labeled siRNA to the contralateral 
side was detectable. Animals that were injected with a mixture of NC siRNA and HiP seem 
to show higher transfection efficiencies compared to animals injected just with the siRNA 
in PBS. Based on these results further experiments were conducted using 250 pmol 
miRNA mimic or NC siRNA. 
 
 
3.5.2 Lipid-based transfection reagent does not lead to increased microglial 
invasion in the murine SNpc 
With the intention of excluding potential side effects of the used transfection 
reagent (HiP) on microglial invasion the microglia numbers were analyzed in animals 
injected with NC siRNA without HiP and in animals injected with NC siRNA with the use of 
HiP. To this, animals were sacrificed 48 h post-injection, SNpc sections were 
immunolabeled for the microglial marker Iba 1 and stereological counting of microglial 
numbers around the injection site was performed (figure 3.5/2 a and b).  
 In figure 3.5/2 c the results of the stereological analyses are displayed. Animals 
injected with NC siRNA and HiP showed no significant increase in microglial numbers 
around the injection site compared to animals injected with NC siRNA in PBS only. 
Consequently, it was concluded that the lipid-based transfection reagent HiP does not 
lead to an increased microglial invasion around the injection site. On the basis of this 
result it was decided that injections of small RNA species in further experiments were 





Figure 3.5/2: Transfection using a lipid-based transfection reagent is not increasing microglial invasion around the 
injection site. (a) Experimental layout. A fluorescently labeled NC siRNA mixed with PBS or HiP was injected in the right 
SN of 8 weeks old male C57Bl/6J mice, 48 h post-injection animals were sacrificed and tissues prepared for IHC analysis 
of Iba1 + cells around the injection site (DOI = day of injection). (b) Exemplary micrograph of the SN injection site. 
Sections were stained for Iba1 and nuclear staining was performed using DAPI. The white circle (ᴓ 330 µm) is indicating 
the site for stereological counting of Iba1 + cells around the injection site. (c) Stereological quantification of Iba 1 + 




3.5.3 Injection of miR-182 and miR-183 mimics into the murine SNpc leads to a 
stable increase in miR-182 and miR-183 levels detected by qRT-PCR 
 For the assessment of transfection efficiency and stability of miRNA mimics in vivo, 
250 pmol miR-182 or miR-183 mimic or NC siRNA were injected in the SNpc of mice. 6h, 
48h and 7d post-injection animals were sacrificed, total RNA from the substantia nigra 




 Six hours after nigral injection of miR-182 and miR-183 mimics a strong increase in 
miR-182 and miR-183 levels in the SNpc compared to NC siRNA injected animals was 
detected by qRT-PCR (figure 3.14 b and c first column; miR-182 13.3 ± 0.5 log2 fc; miR-183 
13.5 ± 0.3 log2 fc). After 48 h miR-182 (9.8 ± 0.2 log2 fc) and miR-183 (10.1 ± 1.2 log2 fc) 
levels in miRNA mimic injected animals decreased slightly compared to animals 6 h post-
injection and remained stable 7 days (miR-182 10.0 ± 1.5 log2 fc; miR-183 8.0 ± 0.3 log2 fc) 
after injection. However, compared to NC siRNA injected animals the miR-182 and miR-





Figure 3.5/3: Increase in miRNA levels is stable several days after injection of synthetic miRNA mimics into the 
murine SN in vivo. (a) Experimental layout for analysis of transfection efficiency and stability. The respective synthetic 
miRNA mimic or NC (250 pmol) was injected in the right SN of 8 weeks old male C57Bl/6J mice. 6 h, 48 h or 7 d post-
injection animals were sacrificed, the midbrain containing the SN region was dissected and total RNA was isolated for 
qRT-PCR to evaluate miRNA expression levels. (b) and (c) Relative miR-182 (b) and miR-183 (c) expression levels 6 h, 48 
h and 7 d after injection of miR-182 mimic or miR-183 mimic respectively (n = 3 animals per condition; mean ± SEM; 






3.5.4 Increased miR-182 levels lead to a higher survival of dopaminergic neurons 
in the SNpc of mice after MPTP intoxication 
In order to investigate the potential neuroprotective effects of increased miR-182 
and miR-183 levels in an in vivo model for PD, animals received stereotactical injections of 
miR-182 or miR-183 mimics in the right SNpc. Control animals were injected with a NC 
siRNA. Beginning 48 h after stereotactical injection animals received intra-peritoneal 
MPTP (30 mg / kg body weight) injections at five consecutive days. At day 14 after the 
first MPTP injection animals were sacrificed and tissues were processed for stereological 
analysis of the SNpc dopaminergic neuron numbers as well as Nissl positive cells (figure 
3.5/4 a). 
After MPTP intoxication, NC siRNA injected animals showed a dramatic loss of TH 
positive dopaminergic neurons in the SNpc (figure 3.5/4 b + c). The stereological analysis 
of the ipsilateral SNpc resulted in a loss of about 45 % in NC siRNA injected MPTP lesioned 
animals (NC + MPTP 8633.5 ± 753.8 TH + neurons per SN) compared to non-lesioned 
controls (PBS 15533.8 ± 976.7 TH + neurons per SN). Animals that were injected with 250 
pmol of miR-182 mimic and intoxicated with MPTP showed a significantly higher number 
(14424.4 ± 1165.8) of TH-positive dopaminergic neurons in the SNpc than MPTP 
intoxicated animals injected with NC siRNA. A similar trend was observable in MPTP-
intoxicated mice that received an injection of miR-183 mimics (11168.8 ± 457.2 TH + 
neurons), although these results were not significant.  
In order to identify the total number of neuronal cells in the SNpc, Nissl staining 
was performed. The total number of neurons in the SNpc allows the conclusion if the loss 
of TH-positive dopaminergic neurons resulted from dopaminergic cell death or from a 
MPTP-induced downregulation of TH expression. As displayed in figure 3.5/4 d MPTP 
intoxication led to a severe loss of Nissl positive cells in the SNpc (PBS 16538.6 ± 850.5; 
NC + MPTP 9015.8 ± 833.6) that was comparable to the loss of TH-positive dopaminergic 
neurons, indicating a robust dopaminergic neurodegeneration upon MPTP treatment. In 
miR-182 mimic injected MPTP-intoxicated animals the loss of Nissl positive cells was 
significantly less (15815.9 ± 1264.4) than in NC siRNA injected animals. Also in miR-183 
injected animals (12742.3 ± 688.9) an attenuation of Nissl positive cell loss is detectable, 





Figure 3.5/4: Increase in miR-182 levels leads to an increase in survival of dopaminergic TH+ neurons in the MPTP 
mouse model. (a) Experimental layout. 8 weeks old male C57Bl/6J mice received a stereotactic injection of 250 pmol 
miRNA mimic or NC mixed with HiP (d-1) into the right SN. 48 h later (d1) intra-peritoneal MPTP injections (30 mg/ kg 
bw) were started and repeated for 5 consecutive days. 14 d after the first MPTP injection animals were sacrificed and 
tissues were harvested for IHC analysis. (b) Representative micrographs of SN sections of animals in experimental 
groups as indicated and immunolabeled against TH (scale bar = 1 mm). (c, d) Quantitative stereological analysis of TH + 
(c) and Nissl + (d) neurons in the ipsilateral SNpc of experimental animals (PBS n = 5, all other groups n = 6; mean ± SEM; 





 In non-MPTP treated animals the injection of NC siRNA or miRNA mimics did not 
lead to a change in TH positive dopaminergic neuron numbers (PBS: 15533.8 ± 976.7; NC 
siRNA + PBS: 15064.4 ± 1357.6; miR-182 + PBS: 16504.9 ± 1057.3; miR-183 +PBS: 16747.1 
± 322.6) or Nissl positive neurons (PBS: 16538.6 ± 850.5; NC siRNA + PBS: 16279.4 ± 




3.5.5 Increased nigral miR-182 levels lead to attenuated dopaminergic fiber loss 
and increased dopamine levels in the striatum of MPTP-intoxicated mice 
 To investigate the potential protective effects of increased miR-182 and miR-183 
levels on the nigral dopaminergic nerve terminals in the striatum after MPTP lesion, the 
density of DAT-positive dopaminergic fibers in the striatum was analyzed 14 days after 
the first MPTP injection (figure 3.5/5 a).  
 The representative micrographs in figure 3.5/5 b show a strong reduction in DAT 
immunoreactive fiber density in the striatum of NC siRNA injected animals after MPTP 
lesion. In comparison to this the micrographs of miR-182 mimic injected animals show a 
less extensive reduction of dopaminergic fibers. A similar trend was observed in miR-183 
injected animals. The quantification of DAT-positive fiber density (figure 3.5/5 c) showed 
a significant reduction of 57.0 ± 6.8 % in NC siRNA injected animals after MPTP lesion. 
Animals treated with miR-182 mimic showed significantly less fiber decline after MPTP 
treatment (36.9 ± 8.4 %). A trend for decreased degeneration of dopaminergic fibers in 
the striatum was observed also in miR-183 injected animals, here 46.8 ± 6.0 % of the 
fibers degenerated, although this was not significant. 
 The injection of NC siRNA and miRNA mimics had no effect on striatal 
dopaminergic fiber density in animals that were not treated with MPTP (PBS: 100.0 ± 6.6 
%; NC siRNA + PBS: 102.2 ± 11.1 %; miR-182 + PBS: 103.5 ± 6.7 %; miR-183 + PBS: 102.7 ± 





Figure 3.5/5: Increase in miR-182 levels leads to a higher dopaminergic striatal fiber density in the MPTP mouse 
model. (a) Experimental layout. 8 weeks old male C57Bl/6J mice received a stereotactic injection of 250 pmol miRNA 
mimic or NC mixed with HiP (d-1) into the right SN. 48 h later (d1) intra-peritoneal MPTP injections (30 mg/ kg bw) were 
started and repeated for 5 consecutive days. 14 d after the first MPTP injection animals were sacrificed and tissues 
were obtained for IHC analysis. (b) Representative micrographs of striatal sections of animals in experimental groups as 
indicated and immunolabeled against DAT (scale bar = 1 mm). (c) Relative quantification of DAT + fiber density 
normalized to PBS injected animals (PBS n = 5, all other groups n = 6; mean ± SEM; one- a  ANOVA ith Du ett s test 
post-hoc test). 
 
In order to determine whether the observed morphological preservation of 




terminals the content of dopamine and its metabolites DOPAC and HVA in the striatum 
were measured by HPLC. To this, fresh striatal tissue was prepared 14 days after first 
MPTP injection to purify dopamine and its metabolites for neurochemical analysis. The 
results of the neurochemical analysis are displayed in figure 3.5/6. MPTP intoxication led 
in all experimental conditions to a massive decrease in striatal dopamine contents (figure 
3.5/6 a). Compared to PBS injected control animals (18.0 ± 1.0 ng / mg wet tissue) striatal 
dopamine decreased about approximately 72 % in NC siRNA treated and MPTP 
intoxicated mice (NC + MPTP: 5.1 ± 0.2 ng / mg wet tissue). Striatal dopamine levels in 
miR-182 mimic-injected animals (miR-182 + MPTP: 6.7 ± 0.4 ng / mg wet tissue) were 
significantly higher compared to NC siRNA treated animals. These results correlate 
partially with the morphological preservation of dopaminergic fibers in the striatum. In 
miR-183 mimic-injected animals (5.4 ± 0.2 ng / mg wet tissue) no difference in the 




Figure 3.5/6: miR-182 increase leads to higher levels of striatal dopamine (DA) in the MPTP mouse model. 
Quantification of striatal DA (a), (3,4-dihydrophenylacetic acid (DOPAC) (b) and homovanillic acid (HVA) (c) contents in 
ipsilateral striata of experimental animals (PBS n = 5; NC + MPTP n = 9; miR-182 + MPTP n = 8; miR-183 + MPTP n = 9; 
mean ± SEM; one- a  ANOVA ith Du ett s test post-hoc test). 
 
 Regarding the dopamine metabolites DOPAC and HVA a similar but not as 




intoxicated animals the striatal DOPAC levels decreased to 0.5 ± 0.0 ng / mg wet tissue 
(PBS: 1.2 ± 0.1 ng / mg wet tissue) as displayed in figure 3.5/6 b. Injection of miR-182 or 
miR-183 mimics had no significant effect on striatal DOPAC contents (miR-182 + MPTP: 
0.7 ± 0.1 ng / mg wet tissue; miR-183 + MPTP: 0.7 ± 0.1 ng / mg wet tissue). Striatal HVA 
levels decreased in all MPTP treated groups (figure 3.5/6 c). Again miR-182 or miR-183 
increase led to no significant differences in striatal HVA compared to NC siRNA treated 
animals (PBS: 1.4 ± 0.1 ng / mg wet tissue; NC + MPTP: 1.0 ± 0.0 ng / mg wet tissue; miR-
182 + MPTP: 1.1 ± 0.0 ng / mg wet tissue; miR-183 + MPTP: 0.9 ± 0.0 ng / mg wet tissue).  
 In animals not intoxicated with MPTP the nigral injection of NC siRNA or miRNA 
mimics had no effect on striatal dopamine, DOPAC or HVA contents (NC + PBS: 17.4 ± 0.7 
ng dopamine / mg wet tissue; 1.5 ± 0.1 ng DOPAC / mg wet tissue; 1.3 ± 0.1 ng HVA / mg 
wet tissue; miR-182 + PBS: 16.9 ± 0.7 ng dopamine / mg wet tissue; 1.1 ± 0.0 ng DOPAC / 
mg wet tissue; 1.2 ± 0.1 ng HVA / mg wet tissue; miR-183 + PBS: 16.2 ± 0.8 ng dopamine / 
mg wet tissue; 1.2 ± 0.1 ng DOPAC / mg wet tissue; 1.3 ± 0.1 ng HVA / mg wet tissue; NC + 
PBS n = 5; all other groups n = 6). 
 
 
3.5.6 Increased miR-182 and miR-183 levels lead to a partial restoration of motor 
deficits 
 In addition to the morphological and neurochemical analysis, animal behavior was 
assessed 13 days after the first MPTP injection. For analysis of motor coordination the 
cylinder rearing test was utilized. General motor behavior was tested in the open field 
test. 
  In the cylinder test the mouse natural exploratory behavior is used to study motor 
coordination. Not intoxicated animals (PBS) mainly performed free rears (45.5 ± 3.5 %) 
and rears assisted with both paws (42.4 ± 3.4 %), whereas lateralized assisted rears were 
exceptions (left: 8.6 ± 1.8 %; right: 3.5 ± 1.9 %) as displayed in figure 3.5/7 b (black bars). 
In animals treated with NC siRNA and injected with MPTP these proportions changed 
significantly. NC siRNA-treated and MPTP-intoxicated mice showed an increase in rears 




3.3 %). Left and right paw assisted rears were not significantly different from non-MPTP 
intoxicated animals (figure 3.5/7 b dark grey bars).  
 
 
Figure 3.5/7: Effect of increased miR-182 and miR-183 levels on motor behavior in the MPTP mouse model. (a) 
Experimental layout. 8 weeks old male C57Bl/6J mice received a stereotactic injection of 250 pmol miRNA mimic or NC 
mixed with HiP (d-1) into the right SN. 48 h later (d1intra-peritoneal MPTP injections (30 mg/ kg bw) were started and 
repeated on 5 consecutive days. On day 13 afte  the fi st MPTP i je tio  the a i als  oto  eha io  as tested i  the 
cylinder test (coordination) and the open field test (OFT; general motor behavior). Animals were sacrificed on day 14 




paws (both), the left (left) or the right (right) paw, and without the use of their paws (free). (c, d, e) General motor 
behavior was assessed using the OFT. (c) Quantification of the total distance the animal moved within the 5 min testing 
time. (d) Analysis of the mean velocity of the animals during the 5 min testing time. (e) Quantification of the average 
time the animals were not moving during the testing period (PBS n = 5; all other groups n = 15 animals per group; mean 
± SEM; one- a  ANOVA ith Du ett s test post-hoc test). 
 
Animals treated with miR-182 showed an effective restoration of the observed deficits in 
rearing behavior in NC siRNA-treated and MPTP-intoxicated animals (figure 3.5/7 b 
middle grey bars). After MPTP intoxication miR-182-treated animals performed 46.8 ± 2.6 
% of the total rears with assistance of both paws and 41.0 ± 3.2 % as free rears without 
assistance. Thus, these animals did not perform significantly different from non-MPTP 
intoxicated animals (PBS). The left and right paw assisted rear numbers were similar to all 
other treatment groups (left: 8.7 ± 1.4 %; right: 3.5 ± 0.8 %). In miR-183 injected animals 
comparable results were observable. After MPTP intoxication they still performed 40.8 ± 
2.4 % of the rears as free rears and 47.4 ± 2.2 % under assistance of both paws. Left paw 
assisted rears (6.6 ± 1.4 %) and right paw assisted rears (5.2 ± 1.2 %) occurred in similar 
proportions as in all other groups (figure 3.5/7 b light grey bars). miR-183 treated animals 
performed not significantly different than non-lesioned animals. 
 The injection of miRNA mimics or NC siRNA without intoxication with MPTP had 
no effect on the rearing behavior of the animals (NC siRNA: both 44.6 ± 1.4 %; right 2.8 ± 
0.5 %; left 4.7 ± 1.2 %; free 47.9 ± 1.4 %; miR-182: both 47.9 ± 2.9 %; right 3.9 ± 0.9 %; left 
7.3 ± 1.5 %; free 40.9 ± 3.3 %; miR-183: both 42.1 ± 1.8 %; right 3.9 ± 1.0 %; left 9.4 ± 1.1 
%; free 44.4 ± 1.2 %). 
 I  the ope  field test the e aluatio  as fo used o  the pa a ete s dista e 
o ed , elo it  a d ti e ot o i g  (figure 3.5/7 c, d + e). Non-intoxicated animals 
(PBS) moved a distance of 2416.5 ± 248.4 cm in total. MPTP intoxication and treatment 
with the NC siRNA led to no significant change in this parameter (3385.8 ± 145.1 cm). In 
the miRNA mimic treated animals there was also no significant difference observable 
(miR-182 + MPTP: 3294.3 ± 126.3 cm; miR-183 + MPTP: 2800.8 ± 115.9 cm). Similar 
esults e e o tai ed fo  the pa a ete s elo it  a d ti e ot o i g , agai  o 
significant difference between treatment groups could be shown. On average, non-
intoxicated animals (PBS) moved with a velocity of 8.8 ± 1.1 cm / s. All MPTP-intoxicated 




mimics (NC + MPTP: 10.3 ± 0.5 cm / s; miR-182 + MPTP: 11.0 ± 0.5 cm / s; miR-183 ± 
MPTP: 9.3 ± 0.4 cm / s). PBS injected animals spent on average 104.3 ± 7.8 s without 
movement in the arena. This time was not significantly different in the MPTP lesioned 
animals independent of whether they received the NC siRNA or the miRNA mimics (NC + 
MPTP: 82.7 ± 2.5 s; miR-182 + MPTP: 95.0 ± 2.8 s; miR-183 + MPTP: 108.2 ± 4.3 s). 
Therefore, the lesion itself as well as the treatment with miRNA mimics or NC siRNA did 





 Today, PD is diagnosed with the appearance of motor symptoms; these occur late 
in disease progression when the majority of nigrostriatal projections are already 
degenerated. Other major obstacles in the treatment of PD are the lack of knowledge 
regarding the cause for the formation of the disease and missing treatment options that 
prevent further degeneration of the nigrostriatal system and induce regeneration of 
dopaminergic neurons. Although PD is a system disorder involving most parts of the 
brain, the malfunction of the nigrostriatal dopaminergic projections is of prime clinical 
importance. So far, several pathomechanisms for the degeneration of dopaminergic 
neurons have been proposed and studied; among them protein mishandling and 
aggregation, oxidative stress, mitochondrial dysfunction and energy failure. All mentioned 
mechanisms seem to be involved in PD pathogenesis, however, whether they are cause 
or consequence is still not known. 
 Since their discovery, miRNAs have been extensively studied and their importance 
for the development and maintenance of the CNS has become clear. Even though in 
recent years it was shown that miRNAs are also involved in the formation of 
neurodegenerative diseases, their role in PD is still under debate. Understanding miRNA-
dependent regulations in dopaminergic neuron biology and PD can provide valuable 
insights into PD pathogenesis and also might lead to new therapeutic strategies for 
neuroprotection and regeneration of the nigrostriatal system. The present work aims to 
elucidate miRNA expression changes in dopaminergic neurons upon development and 
neurite outgrowth, as well as in the degenerating and regenerating substantia nigra. 
Furthermore, it should be exploited if specific miRNAs have a neuroprotective or 
neuroregenerative potential in dopaminergic neurons in vitro and in vivo. 
 
 
4.1 miRNAs in maturation and neurite outgrowth of PMNs 
 In order to analyze miRNA expression changes upon development and neurite 
outgrowth of PMNs, small RNA sequencing of PMN cultures at different time points of 
maturation was performed. Additionally, the effect of the pro-dopaminergic growth 




neuronal cultures containing 5 – 8 % dopaminergic neurons together with GABAergic and 
serotonergic neurons. Therefore, it is important to mention that the sequencing results 
do not reflect the miRNA expression changes of a pure dopaminergic neuron population, 
but represent the miRNA expression changes in developing midbrain neurons. We 
assume that the cellular mechanisms that drive neuronal fate and neurite outgrowth are 
global and thus similar among different neuronal subtypes. Therefore, the present study 
gives important insights into miRNA regulations upon neuronal development and neuron 
outgrowth. However, because the growth factor GDNF acts specifically on dopaminergic 
neurons and has no effect on the differentiation and survival of GABAergic or 
serotonergic neurons (Lin et al. 1993) it is very likely that the observed effects of GDNF on 
PMN miRNA expression are specific for dopaminergic neurons. 
 
 
4.1.1 miRNA expression in developing PMNs – major changes occur during early 
development 
 Sequencing of small RNA libraries derived from PMN cultures at DIV 1, DIV 5 and 
DIV 10 detected 848 out of 1410 known murine mature miRNAs. Differential expression 
analysis revealed that the major changes in miRNA expression occur during early 
development of PMNs, between DIV 1 and DIV 5. Out of the 848 detected miRNAs the 
expression of 163 miRNAs was significantly regulated between DIV 1 and DIV 5, with a 
e  p o ou ed egulatio  ≥ -fold) of 47 miRNAs. The massive regulation in miRNA 
expression between DIV 1 (E 13.5) and DIV 5 (E 17.5) and the lack of major miRNA 
expression changes between DIV 5 and DIV 10 (P 0) indicate that the fate of PMNs 
including dopaminergic neurons is already determined at DIV 5. This is confirmed by 
different studies analyzing differentiation and maturation of rodent midbrain 
dopaminergic neurons in vitro and in vivo (reviewed in Perrone-Capano & Porzio 2000). 
Perrone-Capano & Porzio propose a model in which differentiation (requiring global 
changes in gene expression) of dopaminergic midbrain neurons occurs between E 11 and 
E , he eas the fi al atu atio  e ui i g ode ate fi e tu i g  takes pla e et ee  
E 15 and E 18. These findings were confirmed by analyses of DA uptake and expression of 
specific transcription factors. The importance of miRNAs for the final maturation of 




depletion led to strongly reduced numbers of dopaminergic neurons differentiated from 
ES cells whereas other neuron classes like GABAergic neurons were not affected in the 
same extent. This phenotype could be rescued by transfection of the small RNA fraction 
isolated from rodent embryonic midbrains. The target prediction analyses for regulated 
miRNAs between DIV 1 and DIV 5 and the functional annotation of these target genes 
also indicate important effects of miRNA expression changes on PMN differentiation and 
maturation. Taken together, the major changes in miRNA expression occur during 
differentiation of PMNs, whereas maturation and neurite outgrowth require milder 
changes in miRNA expression. 
 
 
4.1.2 The regulated miRNAs are important for neuronal differentiation and function 
 Among the highly regulated miRNAs between DIV 1 and DIV 5 (with more than 500 
reads per condition) there are several miRNAs that are known to play a role in neuronal 
development. miR-92a is down regulated at DIV 5 and is important for neural stem cell 
expansion (Bian et al. 2013). Beveridge and colleagues could show that neuronal 
differentiation lead to a down-regulation of the miR-17 family including miR-92a 
(Beveridge et al. 2009), underlining the present results that show that miR-92a is down 
regulated in differentiated PMNs. In contrast to this decreased expression of miRNAs 
involved in differentiation, there are several miRNAs significantly up-regulated in PMNs at 
DIV 5 that play a role in neurite growth, spine formation and synaptic plasticity. Among 
them is miR-138; a miRNA that is involved in regulation of neurite outgrowth by targeting 
SIRT1 mRNA (Liu et al. 2013). Interestingly, Shi and colleagues could demonstrate that 
miR-138 is also involved in synaptic plasticity, as it regulates synaptic Lypla1 protein levels 
(Shi et al. 2010). Another miRNA important for neurite growth, spine formation and 
synapse formation and function is miR-132 that is up regulated in PMNs at DIV 5. miR-132 
overexpression lead to an increase in dendritic branching and increased dendritic 
protrusion width in primary hippocampal cultures (Edbauer et al. 2010). Pathania and 
colleagues could show that miR-132 enhances dendritic morphogenesis, synaptic 
integration and survival of newborn olfactory bulb and hippocampal neurons (Magill et al. 




miR-129 family: miR-129-5p and miR-129-2-3p. The precise functions of these miRNAs are 
not fully understood yet, but it is known that they play a role in cell proliferation, are 
important for synaptic functions and neuronal excitability (Cao et al. 2012; Sosanya et al. 
2013; Wu et al. 2014). There are also indications for a dysregulation of these miRNAs in 
neurodegenerative diseases like AD and PD, even though their role in the formation of 
these diseases is not elucidated yet (Briggs et al. 2015; Satoh 2012). The up-regulated 
miR-7b has been shown to regulate neurite length in developing hippocampal neurons 
and controls the growth of the cortex in mice (Pollock et al. 2014; van Spronsen et al. 
2013). Interestingly, other miRNAs known to be regulated in neuronal development and 
function were not significantly regulated in the present study. There is evidence that miR-
9 and miR-124 expression is regulated during neuronal differentiation (reviewed in Gao 
2010). However, in the present study the expression of those miRNAs was not 
significantly altered. One possible explanation is that the selected time intervals were too 
long to detect more subtle changes. It also might be that the effects of these miRNAs in 
PMNs are exerted at earlier time points during development. 
 In order to find potential candidate miRNAs that might enhance 
neuroregeneration and act neuroprotectively among the regulated miRNAs in this study I 
performed target prediction analyses and functional annotation of these target genes. 
Additionally, I searched for already experimentally validated target genes. Based on these 
analyses, a list with appropriate candidate miRNAs was assembled; these miRNAs will be 
tested for their effects in PMNs in other experiments that are not part of this thesis. 
 
 
4.1.3 GDNF treatment leads to a specific regulation of miR-182 and miR-183 expression  
In order to analyze the influence of the pro-dopaminergic growth factor GDNF on 
miRNA expression in PMNs, a small RNA sequencing was performed. The small RNA 
sequencing and differential expression analyses comparing the miRNA expression in 
GDNF-treated PMN cultures with control-treated PMN cultures showed that out of the 
848 detected miRNAs only two were significantly changed in their expression levels upon 
GDNF treatment. At DIV 5, miR-182 and miR-183 expression was significantly higher in 
GDNF-treated cultures than in control-treated PMNs, indicating that in untreated cultures 




results we performed qRT-PCR to determine the miR-182 and miR-183 expression in 
GDNF and control-treated PMNs at DIV 1, DIV 3, DIV 5 and DIV 7. In contrast to the 
sequencing data, the qRT-PCR showed that GDNF treatment lead to a constant increase in 
miR-182 and miR-183 expression at all time points, including DIV 1. The very specific 
effect of GDNF on the miRNAome of PMNs indicates that the regulated miRNAs are 
involved in mediating the beneficial effects of GDNF on dopaminergic neurons. 
Furthermore, it could be speculated that the regulation of these miRNAs is specific for 
dopaminergic PMNs as GDNF acts particularly on dopaminergic neurons. In order to even 
further verify this hypothesis it would be necessary to perform miR-182 and miR-183 
expression analyses exclusively from GDNF-treated dopaminergic PMNs. Therefore, 
dopaminergic neurons would have to be isolated from other neuronal cells in the mixed 
PMN culture. This, however, is difficult to achieve, because cell sorting of adherent 
cultures requires trypsinization; a process that is very likely to change gene expression 
and thus also miRNA expression. Another possibility would be single cell PCR, a technique 
that allows the isolation and expression analysis of single cells. Recently, the first kits 
were developed that allow miRNA expression analysis from single cells or with minimal 
RNA amounts. These might give insight if the GDNF-mediated increase of miR-182 and 
miR-183 is specific for dopaminergic neurons. 
A mutual regulation of neurotrophic factors and miRNAs has been previously 
reported, even though the finding that GDNF regulates the expression of certain miRNAs 
in neurons is new. There is only one previous study, which reports that acute treatment 
with high doses of GDNF leads to a differential expression of miRNAs in 6-OHDA treated 
MN9D cells (Li et al. 2013). The effects of chronic GDNF treatment on miRNA expression 
in neurons are not discussed there and the results are not comparable to the present 
study, because of a totally different methodology and the use of the mouse 
neuroblastoma fusion cell line MN9D, which is immortalized and thus its comparability to 
primary neurons is very limited. One of the best studied examples for neurotrophin 
regulated miRNA expression is the interaction between brain derived neurotrophic factor 
(BDNF) and the miR-212/132 cluster. A deep sequencing experiment revealed that BDNF 
induces the expression of the miR-212/132 cluster via the ERK1/2 pathway in primary 
cortical neurons (Remenyi et al. 2010). These findings led to the assumption that some of 




regulators of neurite growth, dendritic development and synapse function. This 
hypothesis was supported by the discovery that MeCP2 expression, a protein that is 
crucial for neuronal development, is regulated by miR-132 and miR-212. Interestingly, 
MeCP2 takes part in the control of BDNF expression, thereby creating a feedback loop for 
homeostatic control of MeCP2, BDNF and miR-132/miR-212 respectively (Im et al. 2010; 
Klein et al. 2007). Another example for neurotrophin-mediated miRNA expression is the 
induction of miR-221 and miR-222 by nerve growth factor (NGF) due to sustained 
activation of ERK1/2 (Terasawa et al. 2009). In both mentioned examples neurotrophin-
induced miRNA expression is mediated via increased ERK1/2 signaling. GDNF can also 
activate the ERK1/2 pathway which in turn activates several transcription factors 
(Stamboulian et al. 2010; Yang et al. 2001), among them SP1, a transcription factor that 
was shown to mediate expression of miR-182 and miR-183 (Yang et al. 2014). Thus, it is 
possible that GDNF induces miR-182 and miR-183 expression by activation of ERK1/2 and 
subsequent phosphorylation of SP1. However, by now there is no experimental evidence 
for this hypothesis. Nevertheless, there is accumulating evidence that miRNAs and 
neurotrophic factors regulate each other, a fact that is of major importance for the 
understanding of neuronal development, function and maintenance.  
 
 
4.2 miRNA expression changes in the degenerating and regenerating murine SN 
 In order to reveal the miRNAome of the midbrain and analyze the changes in 
miRNA expression levels upon degeneration and regeneration of SN dopaminergic 
neurons in vivo, the unilateral striatal 6-OHDA mouse model was employed and small 
RNA sequencing of the midbrain was performed 4 weeks (degeneration) and 12 weeks 
(regeneration) after intrastriatal injection. By small RNA sequencing 780 mature miRNAs 
were detected in the murine midbrain. In contrast to a deep sequencing analysis of the 
whole mouse brain where miR-9 was found to be most abundant (Chiang et al. 2010), in 
the unlesioned murine midbrain miR-181a showed the highest expression. Nonetheless, 
also other abundant brain miRNAs like miR-127, miR-9, miR-99b and miR-125b were 




Four weeks after intrastriatal 6-OHDA application - at the time point when the 
degeneration of the nigrostriatal system is at its maximum - out of the 780 detected 
miRNAs 5 showed significantly changed expression levels. Upon spontaneous recovery 12 
weeks after the striatal 6-OHDA lesion the expression of 12 miRNAs was significantly 
regulated. Even though the analysis was done with total midbrain samples, the observed 
miRNA expression changes are very specific, indicating that the regulated miRNAs play 
important roles upon degenerative and regenerative processes of SN dopaminergic 
neurons. Additionally, it has to be mentioned that the midbrain used for the analysis 
naturally contains all types of neuronal and glial cells. Thus, it is possible that the 
observed changes in miRNA expression derive from different cell types, although the 
striatal 6-OHDA application excludes a mechanical lesion of the substantia nigra and the 
selective catecholaminergic toxicity of 6-OHDA-induced retrograde axonal degeneration 
imply a predominant lesion of dopaminergic neurons in the SNpc. 
 
 
4.2.1 miRNA expression changes in the degeneration model 
 Only 0.6 % of all detected miRNAs were regulated 4 weeks after striatal 6-OHDA 
injection. This reflects that the analysis was done at a time point were the degeneration is 
maximal and not in the acute phase shortly after the 6-OHDA injection, where a much 
stronger regulation might take place. Thus, this very specific pattern indicates that the 
regulated miRNAs play a role in progressive degeneration of dopaminergic neurons.  From 
the 5 miRNAs with differential expression levels in the midbrain miR-501-3p, miR-100 and 
miR-331-3p were significantly up-regulated, whereas miR-486 and miR-3107 showed a 
decreased expression. The functional annotation of the target genes of these miRNAs 
revealed that they are important regulators of the MAPK, Wnt and mTor signaling 
pathways, reflecting the impact of 6-OHDA on the physiology of dopaminergic neurons. 
Until now there is no other study published that investigates miRNA expression in a 
mouse model for PD, neither for 6-OHDA nor for MPTP. Thus, the present data cannot be 
compared to other studies. Even the effect of the mentioned neurotoxins on PMNs or 
other neuronal cultures with respect to miRNA expression is not studied so far. There is 




but this is obviously not comparable to the present data and none of miRNAs reported to 
be regulated in this paper (Li et al. 2013b) were regulated in our study.  
 Some of the regulated miRNAs have been reported to be involved in 
neurodegeneration in other contexts than PD. The up-regulated miR-501-3p is also 
increased in animals infected with Venezuelan equine encephalitis virus (VEEV), a virus 
that primarily affects neurons and glial cells and results in neurodegeneration (Bhomia et 
al. 2010). Interestingly, miR-501-3p as well as miR-100 and miR-331-3p were also 
increased in a mouse model for AD, here the authors discuss the function of this 
regulation as maintenance of cell homeostasis (Luo et al. 2014). miR-100 is also up-
regulated in the cerebellum and the medial frontal gyrus of AD patients (Cogswell et al. 
2008) and miR-331-3p levels are elevated in a mouse model for prion-induced 
neurodegeneration (Saba et al. 2008). In the present study miR-486 levels are decreased 
in the SN 4 weeks after 6-OHDA lesion, this is interesting, because it was shown that up-
regulation of miR-486 prevents neurons from regeneration in spinal cord injury by 
repression of NeuroD6, a factor that protects neurons from oxidative stress (Jee et al. 
2012). Thus, decreased miR-486 levels in our degeneration model might lead to 
protection from oxidative stress by increased NeuroD6 expression, which is important as 
6-OHDA toxicity is mediated via ROS formation. The comparable miRNA expression 
changes in different models for neurodegeneration and different neurodegenerative 
diseases indicate once more that the molecular mechanisms underlying 
neurodegeneration are similar, independent from the affected neuron type and the 
underlying disease. 
 Unfortunately, there are only few studies analyzing global miRNA expression 
changes in brains of PD patients and none of them reports changes in expression levels of 
the miRNAs that were regulated here. However, as miRNA analysis from post-mortem 







4.2.2 miRNAs involved in spontaneous recovery of SNpc dopaminergic neurons after 6-
OHDA lesion 
 In the regeneration model 12 weeks after the striatal 6-OHDA lesion 12 out of 780 
miRNAs were significantly regulated in the midbrain. Thereof three miRNAs were up-
regulated, including miR-132*, miR-128-1* and miR-146b, whereas 9 miRNAs were down-
regulated. Among the down-regulated miRNAs were miR-100, which is up-regulated upon 
degeneration, miR-199a, miR-199b and miR-99a. The KEGG pathway analysis of the target 
genes of these miRNAs revealed that especially proteins involved in growth-associated 
pathways as ErbB signaling pathway, glioma and neurotrophin signaling pathway are 
affected by the regulated miRNAs; pathways that are likely to play a role in a regenerative 
response. So far, except for a few reports on spinal cord injury and stroke there are no 
studies investigating the role of miRNAs in the spontaneous recovery of central nervous 
system structures. However, some of the regulated miRNAs in the present study have 
been previously reported to be involved in neuroregenerative and growth-associated 
processes. The up-regulated miR-146b targets interleukin-1 receptor-associated kinase 1 
(IRAK1), a kinase that regulates a pro-inflammatory response, and thus might prevent 
excessive inflammation of brain tissue, which is also present in the SN of PD patients 
(Hirsch & Hunot 2009; Urdinguio et al. 2010). This indicates a primary role of this miRNA 
in glial and especially microglial function. In the neuronal context, an increase of this 
miRNA is associated with neurogenesis and neural stem cells (Liu et al. 2011; Stevanato & 
Sinden 2014). It is interesting that miR-100, a miRNA up-regulated in the degeneration 
model, is down-regulated with spontaneous recovery. One miR-100 target is mTOR, a 
kinase that has different functions in cell growth, autophagy, protein synthesis and 
transcription (Torres et al. 2012). There is evidence that inhibition of the mTOR pathway 
is neuroprotective in acute toxin-induced models for PD (Malagelada et al. 2010); 
elevated miR-100 levels leading to a decrease in mTOR protein levels might be involved in 
this neuroprotective mechanism. In contrast, it has been shown that increased mTOR 
levels and activity, as expected with decreased miR-100, are promoting axon regeneration 
in the CNS (Park et al. 2008). Interestingly, also two other down-regulated miRNAs in the 
regeneration model, miR-199b and miR-99a, target mTOR (Torres et al. 2012). This 
indicates that the spontaneous regenerative response of the nigrostriatal system in the 6-




and miR-99a is sirtuin1 (Sirt1) (Saunders et al. 2010). Sirt1 is a NAD-dependent histone 
deacetylase (HDAC), which in neurons is involved in neuroprotection, longevity and axon 
growth. Decreased levels in miR-199b and miR-99a might lead to an increase in Sirt1 
protein levels. There is accumulating evidence that increased Sirt1 levels and activation 
promote CNS axon regeneration and protect against neurodegeneration in vivo and in 
vitro (Cho & Cavalli 2014; Kim et al. 2007; Li et al. 2013; Liu et al. 2013). 
 Taken together, the present data suggests that the spontaneous recovery in the 6-
OHDA mouse model for PD 12 weeks after striatal lesion could be mediated by a 
decreased microglial inflammatory response through increased miR-146b levels and 
increased mTOR and Sirt1 levels through decreased miR-100, miR-199b and miR-99a 
levels. In order to prove this hypothesis further studies analyzing the expression levels of 
the discussed proteins in the midbrain of this model are necessary. 
 
 
4.3 Effects of increased miR-182 and miR-183 levels on dopaminergic PMNs 
 The manipulation of miRNA levels in cell culture by transfection of either synthetic 
miRNA mimics or miRNA inhibitors is a promising tool for the functional analysis of 
specific miRNAs. The small RNA sequencing of GDNF treated PMNs revealed the specific 
up-regulation of miR-182 and miR-183 upon GDNF treatment. miR-182 and miR-183 
belong to the miR-96~182~183 cluster, an intergenic miRNA cluster that is located on the 
murine chromosome 6 and leads to the simultaneous expression of miR-96, miR-182 and 
miR-183. The regulation of miR-182 and miR-183 by GDNF indicates that GDNF might 
execute some of its effects via miR-182 and miR-183. The functional annotation of 
predicted target genes of these miRNAs also suggests that they might be involved in 
GDNF-mediated effects like neuroprotection and survival of dopaminergic neurons. PMN 
cultures were transfected with synthetic miR-182 or miR-183 mimics or NC siRNA, 
followed by analyses of neurite length, neurite regeneration and neuroprotection in 
different experimental setups. As mentioned before, PMNs are mixed neuronal cultures 
and the miRNA mimic transfection affected all present cell types, but for the analyses only 
dopaminergic neurons were included. Thus, the observed effects are experimentally 
validated for dopaminergic PMNs, but the possibility that also other neuronal cell types 




in a highly specific manner on dopaminergic neurons and thus the initial GDNF-mediated 
up-regulation of miR-182 and miR-183 is very likely to occur specifically in these cells. 
 
4.3.1 Increased miR-182 and miR-183 levels lead to longer neurites and increased 
neurite regeneration in dopaminergic PMNs 
 Transfection of PMN cultures with synthetic miR-182 or miR-183 mimics led to an 
increased neurite growth and regeneration of dopaminergic neurons. Interestingly, the 
effect of the miRNA mimics was comparable to the effect of GDNF treatment in NC siRNA 
transfected cells. This indicates that miR-182 and miR-183 are mediating at least some of 
the beneficial effects of GDNF. The possibility that the observed increase in neurite length 
and regeneration was caused by the mere transfection of miRNA mimics can be excluded, 
because transfection of PMNs with miR-1a-3p mimics, a miRNA that was previously 
shown to have no effect on neurite growth, did not lead to longer neurites or increased 
neurite regeneration in dopaminergic neurons. In general, the effects of miR-182 mimics 
were a little more pronounced than the effects of miR-183 mimic transfection. Another 
noticeable fact is that a combined transfection of miR-182 and miR-183 mimics did not 
lead to a cumulative effect. One possible explanation for this is a saturation of the miRNA 
machinery like dicer (Castanotto & Rossi 2009), another possibility is the mutual 
regulation of miR-182 and miR-183 mimic-mediated effects. As the neurite length in all 
experimental conditions increased between 70.4 % and 83.9 % compared to NC siRNA 
transfected cells one could also speculate that there might be a physiological limit to 
neurite outgrowth in dopaminergic PMNs, e.g. by limited growth substrate supply or 
speed of substrate production. 
 Until now there is no study published reporting the influence of miR-182 and miR-
183 on neurite outgrowth of dopaminergic neurons. Nevertheless, inhibition of the miR-
182 target genes Foxo3 and Foxo1 as well as the miR-183 target gene Taok1 are reported 
to be involved in neurite outgrowth (Gu et al. 2014; Schubert et al. 2003; Tavares et al. 
2013; Wang et al. 2013). The present work shows a decrease in Foxo3 and Foxo1 
expression in miR-182 mimic transfected PMN cultures. Interestingly, also in GDNF 
treated and miR-183 transfected PMNs a similar decrease in Foxo protein levels can be 




to a decrease in Foxo1 and Foxo3 protein expression and activation (Anitha et al. 2006; 
Srinivasan et al. 2005). In contrast, Foxo1 until now was not validated as a target for miR-
183 in mice, but in humans. Thus, it is very likely that miR-182 and miR-183 induced 
increase in neurite length is mediated among others via decreased expression of Foxo 
transcription factors. There was a trend of decreased Taok1 protein levels in miR-183 
transfected as well as in GDNF treated PMNs, even though this did not reach statistical 
significance. This indicates that also a decrease in Taok1 protein levels might be involved 
in the miR-182/miR-183/GDNF mediated increase in neurite length and regeneration. 
Additionally to the direct targets of miR-182 and miR-183 the levels and activation of 
different growth-associated proteins were analyzed. Transfection of PMNs with miR-182 
and miR-183 mimics led to no changes in Akt levels. Nevertheless, the increase in miR-182 
and miR-183 levels resulted in a significantly higher amount of pAkt in PMNs, giving 
evidence for an increased activation of the PI3K-Akt pathway. A similar trend was 
observed in PMNs treated with GDNF. Furthermore, our results show a trend for an 
increased activation of the Mapk pathway in miR-182, miR-183 and GDNF treated cells, 
shown by the increased phosphorylation of Erk1 and Erk2. Again, the unphosphorylated 
isoforms were not affected by the different treatments. It was previously shown that 
GDNF leads to an increased activation of PI3K-Akt and Mapk signaling in dopaminergic 
cells and that this is required to mediate the GDNF effects (Carnicella et al. 2008; Pong et 
al. 2002). Both pathways are involved in mediating neurite growth and regeneration, thus 
it is not surprising that the increased neurite length and regeneration in miR-182 and miR-
183 transfected dopaminergic PMNs are accompanied by increased PI3K-Akt and Mapk 
signaling pathway activity, although the relation between miR-182/miR-183 and 
increased Akt and Mapk activity is not described in the literature yet. Interestingly, the 
increased Akt activation might lead to an additional inhibition of Foxo transcription 
factors by phosphorylation, since Foxo is a downstream target of the PI3K-Akt signaling 
and thus amplifies the miRNA-mediated effects (Brunet et al. 2001). In miR-182 and miR-
183 mimic transfected cells an increase in Bcl-2 and phospho-S6 proteins was observable 
that can also be explained by an increase in PI3K-Akt signaling, since Bcl-2 and mTor 
(upstream of phospho-S6) are both downstream targets of Akt. The present data 




dopaminergic PMNs are mediated via down-regulation of Foxo transcription factors and 
increased signaling via the PI3K-Akt and Mapk pathways.    
    
 




  In order to validate if increased miR-182 and miR-183 levels protect dopaminergic 
PMNs from MPP
+
 induced toxicity in the same way as GDNF, 2 µM MPP
+ 
were applied 24 
h post-transfection. Application of MPP
+
 for 24 h led to a significant cell death of 
dopaminergic PMNs in all treatment groups. Nevertheless, in miR-182 and miR-183 mimic 
transfected PMNs as well as in GDNF treated cultures a significantly higher amount of 
surviving dopaminergic neurons was detected compared to NC siRNA transfected PMNs. 
Again, the miRNA effects were comparable to the effects of GDNF treatment. As an 
additional control the dopaminergic survival in miR-1a-3p transfected PMNs was 
analyzed: there the survival was comparable to NC siRNA transfected PMNs. 
Consequently, the observed neuroprotective effect of miR-182 and miR-183 transfection 
is not caused by a mere miRNA increase. 
 The fact that increased miR-182 and miR-183 levels protect dopaminergic neurons 
from MPP
+
 induced neurotoxicity is not published so far. MPP
+
 mediates its toxicity via 
inhibition of complex I of the respiratory chain and leads to increased ROS production and 
oxidative stress. Interestingly, there are several studies on other cell types that report 
that miR-182 and miR-183 protect from apoptosis caused by oxidative stress via inhibition 
of Foxo transcription factors (Gheysarzadeh & Yazdanparast 2014; Tang et al. 2015). 
Beside the inhibition of Foxo transcription factors also the up regulation of PI3K-Akt and 
Mapk signaling and subsequent increase in Bcl-2 expression are known to be involved in 
the GDNF-mediated protection of dopaminergic neurons from toxin-induced cell death 
(Sawada et al. 2000; Ugarte et al. 2003). Thus, it is likely that miR-182 and miR-183 
induced protection of dopaminergic PMNs is mediated by a decreased Foxo-induced 
apoptosis and increase in survival signaling. 
 The precise mechanism how GDNF regulates miR-182 and miR-183 expression and 
if there is possibly a concerted action or a feedback mechanism between GDNF and the 




that the transcription of the GDNF gene and the miR-96~182~183 cluster are, among 
others, initiated by the transcription factor Sp1 (He & Ron 2006; Hung 2013; Yang et al. 
2014). It is also known that this transcription factor is involved in GDNF-regulated auto-
expression (He & Ron 2006). Foxo1 reduces the transcriptional capacity of Sp1. 
Consequently decreased Foxo1 through miR-182 or miR-183 increase might lead to a 
higher transcriptional activity of Sp1 (Deng et al. 2012), which in turn might lead to an 
increased neuronal GDNF expression. Another point that favors this hypothesis is the 
increased activation of the PI3K-Akt and Mapk signaling pathways upon miR-182/miR-183 
increase that could easily be induced by secreted GDNF binding to its receptor. 
Additionally, the activation of PI3K-Akt and Mapk signaling pathways leads to a 
phosphorylation and thus higher transcriptional activity of Sp1 (Merchant et al. 1999).  
 In order to prove this hypothetical feedback mechanism between GDNF, miR-
182/miR-183 and Sp1 (see figure 4.3/1), a series of experiments needs to be performed 
investigating if increased miR-182 and miR-183 induce GDNF expression via Foxo 
inhibition and activation of Sp1. Furthermore, experimental evidence is needed to prove 
that Sp1 is the transcription factor responsible for GDNF-induced miR-182 and miR-183 
expression.  
 Taken together, the present results show that increased levels of miR-182 and 
miR-183 mimic GDNF effects with respect to neurite length, regeneration and protection 
from MPP
+
-induced cell death in dopaminergic PMNs. Furthermore, miR-182 and miR-183 
increase as well as GDNF treatment lead to a decreased expression of Foxo transcription 
factors and an increased activation of PI3K-Akt and Mapk signaling pathways that might 





Figure 4.3/1 (following page): Proposed model for GDNF and miR-182/miR-183 interactions and their effects on 
dopaminergic neurons. (a) Without GDNF treatment or miR-182/miR-183 transfection (Normal state) miR-182/miR-183 
are expressed at normal levels, inhibiting Foxo1 and Foxo3 translation. Nuclear Foxo inhibits Sp1 activation, resulting in 
a limited expression of GDNF and miR-182/miR-183. (b) Bi di g of GDNF to GDNF fa il  e epto  α-1 (GFRA1) leads to 
an activation of PI3K-Akt and Mapk signaling which in turn leads to activation of growth and survival pathways and to 
nuclear import of Sp1, resulting in increased GDNF and miR-182/miR-183 expression. Increased miR-182/miR-183 levels 











4.4 Effects of increased miR-182 and miR-183 levels in the MPTP mouse model 
for PD 
 The previous results revealed that increased miR-182 and miR-183 levels lead to 
an increased neurite growth and regeneration and protect dopaminergic PMNs from 
MPP
+
 induced cell death, indicating that these miRNAs might be a valuable target for the 
treatment of PD. Consequently, it was necessary to analyze the effect of increased miR-
182 and miR-183 in an in vivo setting. In order to test the neuroprotective effect of miR-
182 and miR-183 in a mouse model for PD the acute MPTP paradigm was applied. The 
MPTP mouse model has been used for over 20 years and is well characterized (Schober 
2004). This model was used in numerous studies for testing of neuroprotective effects of 
different substances. In the present work the miRNA mimics were injected into the right 
substantia nigra of mice 48 h prior to the first MPTP injection to make sure that a 
sufficient amount of miRNA mimics enters the dopaminergic neurons of the SN and to 
have a comparability to the previous in vitro study, where the transfection took place 24 
h before MPP
+
 addition. Additionally, since MPTP-injected animals excrete the toxin and 
have to be handled with special precautions, stereotactic surgery on MPTP-injected 
animals is not advised. As miRNAs are highly charged molecules they cannot cross the 
blood brain barrier and thus have to be injected directly into the brain. The miRNA mimics 
were mixed with HiPerfect transfection reagent according to a protocol that was already 
used for hippocampal injection (Banzhaf-Strathmann et al. 2014; Zovoilis et al. 2011). 
Concentration, injection parameters and coordinates were adapted for injections in the 
SN and transfection of dopaminergic neurons in the SN 48 h post-injection was verified by 
injection of a fluorescently labeled siRNA. Interestingly, the transfected cells were almost 
exclusively neurons and only very small number of glial cells showed siRNA-mediated 
fluorescence. This is in accordance with previous studies reporting that the transfection of 
neurons with small oligonucleotides is very potent and outclasses the transfection of glial 
cells (Sommer et al. 1998). Quantitative PCR of the SN midbrain region of injected animals 
demonstrated that the injection of 250 pmol miRNA mimic led to an increase in detected 






4.4.1 Increased levels of miR-182 lead to protection of the nigrostriatal system in MPTP-
intoxicated mice and partially rescue behavioral deficits 
 Injection of miRNA mimics or NC siRNA in non-intoxicated PBS-injected control 
animals had no significant effect on TH-positive cell numbers in the ipsilateral SN 
compared to animals that were systemically treated with PBS but had no stereotactic 
surgery. Furthermore, the obtained numbers of TH-positive cells in control animals were 
comparable to previous studies (Saal et al. 2015; Tönges et al. 2012). Thus, the 
mechanical lesion caused by the nigral injection as well as the injected oligonucleotides 
have no effect on dopaminergic cell survival in the ipsilateral SNpc. After MPTP 
intoxication a massive decrease in TH-positive cell numbers of animals injected with NC 
siRNA was observed and the obtained cell numbers were comparable to previous studies 
employing the MPTP mouse model (Tönges et al. 2012). Quantification of Nissl positive 
cells showed a similar decline in neuronal cells, giving evidence that MPTP induced a 
specific dopaminergic cell death. 
 Dopaminergic cell survival was significantly higher in animals injected with miR-
182 mimics and a similar trend was observed in animals that received nigral injections of 
miR-183 mimics. Compared to the previously performed in vitro study on dopaminergic 
PMNs, the dopaminergic survival after MPTP-intoxication in vivo is much better than after 
MPP
+
 intoxication in vitro. A possible reason for this finding is that the brain in a living 
animal has a higher capacity to cope with toxic insults than isolated neurons in a pure 
primary cell culture without the support of glial cells. In control PMN cultures 70 percent 
of the dopaminergic neurons degenerated after MPP
+
 treatment, in comparison the 
MPTP effect in control mice was milder and led to a degeneration of ~45 percent of TH-
positive cells. Interestingly, the rescue effect of miR-182 and miR-183 was similar in MPP
+
 
treated PMN cultures, whereas the miR-182 effect exceeded the miR-183 effect in vivo. 
The protein expression analysis in vitro also revealed a higher effect of miR-182 on the 
activation of PI3K-Akt and Mapk signaling compared to miR-183, which might reflect the 
stronger effect of miR-182 in vivo. In the present study an additional GDNF-treated group 
was not included. Nevertheless, previous studies of other groups using nigral injections of 
recombinant GDNF in the MPTP mouse model can be utilized for comparison. Injection of 
recombinant GDNF to the SNpc 24 h prior to MPTP treatment for 2 consecutive days (40 




Approximately 90 percent of the dopaminergic neurons in the SNpc survived the MPTP 
intoxication after GDNF treatment (Tomac et al. 1995). Thus, the miR-182 mediated effect 
on dopaminergic neuron survival (~92 % surviving TH+ neurons) is comparable to the 
effects after GDNF treatment, reflecting the results of the in vitro studies on PMNs. The 
results from the neuronal PMN cultures showing a specific effect of GDNF on 
dopaminergic neurons leading to an upregulation of the analyzed miRNAs indicate that 
miR-182 and miR-183 act on dopaminergic neurons. This is further supported by the 
preferential transfection of neurons in the brain (Sommer et al. 1998). Of course it cannot 
be excluded that other neuronal cells in the SNpc mediate the neuroprotective effect of 
miR-182/miR-183 on dopaminergic cells as a secondary effect, but as the majority of 
neurons in the SNpc are dopaminergic this is not very likely. The results of the PMN study 
revealed that the down-regulation of Foxo transcription factors and an increased activity 
of pathways involved in survival and growth after miR-182 and miR-183 transfection are 
involved in mediation of the miRNA effects. 
 The histological analysis of DAT-positive striatal fibers revealed a more 
pronounced degeneration of striatal dopaminergic terminals than cell bodies in the SNpc. 
This reflects the situation in PD patients where with onset of motor symptoms already 
~70 to 80 percent of the nigrostriatal injections are degenerated but only ~30 percent of 
nigral dopaminergic neurons are missing Bu ke & O Malle  . This suggests that the 
degenerati e p o ess i  PD sta ts at the e e te i als a d that a so alled die a k  
pathology leads to loss of nigral neurons (Dauer & Przedborski 2003). This phenomenon is 
also occurring in the MPTP mouse model for PD, explaining the larger impact on the 
striatal terminals (Li et al. 2009; Tomac et al. 1995). Nevertheless, nigral miR-182 mimic 
injection led to a significant decrease in dopaminergic fiber degeneration in the striatum. 
A similar trend was observed in miR-183-treated animals, although this was not 
significant. The extent of the observed effects is comparable to findings in GDNF-treated 
animals (Tomac et al. 1995), indicating again that miR-182/miR-183 are involved in GDNF-
mediated protection of dopaminergic neurons. In order to determine whether the 
observed morphological preservation of dopaminergic striatal fibers correlates with 
functional maintenance of these axonal nerve terminals, the content of dopamine and its 
metabolites DOPAC and HVA in the striatum were measured by HPLC. The extent of DA, 




Nevertheless, miR-182-injected animals showed a significant higher amount of striatal DA 
compared to NC siRNA-injected animals. In miR-183-injected mice there was no increase 
in striatal DA observable. The amount of DA metabolites was not significantly changed in 
the miRNA-injected animals compared to NC siRNA-injected animals. Thus, there is 
functional preservation of dopaminergic terminals in miR-182 injected animals but the 
morphological preservation is much more pronounced. Interestingly, again the present 
data is comparable to the results of the study analyzing the effect of nigral GDNF injection 
in the MPTP mouse model. There, the depletion of DA and its metabolites in the striatum 
was also more extensive than the morphological degeneration and GDNF application led 
only to a small but significant increase in striatal DA (Tomac et al. 1995). Taken together, 
nigral injections of miR-182 (and to a lesser extent of miR-183) led to a preservation of 
dopaminergic neurons in the SNpc and their nigrostriatal projections in MPTP-intoxicated 
animals that is comparable to the effect of nigral GDNF application. Thereby, the 
morphological preservation was more pronounced than the functional preservation 
similar to previous studies investigating the neuroprotective effects of different 
substances (Saal et al. 2015; Tomac et al. 1995; Tönges et al. 2012). 
 The neuroprotective effects of miR-182 and miR-183 injections could also be 
visualized in a behavioral analysis of motor functions utilizing the cylinder test. The 
cylinder test gives information about whole body coordination and forelimb use. A bias 
towards a higher number of rears assisted with both paws observed in NC siRNA treated 
and MPTP-intoxicated animals was rescued in miR-182 and miR-183 injected MPTP-
intoxicated mice, showing no significant difference to PBS treated control animals. 
Keeping in mind the mild increase in striatal DA in miR-182 injected animals, the observed 
clear behavioral response is somewhat surprising. This could either indicate that the 
behavioral paradigm was not sensitive enough, even though it was demonstrated in other 
studies that it is adequate for investigation of motor behavior in the MPTP mouse model 
(Tönges et al. 2012), or that the moderate increase in striatal DA was sufficient to restore 
motor behavior in this task. Interestingly, the study by Tomac et al. (1995), investigating 
the effect of nigral injections of recombinant GDNF on the MPTP mouse model, shows 
similar findings. As mentioned above, GDNF application led to a morphological 
preservation of dopaminergic neurons and striatal terminals and to a mild increase in 




by a strong rescue effect on the rearing behavior. Additionally, the present results show 
that the cylinder test is sensitive enough to detect motor impairment after MPTP 
treatment, indicating that the test is sufficient for testing motor behavior after MPTP 
treatment. Considering the discrepancy between onset of motor symptoms and loss of 
nigrostriatal projections in PD it would be reasonable that a slight improvement of striatal 
DA content could lead to pronounced behavioral effects. Furthermore, in comparison 
with humans, rodents with a damaged nigrostriatal sytem show very pronounced 
compensatory mechanisms that rescue behavioral deficits. 
 Taken together, the present study gives evidence that increased levels of miR-182 
and miR-183 in the SN lead to a rescue of MPTP-mediated behavioral deficits. 
 
 
4.5 miRNAs as therapeutic targets 
 Since their discovery miRNAs have been extensively studied and there is a growing 
body of evidence that they might be viable therapeutic targets for different diseases, 
including neurodegenerative diseases, cancer and cardiovascular diseases. As a single 
miRNA modulates the expression of a high number of different genes, they 
simultaneously control multiple cellular pathways. This entails different risks and chances. 
Of course, it would be valuable to replace or inhibit a miRNA that is deregulated. On the 
other hand, several safety concerns are important to consider. In order to avoid off-target 
side effects it would be important to restrict the replacement/inhibition to the cell type 
and organ of interest and to clearly understand the pharmacokinetics of miRNA (Bouchie 
2013). Thus, the application mode of miRNA-based therapeutics is crucial. There are 
different possibilities to replace or inhibit miRNAs, such as expression of miRNA or miRNA 
inhibitor constructs by viral vectors as well as application of synthetic miRNA mimics or 
antisense oligonucleotides (inhibitors).  
 Viral vectors expressing shRNA- or miRNA-constructs lead to a constant expression 
of their construct. The possibility to use different serotypes in combination with tissue 
specific promoters allows a relatively precise transduction of the cell type/tissue of 
interest (van Rooij et al. 2012). However, there is a growing body of evidence that AAV-
mediated shRNA/miRNA overexpression has toxic side effects, presumably due to a 




the development and application of synthetic miRNA mimics or inhibitors has become 
more important. Several modifications of synthetic oligonucleotides have been employed 
to improve their cellular uptake and affinity. The major challenges in synthetic miRNA 
therapeutics are a targeted delivery and prevention of introduction of supraphysiological 
levels (E. van Rooij & Kauppinen 2014). Possible strategies are conjugation of the nucleic 
acid with targeting molecules or encapsulation to enhance cell specific uptake. Until a 
more specific application is possible, local device based application by catheters or local 
injection could be applied, which of course implies the risk of all invasive procedures, such 
as bleeding and infection. So far many miRNA based therapeutics were tested in 
preclinical studies but only few entered clinical trials. Nevertheless, clinical phase I and II 
trials with miRNA mimics (miR-34; liver cancer (Bouchie 2013)) or inhibitors (miR-122; 
Hepatitis C (Janssen et al. 2013)) demonstrated their promising therapeutic potential and 
implied that miRNA-based therapeutics can indeed become reality. 
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5. Concluding remarks 
 All experiments performed in the context of this thesis underline the importance 
of miRNAs in dopaminergic neurons and the nigrostriatal system. The present study gives 
evidence that a pronounced regulation of miRNA expression is involved in the maturation 
of PMNs. Additionally, two novel GDNF-regulated miRNAs were detected and their effect 
on dopaminergic neurons in vitro and in vivo was extensively studied. Furthermore, a 
novel set of miRNAs involved in the degeneration and spontaneous recovery of 
dopaminergic neurons was presented. 
The investigation of GDNF-regulated miR-182 and miR-183 revealed that higher levels of 
these miRNAs lead to increased neurite outgrowth and regeneration in dopaminergic 
PMNs and protect those cells from MPP
+
 toxicity. These effects were mediated by the 
down-regulation of Foxo transcription factors and increased activation of PI3K-Akt and 
Mapk signaling pathways. Interestingly, the miRNA effects were in most cases 
comparable to GDNF-mediated effects, leading to the assumption that GDNF acts at least 
partially via miR-182 and miR-183. In the MPTP mouse model for PD nigral injection of 
miR-182 mimics led to morphological and, to a lesser extent, functional preservation of 
dopaminergic neurons and their nigrostriatal projections. Furthermore, the MPTP-
mediated behavioral deficits were restored by miR-182 or miR-183 mimic injections in the 
SN. Further experiments are needed to completely understand the interplay between 
GDNF and miR-182/miR-183. 
The present work underscores that miRNAs are important regulators in dopaminergic 
neuron development and function in health and disease and that they have the potential 
to act neuroprotectively or induce neuroregeneration in models for PD. Thus, miRNAs are 
auspicious targets to find new therapeutic strategies for the treatment of PD and a 









 PD is the second most frequent neurodegenerative disorder affecting over 3 % of 
the population older than 80 years of age. Although PD is a system disorder which affects 
most regions of the brain, the progressive demise of the nigrostriatal projections and the 
inability of this system to regenerate are mainly responsible for the functional deficits 
observed. The etiology underlying PD is not finally resolved. Recent studies suggest that 
gene expression regulators might contribute to a large variety of disease states. miRNAs 
are small non-coding RNAs that are important for the post-transcriptional regulation of 
gene expression. Alterations in miRNA function have been reported in different 
neurodegenerative diseases including PD. Furthermore, miRNAs are auspicious 
therapeutic targets, as the manipulation of their expression might be neuroprotective or 
could induce the regeneration of neurons. 
In the present study the miRNAome of developing PMN cultures was analyzed and 
it was demonstrated that the major changes occur during early development. 
Furthermore, the influence of GDNF on the PMN miRNAome was investigated and a 
specific up-regulation of miR-182 and miR-183 upon GDNF treatment was discovered. In 
order to analyze miRNA expression changes during degeneration and spontaneous 
regeneration of the murine nigrostriatal system a small RNA sequencing of the midbrain 
of the 6-OHDA mouse model for PD was performed and revealed novel sets of miRNAs 
involved in degeneration and regeneration of DA neurons in vivo.  
With the objective to investigate the effect of increased GDNF-regulated miR-182 
and miR-183 levels on DA neurons, transfection of PMNs with miRNA mimics was 
performed and revealed increased neurite growth and regeneration, as well as protection 
of DA PMNs from MPP
+
 toxicity. Increased miR-182 and miR-183 led to decreased levels 
of Foxo transcription factors and increased PI3K-Akt and MAPK signaling, that presumably 
mediate the reported effects. Application of miR-182/miR-183 mimics in vivo revealed 
morphological and partially functional preservation of DA neurons, as well as restoration 
of rearing behavior after MPTP treatment.  
Taken together, miRNAs play an important role in development, maintenance and 
degeneration of DA neurons in vivo and in vitro and thus are promising targets for a 
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